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Abstract!
Human plasma contains cortisol (F) and corticosterone (B) at a ratio of ~10:1.  B is 
well studied in mice and rats, which do not produce F due to absent adrenal Cyp17, 
but is largely neglected in humans.  Differential transmembrane export of F>B by 
ABCB1 may account for accumulation of B in the CNS.  Conversely, ABCC1, 
expressed in human adipose tissue, preferentially exports B>F.  Here we tested the 
hypotheses that: (i) negative feedback suppression of the hypothalamic-pituitary-
adrenal (HPA) axis is disproportionately sensitive to B; (ii) adipose tissue is 
disproportionately sensitive to F; and (iii) low plasma B contributes to impaired HPA 
axis negative feedback and increased F action in metabolic syndrome. 
We validated a stable isotope tracer for B in vitro and demonstrated distinct kinetics 
of B and F in vivo.  In a randomised crossover study, we undertook ramped steady 
state infusion of B or F in 10 patients with Addison’s disease.  Although levels of B 
were marginally lower than F, ACTH was similarly suppressed, and yet 
glucocorticoid-responsive transcripts in adipose tissue were much higher following F 
than B (PER1 2.2-fold and LPL 1.3-fold; p<0.05).   
We assessed associations of ACTH-stimulated plasma B and F with features of 
metabolic syndrome in a cross-sectional study (n=279).  Glucose tolerance was 
impaired with higher F (β=0.146, p=0.01) but lower B (β=-0.056, p=0.05). 
These data support the concept of differential tissue sensitivity to B and F, whereby 
B suppresses the HPA axis more effectively than it induces adverse effects in 
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adipose tissue.  Enhanced CYP17 activity, causing ‘relative B deficiency’, may 
contribute to HPA axis activation and enhanced F action in adipose tissue in obesity.  
B therapy might allow control of HPA axis activation without inducing adverse 
metabolic effects. 
The ‘neglected second glucocorticoid’, corticosterone, may optimise glucocorticoid 
action in the human CNS, and simultaneously limit adverse metabolic effects driven 
by cortisol excess. 
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1.1.!Physiological!Actions!of!Glucocorticoid!Hormones!
Glucocorticoid hormones (Figure 1-1) have a wide range of effects on metabolism, 
CNS function, the cardiovascular system and the immune response (Munck et al, 
1984; Sapolsky et al, 2000).  The overarching function of glucocorticoid hormones is 
to co-ordinate the response to actual or perceived threats to homeostasis (stressors).  
Key elements of this response include maintenance of effective circulating volume 
(Saruta, 1996; Whitworth et al, 2000); mobilisation of energy stores (Andrews et al, 
1999; Macfarlane et al, 2008); inhibition of ‘vegetative’ functions such as bone 
formation (Canalis et al, 2002) and reproduction (Whirledge et al, 2010); and 
regulation of the immune system (Rhen et al, 2005).  Reflecting the widespread 
distribution of the glucocorticoid receptor (GR), up to 20 % of mammalian genes are 
glucocorticoid responsive (Quax et al, 2013).    
Figure!1J1.!!Basic!steroid!structure!
A"carbon" skeleton" comprising"a" cyclopentane" ring"and" three" cyclohexane" rings" forms" the"
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1.1.1.!Regulation!of!glucocorticoid!production!
Circulating glucocorticoid concentrations show a characteristic rhythmicity and 
respond rapidly to stressors.  This is mediated by neuro-endocrine signalling within 
the hypothalamic-pituitary-adrenal (HPA) axis.  Adrenocorticotrophic hormone 
(ACTH) is released by the anterior pituitary gland upon stimulation by 
corticotrophin-releasing hormone (CRH) produced in the hypothalamus.  ACTH and 
CRH secretion (Keller-Wood et al, 1984) is inhibited by glucocorticoids in a 
classical negative feedback loop (Figure 1-2). 
In the adrenal cortex, binding of ACTH to the G-protein coupled melanocortin 2 
(MC2R) receptor stimulates cAMP production, which acts upon a cAMP-dependent 
protein kinase to stimulate steroidogenic acute regulatory protein (StAR).  StAR 
facilitates cholesterol movement into the mitochondria (Stocco et al, 1996) and 
acutely regulates steroidogenesis by determining supply of substrate.  Chronic 
regulation of steroidogenesis is determined by a number of enzymes whose promoter 
regions are under regulation by ACTH/cAMP signalling.  These include cholesterol 
side-chain cleavage (P450scc) (Hu et al, 2001), the first and rate-limiting enzyme in 
steroidogenesis, responsible for quantitative regulation of steroidogenesis.  
Downstream ACTH/cAMP responsive enzymes modulate steroidogenesis 
qualitatively, and include 17α-hydroxylase (Rodriguez et al, 1997) and 
21-hydroxylase (Kagawa et al, 1992). 











Circulating glucocorticoid concentrations peak shortly after waking and fall through 
the day towards an overnight nadir (Dallman et al, 1993).  Superimposed upon this 
circadian profile is an ultradian rhythm, with pulses of 40-60 minutes (Veldhuis et al, 
1989; Young et al, 2001) which effect pulsatile gene expression (Stavreva et al, 
2009).   
1.1.2.!Plasma!protein!binding!
The circulating pool of glucocorticoids is largely bound to the plasma proteins 
corticosteroid-binding globulin (CBG) and albumin, with only 5-10 % circulating in 
the free (unbound) state (Hammond et al, 1990).  During the stress response, free 
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cortisol concentrations may be amplified by saturation of CBG; and down regulation 
of CBG production mediated by neutrophil elastase (Perogamvros et al, 2012).    
1.1.3.!Intracellular!glucocorticoid!signalling!
While rapid, non-genomic effects of glucocorticoids are mediated by cell-surface 
receptors (Tasker et al, 2006; de Kloet et al, 2008); the classical actions of 
glucocorticoids are mediated by effects on gene transcription after activation of 
intracellular receptors (Chrousos et al, 2005; Nicolaides et al, 2010).  
Glucocorticoids bind two types of intracellular receptor: the high affinity 
mineralocorticoid receptor (MR), and the low affinity glucocorticoid receptor (GR) 
(Reul et al, 1985; Funder, 1997).  In the unbound state, GR and MR reside in the 
cytoplasm bound to chaperone proteins such as heat shock protein 90 (hsp90).  Upon 
binding, the receptor dimerises and translocates to the nucleus (Pratt et al, 2004) 
where it binds directly to DNA to exert its actions through transactivation of 
glucocorticoid-response elements (GREs).  Alternatively, glucocorticoids may act by 
an indirect pathway (transrepression), whereby monomeric GR binds to other 
transcription factors such as NF-κB to inhibit their up-regulation of target genes 
(Glass et al, 2010). 
1.1.4.!Mechanisms!of!tissueJspecific!glucocorticoid!sensitivity!
Receptors for glucocorticoids are distributed in a manner that confers varying 
sensitivity to their action across different tissues.  While GR is expressed in almost 
all tissues, MR is localised to specific tissues including the kidney and hippocampus 
(Krozowski et al, 1983; de Kloet et al, 1998).  MR has a high and roughly equal 
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affinity (Kd ~ = 0.5-1 nM) for both glucocorticoids and mineralocorticoids 
(Krozowski et al, 1983; Arriza et al, 1987).  However, the circulating concentration 
of cortisol in humans is approximately three orders of magnitude greater than that of 
the major mineralocorticoid, aldosterone.  To maintain sensitivity to aldosterone in 
the face of cortisol excess, in tissues such as the kidney and salivary glands, pre-
receptor inactivation of glucocorticoids occurs through the action of the enzyme 
11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) (Edwards et al, 1988; Funder 
et al, 1988).  11β-HSD2 catalyzes the nicotinamide adenine dinucleotide (NAD+) 
dependent inactivation of cortisol, converting it to cortisone (Figure 1-3).  In those 
tissues where MR is present but significant 11β-HSD2 activity is absent, such as the 
hippocampus, MR is thought to be readily saturated by glucocorticoid, meaning that 
regulation of glucocorticoid action by MR may be restricted to conditions of low 
glucocorticoid production, such as at the diurnal nadir (de Kloet et al, 1998).  More 
recently, it has also been demonstrated that glucocorticoids may act as high affinity 
ligands for MR outwith the CNS, including in adipose tissue (Caprio et al, 2007), 
macrophages (Bienvenu et al, 2012) and vascular smooth muscle (Frey et al, 2004).  
In contrast to MR, the relatively low affinity of GR (Kd  ~ = 10-25 nM) for 
glucocorticoids (Hollenberg et al, 1985) means that expression of GR enables tissues 
to respond to changes in circulating glucocorticoid concentrations under stress or 
during diurnal and ultradian peaks (Reul et al, 1985). 
Glucocorticoid sensitivity is further modulated through the activity of 
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) (Seckl et al, 2001; 
Tomlinson et al, 2004).  In tissue homogenates, 11β-HSD1 is bidirectional, but in 
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intact cells the enzyme acts predominantly as a reductase, due to its co-localisation 
with hexose-6-phosphate dehydrogenase (Atanasov et al, 2008).  As such the main 
action of 11β-HSD1 is to produce cortisol from inactive cortisone, although in some 
circumstances it may act as a dehydrogenase in intact cells (Bujalska et al, 2002).  In 
contrast to 11β-HSD2, 11β-HSD1 is widely expressed in metabolic tissues including 
the liver, adipose, skeletal muscle and islets of Langerhans (Chapman et al, 2013).  
The enzyme acts in an intracrine manner, by regulating access to intracellular 
receptors; and also in an endocrine manner, by determining relative concentrations of 
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1.1.5.!Glucocorticoid!clearance!
In contrast to the reversible inactivation of cortisol by 11β-HSDs, irreversible 
inactivation occurs primarily in the liver, with direct renal excretion of cortisol 
accounting for less than 1 % of its clearance (Arlt et al, 2011).  The major pathway 
for hepatic glucocorticoid metabolism begins with the reduction of the A-ring double 
bond at position 5 (Figure 1-3), catalysed by 5α- and 5β-reductase (Russell et al, 
1994; Palermo et al, 2008).  Dihydro-metabolites are then further reduced at the keto 
group by hepatic 3α-hydroxysteroid dehydrogenases (3α-HSDs) to produce 
tetrahydro-corticosteroids.  Water solubility of these metabolites is enhanced by 
conjugation with glucoronic acid or sulphate, facilitating renal excretion. 
Gas chromatography–tandem mass spectrometry (GC–MS/MS) analysis of 24 hour 
urinary steroid profiles in healthy individuals (Shackleton, 1986; Arlt et al, 2011; 
Baudrand et al, 2011) indicate tetrahydro-corticosteroids account for around two 
thirds of urinary glucocorticoid metabolites, composed of 5αI and 5β-reduced 
metabolites in broadly equal concentrations.  Further reduction of these metabolites 
by 20-hydroxysteroid dehydrogenases (20 HSDs) yields the cortols and cortolones, 
which comprise around one quarter of total urinary glucocorticoid metabolites.  The 
remaining metabolites are produced by pathways other than those described above, 
including hepatic oxidation and hydroxylation reactions. 




In excess, glucocorticoids have a number of adverse effects (Figure 1-4).  This is 
exemplified by Cushing’s syndrome, which occurs either as a result of the 
administration of exogenous glucocorticoids or excess endogenous production.  The 
causes of the latter are an ACTH-producing pituitary adenoma (Cushing’s disease), 
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1.2.2.!Cardiovascular!disease!and!Cushing’s!syndrome!
Among the consequences of overt glucocorticoid excess are a number of metabolic 
abnormalities, including central obesity, hypertension, dyslipidaemia and insulin 
resistance (Figure 1-4), each of which is a major risk factors for cardiovascular 
disease (Hippisley-Cox et al, 2008).  Cardiovascular disease is a major cause of 
premature death in Cushing’s syndrome (Pivonello et al, 2005; Ntali et al, 2013; 
Yaneva et al, 2013).  Study of microvascular dysfunction suggests the severity of 
cardiovascular disease is proportional to the degree of cortisol excess (Fallo et al, 
2013).  Where chronic glucocorticoid excess is induced through exogenous 
administration, cardiovascular disease risk is also increased (Souverain et al, 2004; 
Wei et al, 2004). 
1.2.3.!Endogenous!glucocorticoids!and!metabolic!syndrome!
The clinical features of Cushing’s syndrome share a number of features with the  
‘metabolic syndrome’, a constellation of risk factors for cardiovascular disease 
(Reaven, 1988).  This observation has led to a body of research which implicates 
glucocorticoids in the pathophysiology of cardiovascular disease in the absence of 
overt endogenous glucocorticoid excess or exogenous administration (Walker, 2007).   
Definitions for metabolic syndrome have been devised by a number of national and 
international bodies.  The current definition adopted by the Scottish Intercollegiate 
Guidelines Network (SIGN, 2007) draws upon the recommendations of the 
American Heart Association/National Heart, Lung, and Blood Institute Scientific 
Institute (AHA/NHLBI) (Grundy et al, 2005) and the International Diabetes 
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Federation (IDF) (Alberti et al, 2006) to define metabolic syndrome as any three of 
the following: 
• Increased waist circumference (≥ 102 cm in men and ≥ 88 cm in women; ≥ 
90 cm for Asian men and ≥ 80 cm in Asian women), indicating central 
obesity 
• Elevated fasting plasma triglycerides (≥ 1.7 mM) 
• Decreased plasma HDL cholesterol (< 1.03 mM for men,< 1.29 mM for 
women) 
• Blood pressure above 130/85 mm Hg or active treatment for hypertension 
• Fasting plasma glucose level above 5.6 mM or active treatment for 
hyperglycaemia. 
Although each of these factors is independently associated with cardiovascular risk 
(Stamler et al, 1986; Stamler et al, 1989; Wilson et al, 2008), insulin resistance is 
thought to be central to its pathophysiology (Zimmet et al, 1999).  Research has 
focused on the factors which underlie insulin resistance, including the role of 
glucocorticoid action in metabolic target tissues such as the liver, adipose and 
muscle. 
1.2.4.!Associations!of!cortisol!with!features!of!the!metabolic!syndrome!
The majority of studies investigating associations of endogenous glucocorticoids 
with the metabolic syndrome employ a single (usually morning) measure of plasma 
cortisol.  This has practical advantages compared to urine collections or repeated 
plasma measurements in large population cohorts.  More recently, salivary (Adam et 
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al, 2009) and hair (Meyer et al, 2012) cortisol have been employed as alternative 
biomarkers of glucocorticoid exposure. 
1.2.4.1.!Obesity!
In most studies, morning plasma cortisol is weakly inversely correlated with indices 
of obesity (Phillips et al, 1998a; Walker et al, 2000; Ward et al, 2003; Travison et al, 
2007; Reynolds et al, 2010).  Study of cortisol pharmacokinetics in humans suggests 
this is likely to be due to increased clearance of cortisol in obesity (Lottenberg et al, 
1998), with evidence from rodent models (Livingstone et al, 2000) and human 
urinary steroid profiles (Andrew et al, 1998) suggesting this is a consequence of 
increased activity of 5α-reduction (Russell et al, 1994).  Activation of the HPA axis 
is expected to attenuate any reduction in circulating cortisol concentrations occurring 
due to increased clearance, with a compensatory rise in cortisol production.  
Consistent with this, total urinary glucocorticoid metabolite excretion is increased in 
obesity (Fraser et al, 1999; Reynolds et al, 2001a; Westerbacka et al, 2003).  
Associations of cortisol with obesity are further complicated by the upregulation of 
11β-HSD1 in subcutaneous adipose tissue in obesity (Rask et al, 2001), a finding 
which has provided a therapeutic target to reduce cortisol action in metabolic tissues 
(Hughes et al, 2008).  However, in the presence of an intact HPA axis this 
phenomenon is not expected to influence circulating cortisol concentrations. 
The weak inverse association of cortisol with obesity carries the potential to obscure 
associations of elevated plasma cortisol with other cardiovascular risk factors.  
However, when obesity is adjusted for in multiple regression analyses, elevated 
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cortisol is associated with a number of features of metabolic syndrome, which shall 
be considered in turn.  
1.2.4.2.!Blood!pressure!
In most studies, morning plasma cortisol correlates positively with blood pressure 
(Filipovsky et al, 1996; Phillips et al, 1998b; Walker et al, 2000; Ward et al, 2003), 
although this has not been replicated in all cohorts, perhaps relating to high 
prevalence of antihypertensive use (Reynolds et al, 2010), or the failure to adjust for 
body mass index (Maggio et al, 2006).  Higher blood pressure is also accompanied 
by higher morning salivary cortisol (Oltmanns et al, 2006; Abraham et al, 2013; 
Almadi et al, 2013); while studies of hair cortisol have been inconsistent 
(Manenschijn et al, 2011; O'Brien et al, 2012).  
1.2.4.3.!Dyslipidaemia!
Although the dyslipidaemia that accompanies metabolic syndrome is well 
characterised (section 1.2.3), the effects of cortisol on lipid parameters are less clear.  
In Cushing’s syndrome descriptions of the dyslipidaemia resulting from overt 
glucocorticoid excess are inconsistent (Taskinen et al, 1983; Friedman et al, 1996; 
Colao et al, 1999), reflecting the complex effects of glucocorticoids on lipid 
metabolism (Macfarlane et al, 2008). 
In most studies, no relationship between morning plasma cortisol and HDL 
cholesterol has been found (Walker et al, 2000; Maggio et al, 2006; Reynolds et al, 
2010).  In one study, plasma cortisol was found to positively correlate with HDL 
cholesterol (Varma et al, 1995), and in others inverse associations between HDL 
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cholesterol and free cortisol were found in saliva (Almadi et al, 2013) and urine 
(Fraser et al, 1999).  Triglycerides generally show positive associations with plasma 
cortisol (Phillips et al, 1998a; Walker et al, 2000; Ward et al, 2003), but not in all 
studies (Maggio et al, 2006; Abraham et al, 2013).  Finally, higher total cholesterol 
has also been found to accompany higher plasma cortisol in individuals with 
coronary artery disease (Schwertner et al, 1984) and type 2 diabetes (Reynolds et al, 
2010). 
1.2.4.4.!Insulin!resistance!
A number of studies have demonstrated morning plasma cortisol is positively 
associated with fasting glucose and the Homeostasis Model Assessment - Insulin 
Resistance (HOMA-IR) index of insulin resistance (Phillips et al, 1998b; Ward et al, 
2003; Reynolds et al, 2010).  Similarly, morning salivary cortisol has been found to 
positively associate with fasting blood glucose (Almadi et al, 2013), and diurnal 
salivary cortisol studies have revealed cortisol exposure is elevated in type 2 diabetes 
(Champaneri et al, 2012).  Additionally, hair cortisol has been found to be positively 
associated with glycated haemoglobin in a population-based cohort (Stalder et al, 
2013) and in those with type 2 diabetes (Manenschijn et al, 2013). 
1.2.5.!Associations!of!cortisol!with!cardiovascular!disease!
Evidence from cross-sectional studies suggests these associations between cortisol 
and metabolic syndrome translate into a higher risk of clinical (Reynolds et al, 2010; 
Manenschijn et al, 2013) and subclinical (Matthews et al, 2006) atherosclerotic 
disease.  Because cardiovascular disease is less prevalent than its risk factors, it is 
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likely that many of these studies are not sufficiently powered to characterise 
associations with ‘hard’ end-points.  However, indices of cortisol exposure are 
positively associated with coronary atherosclerosis in elective angiography (Troxler 
et al, 1977) and following myocardial infarction, where they also predict adverse 
myocardial remodelling (Weir et al, 2011).  Additionally, in patients with left 
ventricular failure, higher plasma cortisol is an independent predictor of increased 
mortality (Guder et al, 2007).  It is possible that these findings reflect reverse 
causality, whereby cortisol production increases in response to disease severity.  
Prospective studies are less prone to this bias, and the few such studies which have 
been undertaken do not confirm an association between plasma cortisol and 
ischaemic heart disease (Smith et al, 2005; Phillips et al, 2010; Rod et al, 2010).  
However, these studies have generally failed to include obesity as a confounding 
variable, other than where it has been included as a co-variable with other features of 
metabolic syndrome (Smith et al, 2005).  Additionally, certainty around the estimates 
in these studies is low due to the wide variability in plasma cortisol and relatively 
small number with incident cardiovascular disease. 
1.2.6.!Evidence!of!activation!of!the!HPA!axis!in!metabolic!syndrome!
Accompanying elevated plasma cortisol in metabolic syndrome is evidence of 
dysregulation of the HPA axis (Pasquali et al, 2006).  Tests of HPA axis function 
employed in clinical practice for the detection of overt glucocorticoid excess, such as 
the 1 mg oral dexamethasone suppression test, are usually normal in metabolic 
syndrome (Marin et al, 1992; Stewart et al, 1999; Abraham et al, 2013).  Testing of 
HPA axis suppression using lower doses of dexamethasone has demonstrated subtle 
Scott Mackenzie    PhD thesis, 2015 
 Chapter"1:"Introduction" 16"
dysregulation of the HPA axis (Ljung et al, 1996; Duclos et al, 2001; Reynolds et al, 
2001a), although this finding has not been consistent (Duclos et al, 2005).  However, 
dexamethasone suppression only reflects glucocorticoid receptor mediated negative 
feedback, and fails to test the contribution to suppression of the HPA axis mediated 
by cortisol binding to MR in the hypothalamus and hippocampus (de Kloet et al, 
1998).  The use of a novel test, the Combined Receptor Antagonist Stimulation of the 
HPA axis (CRASH) test, which employs blockade of feedback mediated by both low 
affinity (GR) and high affinity (MR) receptors, demonstrates impaired central 
negative feedback of the HPA axis in obesity (Mattsson et al, 2009).  Additionally, 
dysregulation of central control of the HPA axis is suggested by the finding of 
impaired habituation of plasma cortisol to the stress of repeated sampling (Reynolds 
et al, 2001b).  Furthermore, responsiveness of cortisol to ACTH and CRH is 
increased in abdominal obesity (Pasquali et al, 1996); and the cortisol response to 
wakening is increased (Steptoe et al, 2004).  Compensatory activation of the HPA 
axis in response to increased clearance of cortisol in obesity (section 1.2.4.) might 
partially explain these findings, but does not explain why elevated plasma cortisol 
accompanies other features of metabolic syndrome such as hypertension and insulin 
resistance following adjustment for body mass index. 
1.2.7.!Origins!of!HPA!axis!activation!in!metabolic!syndrome!
A number of hypotheses have been put forward to explain the factors underlying 
chronic activation of the HPA axis in metabolic syndrome.  Genetic factors explain 
variability in stress-responsiveness of the HPA axis to a limited extent (Kirschbaum 
et al, 1992), and initial investigation of environmental factors focused on chronic 
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psychosocial stress (Bjorntorp, 2001).  However, production of cortisol, unlike that 
of adrenomedullary hormones, is elevated in metabolic syndrome, even after 
adjustment for psychosocial factors (Brunner et al, 2002).  Alternatively, events in 
early life may lead to ‘programming’ of the HPA axis resulting in hypercortisolaemia 
in later life.  Low birthweight, reflecting an adverse intrauterine environment, is 
associated with hypercortisolaemia and metabolic syndrome in adulthood (Phillips et 
al, 1998a; Levitt et al, 2000; Reynolds et al, 2001a).  While the mechanisms behind 
these associations have not been firmly established, data from animal models suggest 
that adverse prenatal conditions, accompanied by glucocorticoid excess in utero, 
result in reduced hippocampal GR expression (Levitt et al, 1996), expected to 
increase HPA axis activation; and that glucocorticoids can mediate changes in GR 
expression through epigenetic modification (Weaver et al, 2004).  The extent to 
which early life programming, or alternative, as yet uncharacterised, mechanisms 
account for central ‘resistance’ to the feedback effects of glucocorticoids in 
metabolic syndrome remains to be established.  
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1.3.!Corticosterone!
To date, study of the role of glucocorticoid action and HPA axis function in 
metabolic and cardiovascular disease in humans has focused exclusively on cortisol.  
Little attention has been given to the fact that cortisol is not the only endogenous 
glucocorticoid in humans.  Cortisol production in the human adrenal gland is 
dependent upon 17-hydroxylation of glucocorticoid precursors in the zona 
fasciculata (Figure 1-5).  However, enzymes expressed in the zona fasciculata which 
catalyse the final stages of cortisol biosynthesis, 21-hydroxylation and 
11β-hydroxylation, are also able to act on 17-deoxy glucocorticoid precursors.  As a 
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1.3.1.!Comparative!studies!of!corticosterone!vs!cortisol!
In the well-studied mouse and rat models adrenal 17-hydroxylase is not expressed 
(Slaga et al, 1976; van Weerden et al, 1992), and as a result corticosterone is the 
dominant circulating glucocorticoid.  In most large mammalian species, cortisol is 
the dominant glucocorticoid (Koren et al, 2012), but in some the ratio of 
corticosterone to cortisol is close to one  (Walker et al, 1971; Turner, Jr. et al, 2002), 
and the dominant glucocorticoid may vary depending upon whether the animal 
studied is free-ranging or in captivity (Weiss et al, 1966; Weiss et al, 1970; Oddie et 
al, 1976).  Additionally, in animal studies a considerable shift in relative 
corticosterone and cortisol production has been reported to occur in response to 
ACTH stimulation (Fevold, 1967; Rosenthal et al, 1993; Vera et al, 2012) and stress 
(Vera et al, 2011).  Therefore, modulation of relative cortisol and corticosterone 
production occurs in response to environmental factors, perhaps in some part 
accounting for the wide inter-individual variability in the corticosterone: cortisol 
ratio between individuals which has been noted regardless of the species studied 
(Koren et al, 2012). 
1.3.2.!Adrenal!17αJhydroxylase!
The cytochrome P450 enzyme 17α-hydroxylase (CYP17A1) is a key determinant of 
relative corticosterone and cortisol production.  CYP17A1 is located in chromosome 
10q24.3 (Fan et al, 1992) and is expressed in the gonads and adrenal zona fasciculata 
and reticularis (Missaghian et al 2009).  The enzyme acts in the endoplasmic 
reticulum to transfer two electrons from NADPH via its redox partner, cytochrome 
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P450 reductase (Akhtar et al, 2005).   17-hydroxylase activity is required for the 
synthesis of cortisol from pregnenelone and progesterone (Figure 1-5), but the 
enzyme also catalyses cleavage of the C17-C20 bonds of 17α-hydroxypregnenelone 
and 17α-hydroxyprogesterone, producing dehydroepiandrosterone (DHEA) and 
androstenedione respectively.  In the adrenals, 17-20 lyase activity occurs solely in 
the zona reticularis, and is responsible for increased production of adrenal androgens 
from around 8 years of age during adrenarche (Auchus & Miller 1999). 
A number of factors are involved in the regulation of CYP17A1 activity.  In human 
adrenocortical cell lines, cAMP-responsive sequences have been identified upstream 
of the transcriptional initiation site in CYP17A1, which bind a number of 
transcription factors including Sp1, Sp3 and NF-1C  (Sewer & Waterman, 2003).  
The rate of the lyase reaction is augmented in the presence of the endoplasmic 
reticulum haemprotein cytochrome b5 (Akhtar et al, 2005).  The transcriptional 
regulation of cytochrome b5 in the adrenal is similar to that of CYP17A1 (Huang & 
Miller, 2005).  Finally, post-translational modification of CYP17 by cAMP mediated 
phosphorylation, altered in polycystic ovarian syndrome (Bremner & Miller 2008), is 
a further determinant of  17, 20-lyase activity (Biason-Lauber et al, 2000).  
Mutation in CYP17A1 (Matteson et al, 1986), results in the rare autosomal recessive 
condition 17-hydroxylase deficiency (Costa-Santos et al, 2004).  Affected 
individuals usually present at puberty or early adulthood with sex steroid deficiency 
(Martin et al, 2003), as the maintenance of glucocorticoid production in the form of 
corticosterone rather than cortisol means they do not experience ‘adrenal crisis’ in 
childhood.  The association of polymorphism in this gene with circulating 
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Basal circulating concentrations of corticosterone in humans are around 5-10 % of 
those of cortisol (Table 1-1).  Their reported values vary widely between individuals 
and according to assay methodology.  Early attempts to quantify peripheral venous 
corticosterone and cortisol concentrations generally employed chromatographic 
purification followed by measurement with fluorescence, and were poorly specific 
(Sweat, 1955; Ely et al, 1958).  Specificity was improved with more precise 
chromatographic techniques (Peterson, 1957; Peterson et al, 1960), although the 
large sample volume required limited their practical value. 
The development of radioimmunoassay for corticosterone resulted in improved 
sensitivity, reduced sample volume requirements and the ability to undertake 
repeated measurements on a larger scale.  However, a limited number of studies have 
reported plasma corticosterone concentrations in humans, and the number of subjects 
in each study is small.  In most studies, morning plasma corticosterone 
concentrations are in the region of 10-20 nM, a notable exception being the study 
undertaken by Raubenheimer and colleagues (Raubenheimer et al, 2006), in which 
elevated corticosterone (58.4 ± 9.2 nM) and cortisol (830.4 ± 68.4 nM) were found in 
individuals undergoing lumbar puncture, suggesting a stress response. 
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Interpreting the results of these studies requires knowledge of the cross-reactivity of 
the antibody used in the assay.  This is of particular importance for cross-reactants 
present at high concentrations, such as cortisol, for which cross-reactivity of 2.8 - 7.8 
% has been reported (West et al, 1973; Nabors, Jr. et al, 1974; Nishida et al, 1976).  
In such cases, chromatographic separation of analyte and cross-reactant has been 
employed to minimise assay interference due to cross-reactivity.   
Associations between gender and basal corticosterone concentrations have been 
reported but these have not been consistent (Huther et al, 1970; Nabors, Jr. et al, 
1974; Schoneshofer et al, 1977; Wilens et al, 1984).  In females, concentrations may 
be increased in the luteal phase of the menstrual cycle (Schwartz et al, 1975; 
Schoneshofer et al, 1977), although this may be related to cross reactivity with 
progesterone, which is as high as 44% (Nabors, Jr. et al, 1974). 
Liquid-chromatography mass spectrometry (LC-MS) is a highly sensitive and 
specific technique which has become the gold standard for quantitative steroid 
analysis (Shackleton, 2010).  Measurement of plasma corticosterone by LC-MS in a 
small cohort (Karssen et al, 2001) resulted in measured concentrations that were 






Reference! Gender!(M/F)! Age!(years)! Corticosterone!(B)!nM! Cortisol!(F)!nM! B/F
‡
! n! Time! B!assay!Technique!
Sweat,!1955! ns! ns! 124.1! ±! 14.4! 298.0!±!16.6! 0.416! 21! ns! Fluorometric!method!
Peterson,!1957! 18/12! ns! 31.7! ±! 11.5! 386.2!±!33.1! 0.082! 30! ns! Isotope!dilution/fluorescence!
Ely!et!al,!1958! ns! ns! 86.6! ±! 5.8! 300.7!±!15.1! 0.288! 20! ns!! Fluorometric!method!
Peterson!et!al,!1960! ns! ns! 28.9!(23.1S51.9)!
! ! !
20! ns! Isotope!dilution/fluorescence!
Fraser!et!al,!1968! ns! ns! 19.0!(3.8S66.4)! 270.3!(85.5S557)! 0.067! 29! ns! Double!isotope!assay!
Huther!et!al,!1970!






F! 31.3!±!4.4! 49.7! ±! 6.5! 422.4!±!67.8! 0.118! 10
†
!
Dluhy!et!al,!1972! 8/2! 21S34! 26.3! ±! 3.2! 634.5!±!55.2! 0.041! 10! 0900! Radioimmunoassay!
Newsome,!Jr.!et!al!1972! ns! ns! 11.5! ±! 0.9! 339.3!±!22.1! 0.034! 8! ns! Competitive!protein!binding!




11.4! ±! 1.7! 386!±! 36! 0.030! 15!
0800! Radioimmunoassay!F
1
! 20.4! ±! 2.0! 386!±! 36! 0.053! 9!
F
2
! 16.7! ±! 2.1! 359!±! 21! 0.047! 9!
Meikle!et!al,!1974! ns! 20S55! 13.7! ±! 2.6!















! 15.9! ±! 6.8!




















! 12.7! ±! 1.7!
! !
15!
Kobayashi!et!al,!1979! ns! ns! 6.9! ±! 2.6!









4.4! ±! 0.6! !! !! 10! 1600!
Karssen!et!al,!2001! M! 57!±!1.9! 16.4! ±! 3.1! 350.0!±!81.5! 0.047! 11! ns! LCSMS!
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1.3.3.2.%Regulation%of%corticosterone%production%by%the%HPA%axis%
Like cortisol, circulating corticosterone concentrations peak upon waking and fall 
through the day (Peterson, 1957).  Ultradian pulses are also synchronised with those 
of cortisol (West et al, 1973; Nabors, Jr. et al, 1974; Vagnucci et al, 1974).  Despite 
this synchronicity, cortisol and corticosterone production respond differentially to 
HPA axis signalling.  Under ACTH stimulation, corticosterone shows a consistently 
exaggerated response, with a 2-4 times greater increment (as determined by the ratio 
of stimulated: basal concentrations) in comparison to that of cortisol (Peterson, 1957; 
Peterson et al, 1960; Fraser et al, 1968; Nabors, Jr. et al, 1974; Nishida et al, 1977; 
Ganguly et al, 1977).  Similar findings have been reported following surgical stress 
(Hamanaka et al, 1970), and insulin-induced hypoglycaemia (Fraser et al, 1968).  
Finally, suppression of the HPA axis using the synthetic glucocorticoid agonist 
dexamethasone also results in a rise in the ratio of plasma corticosterone to cortisol 
(Newsome, Jr. et al, 1972; Nishida et al, 1977), perhaps explained by inhibition of 
CYP17 by dexamethasone (Lee et al, 1999). 
1.3.3.3.%Pre=receptor%metabolism%
Cortisol and corticosterone are both metabolised by the 11β-hydroxysteroid 
dehydrogenases (11β-HSDs), which catalyse their interconversion between active 
and inactive forms (section 1.1.4).  Similar to the NAD+-dependent conversion of 
cortisol to cortisone, 11β-HSD2 catalyses the inactivation of corticosterone by 
formation of a keto group at position 11, to produce 11-dehydrocorticosterone 
(Figure 1-6). 
    Scott Mackenzie    PhD thesis, 2015 

























Determination of the Michaelis constant (Km) of human 11β-HSD2 points to the 
enzyme having a greater affinity for corticosterone over cortisol (Figure 1-7 i).  
However, Michaelis-Menten plots generally reveal that at glucocorticoid 
concentrations equivalent to basal concentrations of corticosterone, inactivation of 
both glucocorticoids by 11β-HSD2 proceeds at approximately similar rates.  Under 
ACTH stimulation (section 1.3.3.2), corticosterone might be expected to reach a 
level sufficient to saturate 11β-HSD2, although in most circumstances it appears 
likely that, similar to its effects on cortisol, the enzyme would prevent significant 
corticosterone-mediated MR activation in the distal nephron. 
Activity and directionality of 11β-HSD1 depends on whether intact cells or 
homogenates are studied.  Direct comparison of the reductase activity of the enzyme 
for 11-dehydrocorticosterone and cortisone has been studied in both (Maser et al, 
2002; Arampatzis et al, 2005).  Unlike 11β-HSD2, the Km of 11β-HSD1 for both 
11-keto steroids is within the supraphysiological range, and across the range of 
concentrations studied, production of cortisol exceeds the rate of production of 
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corticosterone for a given concentration of inactive 11-keto substrate (Figure 1-7 ii).  
As such, in tissues where the enzyme is expressed, 11β-HSD1 is likely to amplify 
corticosterone-mediated glucocorticoid signalling to a lesser extent than that of 
cortisol.  Dehydrogenase activity has been studied in liver (Maser et al, 2002), where 
it has been found to be greater for cortisol than for corticosterone, and in the kidney 
(Gong et al, 2008), where little difference was found between the two substrates. 
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Figure%1=7.%Metabolism%of%corticosterone%and%cortisol%by%human%11β=hydroxysteroid%
dehydrogenases%(11β=HSDs)%
Summary( of( studies( comparing( kinetic( properties( of( 11β?HSDs( for( corticosterone( (B)( and(
cortisol((F).( (11β?HSD2((figure(i)(acts(as(a(dehydrogenase,(catalysing(the(conversion(of(the(
active( glucocorticoids( B( and( F( to( inactive( 11?dehydrocorticosterone( (A)( and( cortisone( (E)(
respectively.((11β?HSD1((figure(ii)(acts(predominantly(as(a(reductase,(converting(B(and(F(to(
A( and( E( respectively;( but( also( as( a( dehydrogenase,( catalysing( the( reverse( reactions.((
Modelled( enzyme( kinetics( are( derived( from( data( in( tables( according( to( the(
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ii)%11β=HSD1%
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Circulating concentrations of cortisol and corticosterone are determined by their rates 
of production and clearance (Table 1-2).  Corticosterone production rate has been 
estimated using the principle of isotope dilution, with infusion of [3H]-labelled 
corticosterone, administered as a bolus dose (Peterson et al, 1960), or steady state 
infusion (Huther et al, 1970).  Although these studies were limited by non-specific 
assay methodology, the estimated corticosterone production rate was similar in each 
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determined simultaneously were similar to those of later studies using radio-isotope 
tracers (Zumoff et al, 1974), albeit slightly higher than more recent estimates derived 
from LC-MS analysis of stable isotope tracers (Esteban et al, 1990). 
In comparison to the 10-20 fold difference in circulating concentrations, the 3-4 fold 
difference in production rates points to differential clearance of corticosterone and 
cortisol.  Indeed enhanced clearance of corticosterone relative to cortisol has been 
reported in studies in which radiolabelled isotopes of both glucocorticoids have been 
co-infused at steady state (Huther et al, 1970; Messerli et al, 1976).  More rapid 
clearance of corticosterone is likely to reflect differential affinities of hepatic A-ring 
reductases for the two substrates (Chen et al, 2011) and less efficient regeneration of 
corticosterone by 11β-HSD1 (section 1.3.3.3). More rapid clearance of 
corticosterone accounts at least in part for its shorter half-life in comparison to 
cortisol (Ely et al, 1958; Raubenheimer et al, 2006).  However, it is likely that this is 
also determined by a lower apparent volume of distribution (Vd): following 
administration of equivalent bolus doses (Raubenheimer et al, 2006), the peak 
plasma concentration of corticosterone is approximately 3-fold greater than that of 
cortisol.   
Estimates of half life and volume of distribution in the studies above are derived by 
modelling plasma glucocorticoid concentrations according to a single compartment 
model.  However, when varying doses of corticosterone were infused, 
pharmacokinetic properties were found to vary widely according to the dose 
administered (Peterson et al, 1960), suggesting more complex pharmacokinetic 
modelling is required.  Although a single compartment model was employed by 
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these authors, the data reveal an early rapid decline, which precedes the 
monoexponential phase studied by the authors, suggesting the presence of a second 
compartment (Peterson et al, 1960).  In studies of cortisol pharmacokinetics 
following intravenous bolus administration, there is considerable inter-individual 
variability, and while some have found a single-compartment model best describes 
their data (Bright, 1995; Perogamvros et al, 2011), others suggest a two compartment 
model is more appropriate (Toothaker et al, 1982; Thomson et al, 2007).  The 
presence of a second compartment implies that release of glucocorticoids from 
binding proteins, and subsequent distribution into target tissues, is not instantaneous.  
Corticosterone binds to CBG with an affinity that is high and roughly equal to that of 
cortisol (Stroupe et al, 1978; Dunn et al, 1981).  Where higher doses are infused, and 
proportionately less glucocorticoid expected to be protein-bound, delayed 
equilibration of free hormone from the peripheral compartment to the central 
compartment could explain why ‘pharmacological’ doses of corticosterone (Peterson 
et al, 1960) and cortisol (Toothaker et al, 1982) have a longer half life and higher 













































30! 97! 8! ns! ns! Bolus! Unlabelled! 2!mg/kg! Fluorometric!method! Ely!et!al,!1958!




















































      Scott Mackenzie    PhD thesis, 2015 
 Chapter(1:(Introduction( ( 32(
1.3.3.5.%Receptor%affinities%
Relative binding affinities of corticosterone and cortisol for GR and MR (section 
1.1.4) vary according to the species studied, although MR is consistently reported as 
a high affinity receptor, with a Kd generally < 2.5 nM for both corticosterone and 
cortisol (Veldhuis et al, 1982; Krozowski et al, 1983; Sutanto et al, 1987; Reul et al, 
1990).  In humans, cloned MR has roughly equal affinity for corticosterone and 
cortisol (Kd  ~ = 1.3 nM) (Arriza et al, 1987). 
Limited study has been undertaken comparing the relative binding affinities of 
corticosterone and cortisol for the low affinity GR.  In a comparative study in which 
human foetal lung tissue was studied, GR displayed enhanced binding affinity for the 
dominant glucocorticoid across a range of species, with a binding affinity for cortisol 
1.4 x greater than that of corticosterone in humans (Giannopoulos et al, 1981).  Study 
of mammalian cells transfected with human GR, however, revealed transactivation 
and binding was greater for corticosterone, by a factor of 1.5 and 2.0, respectively 
(Berger et al, 1992).  
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1.4.%Trans4membrane%trafficking%of%corticosterone%and%cortisol%
A further factor that requires consideration when comparing the properties of the 
endogenous glucocorticoids corticosterone and cortisol is their ability to enter the 
cell to reach their principal site of action.  Although glucocorticoids are highly 
lipophilic and likely to readily diffuse across the cell-membrane (Giorgi et al, 1981), 
accumulating evidence suggests active transport of glucocorticoids also occurs, due 
to the action of transmembrane proteins.  This finding is analogous to thyroid 
hormones, for which importers have been discovered relatively recently (Heuer et al, 
2009); however unlike thyroid hormone, active transporters for glucocorticoids 
appear to function exclusively as exporters.  This phenomenon was first reported in 
the late 1960s (Gross et al, 1968), but little-studied until relatively recently.  It 
remains unclear whether the process influences tissue sensitivity to glucocorticoids 
in vivo. 
1.4.1.%ATP4binding%cassette%(ABC)%transporters%
Transport of a substrate against a concentration gradient requires energy, which is 
derived either from coupling its transport with that of an energetically favourable 
substrate (co-transport), or from hydrolysis of adenosine triphosphate (ATP).  
ATP-binding cassette (ABC) transporters are a class of ATP-dependent membrane 
pumps present in all classes of organism (Higgins, 1992; Vasiliou et al, 2009).  The 
49 ABC proteins identified in humans have been classified in sub-families, 
designated A-G, according to phylogenetic analysis and amino acid sequence 
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(Vasiliou et al, 2009).  They include both importers and exporters, and mostly act 
upon lipophilic substrates (Dean et al, 2001). 
ABC proteins comprise two nucleotide-binding domains, which bind and hydrolyse 
ATP, and two trans-membrane domains, which facilitate substrate recognition and 
translocation across the lipid membrane.  Analysis of their molecular architecture 
suggests the pumps operate according to an ‘alternating access’ model (Rees et al, 
2009), with substrate binding resulting in ATP hydrolysis and a conformational 
change from an ‘inward facing’ to an ‘outward facing’ (in the case of an exporter).  
The relative binding affinities for substrate in each conformation are likely to 
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1.4.2.%ABCB1%preferentially%exports%cortisol%over%corticosterone%from%the%central%
nervous%system%
ABCB1, also known as multidrug resistance 1 (MDR1) or P-glycoprotein (Pgp), was 
the first ABC transporter to be characterised, following the discovery of its role in 
anticancer drug resistance (Sugawara et al, 1988).  Evidence from a number of 
sources suggests the protein also plays a role in the transport of glucocorticoids; and 
that this process is of particular relevance in the central nervous system (CNS), 
where it acts as a physiological barrier to the entry of cortisol, but not corticosterone. 
1.4.2.1.%Genetically%modified%mouse%models%
Reduced retention of cortisol in comparison to corticosterone in the rodent brain was 
first reported in the 1970s (McEwen et al, 1976; Pardridge et al, 1979).  Several 
decades later, genetically modified mouse models began to provide insight into the 
role ABC transporters play in glucocorticoid trafficking in the CNS.  In mice, two 
functional isoforms of ABCB1 exist, encoded by Abcb1a and Abcb1b, each with 
differing substrate affinities (Devault et al, 1990). In the most commonly used 
knockout mouse model, the Abcb1a gene is disrupted in isolation.  Study of 
radiolabelled substrate has demonstrated increased CNS uptake of synthetic 
glucocorticoids (Meijer et al, 1998; Karssen et al, 2002) and cortisol, but not 
corticosterone in the Abcb1a (-/-) mouse (Karssen et al, 2001).  This finding has not 
replicated by all investigators (Mason et al, 2012), perhaps related to the use of a 
different strain of mouse, or alternatively to the presence of the ABCB1B isoform in 
the single-knockout mouse.  Findings from the double knockout mouse 
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[Abcb1a/b(-/-)], generally support the concept of ABCB1 specificity for cortisol, 
with little (Uhr et al, 2002) or no (Mason et al, 2008) effect on corticosterone 
transport. 
It is likely that this process of active transport of glucocorticoids from the central 
nervous system occurs at the blood-brain barrier (BBB).  The BBB is formed by the 
endothelial cells that line cerebral microvessels, with a number of adaptations not 
present in endothelium elsewhere, such as the presence of tight junctions, which 
means it forms a selective barrier to maintain neuronal function (Abbott et al, 2006).  
Knockout of Abcb1a in mice results in increased uptake of cortisol and synthetic 
glucocorticoids throughout the brain, but not in tissues unprotected by the BBB, 
including the pituitary gland (Meijer et al, 1998; Mason et al, 2008), liver, testes or 
intestine (Karssen et al, 2002).  Localisation of ABCB1 to the luminal surface of 
brain capillaries confirms its presence at the BBB (Beaulieu et al, 1997), although it 
has also been detected in the murine parenchymal brain tissue including hippocampal 
neurons (Regina et al, 1998; Karssen et al, 2004).  
1.4.2.2.%In#vitro%studies%
Data from in vitro studies complement the above findings from studies in transgenic 
mice.  Study of various endogenous and exogenous glucocorticoids indicates the 
presence of a hydroxyl group at position 17, the sole difference between cortisol and 
corticosterone, is required for a glucocorticoid to act as an ABCB1 substrate 
(Bourgeois et al, 1993; Karssen et al, 2002).  Glucocorticoid-induced transactivation 
in a mouse fibroblast cell line is increased following inhibition of endogenous 
ABCB1 in the presence of cortisol but not corticosterone (Webster et al, 2002).  
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Additionally, transfection of an epithelial cell line with human ABCB1 results in 
polar transport of cortisol but not corticosterone, and inhibition of ABCB1 returns 
cortisol transport to the wild-type state (Karssen et al, 2001).   
1.4.3.%Role%of%ABCB1%in%glucocorticoid%transport%in%humans%
ABCB1 is expressed in a limited number of tissues in humans.  Many of these tissues 
can be grouped by their location in apical membranes of cells facing excretory 
compartments, including those in the small and large bowel, exocrine pancreas, 
hepatic canalicular and biliary epithelium, and brush border of the renal tubules 
(Thiebaut et al, 1987), suggesting ABCB1 may play a role in excretion of toxins in 
epithelial tissue.  However, intestinal glucocorticoid transport may also be affected 
by ABCB1 activity, with increased expression of ABCB1 associated with a poorer 
response to glucocorticoid therapy in inflammatory bowel disease (Farrell et al, 
2000).  
In endothelial tissue, ABCB1 is generally not detected (Thiebaut et al, 1987; 
Sugawara et al, 1990).  However, it is present in the adrenal gland, implying a 
possible role in glucocorticoid efflux, the blood-testes barrier, and at the BBB.  
ABCB1 is present in the human BBB from early gestation (Schumacher et al, 1997; 
Daood et al, 2008).  In infancy and adulthood, the protein is present in capillary 
endothelial cells at BBB sites but not in vessels from other tissues, including the 
reproductive system (other than testes), stomach, colon, kidney, lungs and placenta 
(Cordon-Cardo et al, 1989; Jette et al, 1993).  Evidence that the transporter is 
functional at the BBB in humans comes from the finding that administration of the 
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ABCB1 inhibitors cyclosporin and tariquidar increase penetration of the 
radiolabelled ABCB1 substrate ([11C]-verapamil) in the brain and have no effect in 
areas outside the BBB (Eyal et al, 2010; Bauer et al, 2012). 
The finding that the BBB is a major site of ABCB1 activity, together with data from 
murine models and in vitro studies which suggest the protein exports cortisol but not 
corticosterone, have led to investigation of whether the corticosterone/cortisol ratio 
in the human CNS is higher than the corresponding plasma ratio.  Data from non-
human primates provided some support for this hypothesis, with evidence that 
corticosterone is preferentially retained over the ‘dominant’ glucocorticoid cortisol in 
the hippocampus (Gerlach et al, 1976).  In human post-mortem brain tissue, Karssen 
and co-workers (Karssen et al, 2001) noted the corticosterone/cortisol ratio was 
approximately 5-fold greater than the plasma ratio in samples from age-matched 
controls.  Similarly, Raubenheimer and co-workers (Raubenheimer et al, 2006), 
studying individuals undergoing lumbar puncture, found the corticosterone/cortisol 
ratio in cerebrospinal fluid (CSF) was 5.6 fold greater than the ratio from paired 
plasma samples.  Although findings from the latter study reflect transport at the 
blood-CSF barrier, which does not constitute a blood-CNS barrier (Pardridge, 2011), 
ABCB1 is expressed at the blood-CSF barrier (Gazzin et al, 2008), meaning it is 
plausible that the transporter explains relative accumulation of corticosterone over 
cortisol in the CSF.  
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1.4.4.%Selective%export%of%corticosterone%by%an%alternative%transporter%outside%the%
CNS%
Evidence suggests that while ABCB1 functions as a cortisol exporter in the CNS, an 
alternative transporter, ABCC1 (previously referred to as MRP1) exports 
corticosterone over cortisol in peripheral tissues.  In contrast to their findings for 
ABCB1, Webster and colleagues (Webster et al, 2002) noted that glucocorticoid-
induced transactivation in a mouse fibroblast cell line is increased following 
inhibition of endogenous ABCC1 in the presence of corticosterone but not cortisol.  
Unlike ABCB1, ABCC1 is not expressed in the human BBB (Daood et al, 2008) but 
is expressed in adipose tissue (Figure 1-9, supervisor’s unpublished data).  %
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discussed above determine glucocorticoid access to their cytosolic receptors and thus 
influence tissue sensitivity to their action. 
1.4.5.1.%The%HPA%axis%
Few robust markers for glucocorticoid action within the CNS exist, but measurement 
of activity of the HPA axis reflects CNS glucocorticoid action in the hypothalamus 
and hippocampus (in addition to that in the pituitary gland, outside the CNS).  
Activity of ABCB1 at the BBB would be expected to reduce cortisol-mediated 
feedback in the hypothalamus and hippocampus and result in activation of the HPA 
axis.  Because of the differential expression of high and low affinity corticosteroid 
receptors in feedback centres protected or unprotected by the BBB, respectively 
(Reul et al, 1985; de Kloet et al, 1998), the magnitude of such effects may be 
dependent upon prevailing plasma glucocorticoid concentrations. 
In the [Abcb1a/b (-/-)] mouse, plasma corticosterone is reduced (Muller et al, 2003; 
Yau et al, 2007) alongside plasma ACTH concentration and hypothalamic CRH 
mRNA (Muller et al, 2003), consistent with at least a small effect of ABCB1 on 
corticosterone transport as previously described (Uhr et al, 2002).  ABCB1-mediated 
cortisol transport is more difficult to assess in corticosterone-predominant species, 
and it is not known from transgenic mouse studies whether preferential transport of 
cortisol over corticosterone occurs.  However, some insight into ABCB1 transport in 
cortisol-predominant species can be gained from the study of Collie dogs, of which 
approximately one-third to one-half are homozygous for a deletion mutation in 
ABCB1 associated with reduced transporter function (Mealey et al, 2002; Hugnet et 
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al, 2004), accompanied by lower basal and stimulated cortisol concentrations and 
enhanced ACTH suppression to dexamethasone (Mealey et al, 2007).  Similarly, in 
humans, a polymorphism in ABCB1, 3435 C>T (rs1045642), which reduces ABCB1 
mRNA stability (Wang et al, 2005)  has been associated with reduced serum cortisol 
concentration (Nakamura et al, 2009).  
Preferential transport of cortisol would mean that corticosterone might be expected 
to ‘bypass’ the effect of ABCB1 at the BBB and exert a greater effect on the HPA 
axis than would be predicted by its low plasma concentration relative to cortisol.  
Raubenheimer and colleagues (Raubenheimer et al, 2006) assessed this in healthy 
human volunteers by measurement of ACTH following an intravenous bolus of 
cortisol or corticosterone, after suppression of endogenous glucocorticoids with 
metyrapone.  Although no significant difference in ACTH suppression between the 
two steroids was found, direct comparison was difficult due to the administration of 
bolus doses of glucocorticoids, which meant subjects did not attain equivalent 
plasma glucocorticoid concentrations.  Additionally, because metyrapone induces 
accumulation of intermediate steroids such as 11-deoxycorticosterone (Steiner et al, 
1994), which are potent MR agonists (Arriza et al, 1987), its effects on the HPA axis 
are uncertain and potentially confounding. 
1.4.5.2.%Metabolic%syndrome%
In metabolic syndrome, resistance to the negative feedback actions of 
glucocorticoids is seen, for reasons that have not been fully characterised (section 
1.2.7).  Despite this, phenotypic changes consistent with chronic glucocorticoid 
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excess continue to be displayed in peripheral tissues.  In principle, tissue-specific 
expression of ABC transporters may go some way to explain this apparent paradox.  
Activity of ABCB1 at the BBB may limit access of cortisol to the hypothalamus and 
hippocampus.  Differential substrate affinities may mean that this physiological 
barrier is not present for corticosterone. A relatively low plasma corticosterone may 
therefore drive activation of the HPA axis, increasing risk of metabolic syndrome.  
Importantly, the presence of alternative transporters in peripheral tissues (eg. ABCC1 
in adipose), would result in ongoing sensitivity to cortisol excess while 
simultaneously limiting their response to variations in plasma corticosterone. 
1.4.5.3.%Adrenal%insufficiency%
Disproportionate CNS sensitivity to corticosterone over cortisol may also be of 
clinical relevance in adrenal insufficiency.  Adrenal insufficiency is categorised into 
two types, according to the site of pathology.  In primary adrenal insufficiency 
(Addison’s disease), deficiency of glucocorticoids and mineralocorticoids is caused 
by a disease process directly affected the adrenal gland: most commonly 
autoimmune disease, but also including infective, malignant or infiltrative pathology 
(Charmandari et al, 2014).  A further form of primary adrenal insufficiency, 
considered a separate entity to Addison’s disease but sharing many similarities, is 
congenital adrenal hyperplasia (CAH).  CAH encompasses a wide range of clinical 
conditions, each resulting from a congenital defect in adrenal steroidogenesis 
(Speiser et al, 2003).  A shared feature of all forms of CAH, however, is activation of 
the HPA axis due to glucocorticoid deficiency, often causing clinically problematic 
adrenal androgen excess.  Secondary adrenal insufficiency is characterised by ACTH 
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insufficiency, most commonly due to suppression of the HPA axis following chronic 
glucocorticoid therapy, or structural disease of the hypothalamus and/or pituitary. 
Individuals with adrenal insufficiency are unable to mount an adequate stress 
response to illness or injury, and in these situations a potentially fatal ‘adrenal crisis’ 
results from inadequate glucocorticoid and mineralocorticoid replacement.  
Untreated adrenal insufficiency is also accompanied by a number of non-specific 
symptoms, as recognised by Thomas Addison in 1855 in his original description of 
the condition: “anaemia, general languor and debility, remarkable weakness of the 
heart's action, irritability of the stomach, and a peculiar change of colour in the skin.” 
(Addison, 1855).  Individuals with Addison’s disease are generally treated with 15-
25 mg cortisol (hydrocortisone)/day (Hahner et al, 2009), and frequently develop 
non-specific symptoms at lower doses, even though in healthy individuals, normal 
cortisol output is as low as 10 mg/day (Esteban et al, 1991).  Despite current 
treatment strategies, individuals with Addison’s disease are at increased risk of mood 
disorders (Thomsen et al, 2006) and report impaired subjective health status (Lovas 
et al, 2002), even after exclusion of those with co-morbidities (Hahner et al, 2007).  
Non-specific CNS symptoms may reflect deficient or excess glucocorticoid action in 
the brain, or be related to physical manifestations of adrenal insufficiency and its 
treatment.  However, evidence that current replacement strategies inadequately 
replace glucocorticoids in the CNS comes from a UK survey of treated CAH patients 
(Arlt et al, 2010), in whom androgen levels are generally poorly controlled, 
reflecting ACTH excess and inadequate glucocorticoid signalling in the feedback 
centres of the CNS. 
      Scott Mackenzie    PhD thesis, 2015 
 Chapter(1:(Introduction( ( 45(
In the peripheral tissues, adequate biomarkers of glucocorticoid action do not exist.  
However, in the above survey, patients were noted to have an adverse metabolic 
profile, consistent with peripheral glucocorticoid excess.  This may also underlie 
reduced bone mineral density in Addison’s disease (Lovas et al, 2009; Bjornsdottir et 
al, 2011).  Moreover, in patients with primary or secondary adrenal insufficiency, 
cardiovascular mortality is increased (Bergthorsdottir et al, 2006; Bensing et al, 
2008), and in patients with secondary adrenal insufficiency, replacement with >20 
mg cortisol/day is associated with features of metabolic syndrome (Filipsson et al, 
2006).   
The limitations of currently available therapies for adrenal insufficiency are widely 
acknowledged (Debono et al, 2009; Forss et al, 2012; Grossman et al, 2013).  It is 
possible that this is due to difficulty mimicking the normal ultradian and circadian 
profiles of plasma glucocorticoid concentrations due to the pharmacokinetic 
properties of oral glucocorticoids in use.  Varying the dosage and timing of these 
preparations has little effect on subjective health status (Bleicken et al, 2010); instead 
focus has shifted to novel therapies aimed at achieving a more physiological 
circadian profile, including subcutaneous hydrocortisone infusion (Oksnes et al, 
2014), modified-release (Verma et al, 2010) and dual-release (Johannsson et al, 
2009) oral preparations. 
In common with preparations currently used in clinical practice, novel therapies have 
been developed under the assumption that a single glucocorticoid is of importance.  
Limited ability of cortisol and synthetic glucocorticoids to penetrate the CNS due to 
action of ABCB1 may account for central symptoms of glucocorticoid deficiency in 
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treated hypoadrenal patients who continue to display features of glucocorticoid 
sensitivity in peripheral tissues.  Replacing deficient corticosterone may optimise 
CNS glucocorticoid action in this patient group and enable a reduction in cortisol 
dose to better represent normal physiology. 
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1.5.%Hypotheses%
• Physiological negative feedback suppression of ACTH is disproportionately 
sensitive to corticosterone, while adipose tissue is disproportionately 
sensitive to cortisol. 
• In metabolic syndrome, negative feedback suppression of the HPA axis is 
pathologically impaired as a result of low plasma corticosterone. 
• In adrenal insufficiency, replacement of corticosterone in addition to cortisol 
optimises glucocorticoid activity in the CNS. 
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1.6.%Aims%
1. To validate an assay for plasma corticosterone using liquid chromatography-
tandem mass spectrometry (LC-MS/MS) 
2. To validate the stable isotope 2,2,4,6,6,17α,21,21-[2H]8-corticosterone as a 
tracer for corticosterone 
3. To determine the production rates and clearance of corticosterone in healthy 
volunteers using the principle of isotope dilution 
4. To compare cortisol and corticosterone effects on the HPA axis and adipose 
tissue in vivo 
5. To test for ‘relative corticosterone deficiency’ in metabolic syndrome 
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Chapter%2:%Materials%and%methods




Mettler Toledo MT5 microbalance (Mettler Instrumente Ag, Zürich, Switzerland) 
b) Centrifuges 
• Hepatic cytosol preparation (section 4.2.1): Optima TLX Ultracentrifuge, 
(Beckman Coulter, High Wycombe, UK)  
• D8-corticosterone LC-MS/MS (Chapter 5): Eppendorf centrifuge 5810R 
(Cambridge, UK) 
• Clinical sample processing (Chapter 6): Sigma 4K15 centrifuge (Münich, 
Germany) 
c) Homogeniser  
Pro200 homogeniser (Pro scientific Inc, Oxford, CT) 
d) Microplate shaker 
iEMS Incubator/shake (Thermo Fisher Scientific Inc, Waltham, MA) 
e) Microplate washer 
Anthos aw1 automatic plate washer (Anthos Labtec systems, Salzburg, Austria) 
f) Microplate reader 
Optimax tuneable microplate reader (Molecular Devices, Sunnyvale, Ca) 
g) Nitrogen dry-block 
Dri-Block® DB3A sample concentrator (Techne, Staffordshire, UK)  
h) Ovens 
• Memmert D88 oven (Memmert, Nürnberg, Germany) 
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• Hybaid mini oven (VWR International, Radnor, PA) 
i) pH meter 
Jenway 3510 pH meter (Bibby Scientific Ltd, Stone, UK) 
j) Shaking water bath 
OLS 200 Shaking water bath (Grant Instruments, Cambridge, UK) 
k) Vortex  
Rotamixer (Hook and Tucker Instruments, Longfield, UK) 
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2.2.%Materials%
All reagents were obtained from Sigma Aldrich (St. Louis, MO) or VWR 
International (Radnor, PA) unless otherwise stated.  All solvents were glass distilled 
HPLC grade from Thermo Fisher Scientific Inc (Waltham, MA). 
Room temperature is defined as a temperature between 18 and 22 °C. 
2.2.1.%Steroids%
2.2.1.1.%Unlabelled%steroids%
Corticosterone, epi-corticosterone, 11-dehydrocorticosterone, 11-
deoxycorticosterone, cortisol, progesterone and dehydroepiandrosterone sulphate 
(DHEAS).  Each of these steroids were weighed and dissolved in methanol (final 
concentration 1 mg/ml) and stored at -20 °C.  
2.2.1.2.%Deuterium%labelled%steroids%
Deuterium labelled steroids were obtained from Cambridge Isotope Laboratories 
(Andover MA).  Chemical and isotopic purity were assessed by the manufacturer.  
For in vitro studies, these were weighed and dissolved in methanol (final 
concentration 1 mg/ml) and stored at -20 °C.  Preparation of the steroids for their use 
as stable isotope tracers in clinical studies is described in Chapter 6.    
a) D8-corticosterone 
Corticosterone (2, 2, 4, 6, 6, 17α, 21, 21-[2H]8, 98%) 
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b) D4-cortisol 
Cortisol (9, 11, 12, 12-[2H]4, 98%) 
2.2.1.3.%Tritium%labelled%steroids%
Tritium labelled steroids were obtained at the following concentrations (in 
ethanol) and stored at -20 °C. 
a) Corticosterone [1, 2, 6, 7-3H(N)] 
1 mCi/ml, 78.1 Ci/mmol 
b) [3H]4-11-dehydrocorticosterone 
1 mCi/ml, 78.1 Ci/mmol 
(a) and (b) were obtained from American Radiolabelled Chemicals Inc (St 
Louis, MO). 
c) Cortisol [1, 2, 6, 7-3H(N)] 
1 mCi/ml, 95.4 Ci/mmol, Perkin Elmer, Boston, MA 
d) Cortisone [1, 2, 6, 7-3H(N)] 
1 mCi/ml, 51.0 Ci/mmol, Amersham Radiochemicals, Cardiff, UK 
2.2.1.4.%125I%labelled%corticosterone%conjugate%
MP Biomedicals, Cambridge, UK (supplied at 1500-200 µCi/µg).  Diluted 
according to manufacturer’s instructions in borate buffer. 
2.2.2.%Commonly%used%buffers%
a) Potassium phosphate buffer 
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50 mM potassium dihydrogen phosphate (KH2PO4), 1 mM 
ethylenediaminetetraacetate (EDTA) dissolved in distilled water, adjusted to 
pH 7.4 using potassium hydroxide (1 M), and stored at 4 ° C. 
b) Borate buffer 
Boric acid (8.25 g), sodium hydroxide (2.7 g) was dissolved in distilled water 
(1 l) adjusted to pH 7.5. Bovine serum albumin (5 g; fraction V) was added 
and buffer stored at -20 °C in aliquots of 50 ml. 
c) Sodium acetate buffer 
Sodium acetate (0.2 M) dissolved in distilled water, adjusted to pH 4.6 using 
glacial acetic acid, and stored at 4 °C. 
2.2.3.%Drugs%and%reagents%for%corticosterone%radioimmunoassay%
a) Scintillation proximity assay (SPA) beads 
Anti-sheep (yttrium silicate) 500 mg, Perkin Elmer (Buckinghamshire, UK) 
were dissolved in borate buffer (100 ml), stored (-20 °C) in aliquots (5 ml). 
b) Anti-corticosterone antibody 
This was a kind gift from Dr Chris Kenyon (Edinburgh, UK) and was raised 
in sheep.  Antibody was diluted (1 in 800) in borate buffer and stored (-20 
°C) in aliquots (150 µl).  After defrosting, it was diluted (1 in 100) in borate 
buffer to achieve a working dilution (1 in 80 000). 
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2.2.4.%Drugs%and%reagents%for%in#vitro%assays%
Reagents for in vitro assays were obtained from Sigma Aldrich (St. Louis, MO). 
a) Glucose-6-phosphate dehydrogenase (G6P-DH), from baker’s yeast 
(S.cerevisiae). 
Supplied as crystalline suspension in 3.2 M (NH4)2SO4 solution, pH 7.0, 
containing 250 units.  Diluted in potassium phosphate buffer (250 µl) and 
stored (-4 °C) in aliquots (10-20 units). 
b) D-glucose-6-phosphate dipotassium salt hydrate (G6P).  Stored at -20 °C. 
c) β-Nicotinamide adenine dinucleotide 2’-phosphate reduced tetrasodium salt 
hydrate (NADPH).  Stored at -20 °C. 
2.2.5.%Drugs%and%reagents%for%cell%culture%
All cell culture reagents were obtained from Lonza (Slough, UK). 
a) Dulbecco’s Modified Eagle’s Medium 
Containing heat-inactivated fetal calf serum (FCS) (10% v/v), glucose 4.5 g/l, 
glutamine (2 mM) and penicillin (1% w/v)/streptomycin (1% w/v) 
b) Phosphate-buffered saline (PBS) 
Dulbecco’s PBS with calcium chloride dihydrate (0.884 mM) and magnesium 
chloride hexahydrate (0.492 mM) 
c) Trypsin /EDTA 
Trypsin 1:250 (500 mg/l), tetrasodium EDTA (200 mg/l) 
d) Poly-D-lysine (PDL) hydrobromide (0.1 mg/ml). 
This was stored at -20 °C in aliquots of 5 ml. 
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e) Charcoal stripped serum 
Foetal calf serum (FCS; 500 ml) and dextran coated charcoal (5 g) were 
mixed (~16 hours, 4 °C).  The solution was filtered through a 250 µm filter 
funnel and separated into aliquots and stored at -20 °C until use. 
2.2.6.%Human%serum%and%hepatic%cytosol%
a) Human serum, steroid stripped 
This was obtained from TCS Biosciences (Buckingham, UK) and comprises 
pooled sterile filtered serum derived from plasma.  Serum was divided into 
aliquots (5 ml) and stored (-20 °C). 
b) Human hepatic cytosol 
Pooled cytosol (~20 mg per ml) prepared from adult human donors.  Storage 
(-80 °C) was in aliquots (100 µl) of undiluted cytosol which were thawed 
rapidly in a water bath (37 °C) then kept on ice before use. 
2.2.7.%Derivatisation%agents%for%GC4MS%
a) Mobile phase: 98 % cyclohexane (v/v), 1 % hexamethyldisilazane (v/v), 1 % 
pyridine (v/v) 
b) Lipidex 5000 (Packard, Pangbourne, UK): Lipidex 5000 was suspended in 
methanol, and filtered.  Methanol was discarded and beads re-suspended in 
mobile phase (a) (200 ml) and stored, protected from light, at room 
temperature. 
c) Methoxyamine in pyridine: methoxyamine hydrochloride in pyridine (2 % 
w/v) 
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d) Trimethylsilylimidazole (TMSI): undiluted 
2.2.8.%Solutions%and%solvents%for%clinical%studies%
a) Saline (NaCl) 
Sodium chloride (0.9% w/v) (Baxter, Newbury, UK), containing 77 
mmol/500 ml (154 mM) sodium and 77 mmol/500 ml (154 mM) chloride 
b) Dehydrated alcohol BP 
Ethanol (100% v/v) (Martindale, Brentwood, UK) 
c) DEPC (Diethylpyrocarbonate) water 
DEPC (10 drops) was added to distilled water (1 l).  This was mixed and 
allowed to stand (room temperature) for 24 hours before autoclaving.  
Storage was at room temperature. 





Plasma corticosterone levels were measured using an in-house RIA (Al-Dujaili et al, 
1981) modified for microtiter plate scintillation proximity assay (SPA).  Plasma was 
diluted 1 in 10 in borate buffer and stored (-20 °C) prior to assay.  Standard solutions 
(0 – 80 nM) were prepared in borate buffer.  Samples, standards, borate buffer and 
SPA beads were defrosted on wet ice and mixed.  Sample or standard (10 µl) was 
pipetted in duplicate into a 96 well plate (Thermo Fisher Scientific Inc, Waltham, 
MA).  Samples were heat denatured (70 °C, 30 mins) to dissociate glucocorticoids 
from CBG, and then allowed to cool to room temperature.  Sheep anti-corticosterone 
antibody (25 µl) and SPA beads (25 µl) were added under constant magnetic stirring.  
Corticosterone [125I] conjugate (25 µl) was added and plates were sealed, mixed and 
incubated (10 hours, room temperature).  Radioactive emissions were counted by 
liquid scintillation (Wallac al1450 Microbeta Plus Liquid Scintillation Counter, 
PerkinElmer, Waltham, MA). 
2.3.1.2.%Data%Analysis%
Radioactive counts from standards were fitted to a 2 parameter logistic inverse 
sigmoid curve (Assay Zap, Version 3.1, Biosoft, Cambridge, UK).  To assess 
cross-reactivity, IC50 was calculated by determining a four-parameter dose-response 
curve (log (inhibitor) vs. Response – variable slope) using a least squares (ordinary) 
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fit (GraphPad Prism, Version 5.01, GraphPad Software Inc, La Jolla CA).  The best-
fit values of log IC50 were compared using the extra sum-of-squares F test.  Data 
were accepted if the co-efficient of variation (CV) between duplicates was less than 
15 %. 
2.3.1.3.%Cross4reactivity%
Cross reactivity of the assay was determined for steroids chosen on the basis of a 
similar molecular structure to corticosterone (eg. 11-deoxycorticosterone), relative 
abundance in human plasma (eg. DHEAS), or presence of exogenous steroid in 
plasma samples (dexamethasone; section 3.2.1.3).  The assay was performed for 
corticosterone solutions of known concentration (0-80 nM) to create a standard 
curve, which was compared to the standard curve produced from cross-reactants at 
concentrations of 100 nM, 1 µM and 10 µM (Figure 2-1).  Cross-reactivity was 
calculated by determining the ratio of IC-50 for each cross-reactant over the 
corresponding IC-50 for corticosterone. 
Cross-reactivity for all glucocorticoids (Figure 2-1) was less than 1 %, with the 
exception of 11-deoxycorticosterone (2.6 %) and dehydrocorticosterone (1.3 %).  
Importantly, both compounds normally circulate at less than 1 nM (Morris et al, 
1953; Greenspan et al, 2001); indicating cross-reactivity is unlikely to impact 
significantly on estimates of serum corticosterone produced in the assay. 
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Figure%241.%Corticosterone%radioimmunoassay:%cross%reactivity%
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Plasma ACTH was measured using a two-site ELISA (IBL International, Hamburg, 
Germany).  All reagents were stored at 2-8 °C unless otherwise stated, and allowed to 
come to room temperature before each assay.  Assay standards and controls were 
reconstituted by adding deionised water (2 ml) to each standard and control bottle.  
Reconstituted standards and controls were stored (-10 °C) for up to 3 freeze-thaw 
cycles.  Antibody to the N-terminal of human ACTH conjugated to horseradish 
peroxidase (HRP) was freshly diluted 1: 21 in supplied diluent for each assay.  Wash 
buffer concentrate (30 ml) was diluted by adding deionised water (870 ml) and 
stored (room temperature).   
For each patient, samples from both study visits were assayed together.  Assay 
standards (0-89 pmol/l, controls and samples (200 µl) were added in duplicate to a 
96-well microtiter plate coated with antibody to the C-terminal of human ACTH.  
Diluted HRP conjugated antibody (25 µl) was added, forming a “sandwich” of 
solid-phase polyclonal antibody-human ACTH-HRP conjugated monoclonal 
antibody.  Plates were sealed, protected from light and incubated on a plate shaker 
(400 rpm, room temperature, 4 hours).  Unbound antibodies and buffer matrix were 
then removed by washing 5 times with working wash solution (350 µl).  For the 
detection of the immunocomplex, tetramethylbenzidine (TMB) substrate solution 
(200 µl) was added to each well, plates were protected from light and incubated 
(static, room-temperature, 20 minutes).  The HRP/TMB reaction was terminated with 
TMB stop solution (50 µl), plates were gently mixed and absorbance was read (450 
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nm; reference filter 650 nm) in a spectrophotometric microtiter plate reader.  A 
standard curve was generated by plotting absorbance against plasma ACTH 
concentration for each standard by fitting to a 4-parameter curve (SoftMax Pro, 
Sunnyvale, Ca). 
Intra-assay CV, as assessed by measurement of ACTH concentration in supplied 
controls in n = 8 assays, using mean results of duplicates in each assay, was 2.6 % ± 
0.8 % and 4.2 % ± 1.1 % at 31.7 and 322 pg/ml respectively (n = 8).  Inter-assay CV 
was 12.8 % at 7.0 pmol/L and 6.1 % at 70.9 pmol/L.  Mean accuracy at 70.9 pmol/L 
was 97.3 % (range 88.2 % - 105.7 %). 
2.3.3.%Quantification%of%serum%insulin%by%ELISA%
Serum insulin was measured using a two-site ELISA (DRG Diagnostics, Marburg, 
Germany).  All reagents were stored at 2-8 °C and allowed to come to room 
temperature before each assay.  Peroxidase conjugated mouse monoclonal 
anti-insulin antibody was freshly diluted 1: 11 in supplied diluent for each assay.  
Wash buffer concentrate (50 ml) was diluted by adding deionised water (1000 ml).  
Assay standards containing recombinant human insulin (0 - 20 mU/l) and samples 
(25 µl) were added in singlicate to wells of a microtiter plate coated with mouse 
monoclonal anti-insulin antibody.  Diluted peroxidase conjugated antibody (100 µl) 
was added.  Plates were sealed, protected from light and incubated on a plate shaker 
(900 rpm, room temperature, 1 hour).  Unbound antibodies and buffer matrix were 
then removed by washing 5 times with working wash solution (350 µl).  TMB 
substrate solution (200 µl) was added to each well, and plates were incubated (static, 
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room-temperature, 30 minutes).  TMB stop solution (0.5 M H2SO4, 50 µl) was 
added, plates were gently mixed and absorbance read (450 nm) in a 
spectrophotometric microtiter plate reader.  A standard curve was generated by 
plotting absorbance against serum insulin concentration for each standard using 
cubic spline regression (SoftMax Pro, Sunnyvale, Ca). 
2.3.4.%Quantification%of%serum%glucose%by%colorimetric%assay%
Serum glucose was measured by colorimetric assay (Cayman Chemical, Ann Arbor, 
MI).  Sodium phosphate assay buffer concentrate (250 mM, pH 7.2) was diluted 1: 5 
in deionised water and stored (2-8 °C).  Remaining assay reagents were stored at -20 
°C.  Reagents and samples were placed on ice during assay preparation.  Serum 
samples were diluted 1:5 in assay buffer and mixed.  Glucose standards (0 - 1.39 
mM) were prepared by dilution of glucose stock (5.55 mM) in assay buffer.  Glucose 
colorimetric enzyme mixture was reconstituted with 6 ml assay buffer and mixed.  
Assay buffer (85 µl) was added to each of the wells of a 96-well microtiter plate.  
Standards and diluted samples (15 µl) were added, followed by working colorimetric 
enzyme mixture (100 µl), containing glucose oxidase, which undergoes flavin 
adenine dinucleotide (FAD) dependent reduction when incubated with glucose.  The 
plate was covered and incubated (room temperature, 10 mins).  Regeneration of 
glucose oxidase by oxidation results in the formation of hydrogen peroxide, which 
subsequently reacts with 3,5-dichloro-2-hydroxybenzenesulfonic acid and 
4-aminoantipyrine, catalysed by HRP, to generate a pink dye.  After gentle mixing, 
absorbance was read (500 nm) in a spectrophotometric microtiter plate reader and 
serum glucose was quantified from a standard curve generated by linear regression 
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analysis of absorbance (adjusted for zero standard) plotted against glucose 
concentration in standards. 
2.3.5.%Quantification%of%plasma%non4esterified%fatty%acids%by%colorimetric%assay%
Plasma non-esterified fatty acids (NEFAs) were quantified by colorimetric assay 
(Zen-Bio, NC).  Standards (0 - 333 µM, 50 µl), prepared by serial dilution in 
supplied dilution buffer, were added to the wells of a 96-well plate.  Plasma (5 µl) 
was added to empty wells and diluted by adding dilution buffer (50 µl).  
Reconstituted reagent A (100 µl), containing acyl-CoA synthetase, was added to 
each well.  After gently mixing, the plate was incubated (37 °C, 10 minutes) to 
produce fatty acyl-CoA thiol esters, which react with oxygen in the presence of 
acyl-CoA oxidase to produce hydrogen peroxide.  Reconstituted reagent B (50 µl), 
containing peroxidase, was then added to each well, allowing the oxidative 
condensation of 3-methyl-N-ethyl-N-(β-hydroxyethyl)-aniline with 
4-aminoantipyrine to form a purple product.  After gently mixing, the plate was 
incubated (37 °C, 10 minutes) then allowed to equilibrate (room temperature, 5 
minutes).  The optical density of each well was measured (550 nm) and plasma 
NEFA concentration calculated from a standard curve generated by linear regression 
analysis of absorbance (adjusted for zero standard) plotted against NEFA 
concentration in standards. 
2.3.6.%Quantification%of%plasma%glycerol%by%colorimetric%assay%
Plasma glycerol was quantified by colorimetric detection of the product of a coupled 
enzyme reaction involving glycerol kinase and glycerol phosphate oxidase 
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(Sigma-Aldrich; St. Louis, MO).  Reagents (stored at -20 °C) were allowed to come 
to room temperature, with the exception of enzyme mix, which was kept on ice until 
required.  Standards (0 - 1.0 mM; in deionised water) and samples (10 µl) were 
added to the wells of a 96-well plate.  Master reaction mix, containing assay buffer, 
enzyme mix, ATP, and dye reagent (100: 2: 1:1 v/v) was added (100 µl) to each well.  
Plates were incubated, protected from light, in a microplate shaker (37 °C; 400 rpm; 
20 minutes).  Absorbance was measured (570 nm) and plasma glycerol concentration 
calculated from a standard curve generated by linear regression analysis of 





Steroids in urine (20 ml) or water (containing known amounts of steroids), both 
containing internal standard (5 µg epi-cortisol, 30 µg epi-tetrahydrocortisol, 30 µg 
epi-tetrahydrocorticosterone), were retained on conditioned Sep-Pak C18 columns 
(section 4.2.2.3) and steroids were eluted in methanol (2 ml).  Glucocorticoid 
conjugates were hydrolysed by incubating (37 °C; 48 hours) with β-glucuronidase 
(Helix pomatia, Type H-2, 85 000 units/ml; 100 µl) in sodium acetate buffer (2 ml).  
Steroids were retained from hydrolysates by passing through conditioned Sep-Pak 
C18 columns as above, and the eluate reduced to dryness under OFN (60 ºC).  
Steroidal extracts were re-constituted in water (200 µl), re-extracted with ethyl 
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acetate (2 ml) and the organic layer dried (OFN, 60 ºC) in glass Reacti-vials 
(Thermo-Scientific Inc, Waltham, MA). 
2.3.7.2.%Derivatisation%
Preparation%of%Lipidex%5000%occlusion%columns%
Each column was prepared by plugging a 150 mm glass Pasteur pipette with a 
silanised glass wool to create a column depth of  ~ = 1 inch.  Lipidex 5000 (2 ml) in 
mobile phase was added to each column, shaking regularly to prevent settling, and 
excess mobile phase allowed to elute.  The trapped matrix was washed with mobile 
phase (3 x 1 ml) 
Derivatisation%conditions%
The following method was used to form methoxime-trimethylsilyl (MO-TMSi) 
derivatives (Best et al, 1997):  standards/dried organic extracts were dissolved in 
methoxyamine hydrochloride (50 µl, 2 % w/v in pyridine), vortexed, capped and 
incubated (30 minutes, 60 °C).  After drying (60 °C OFN), trimethylsilylimidazole 
was added, and vials were capped, vortexed and incubated (2 hours, 100 °C).  The 
sample was re-suspended in mobile phase (1 ml) before being passed through a 
Lipidex 5000 column.  Reacti-vials were washed with mobile phase (2 x 1 ml), 
which was also applied to the column.  The eluate was collected in 3.5 ml disposable 
glass vials, reduced to dryness (OFN, 60 ºC), re-suspended in decane (100-200 µl), 
transferred to chromatography vials and stored (-20 °C) for analysis by GC-MS/MS. 
      Scott Mackenzie    PhD thesis, 2015 
 Chapter(2:(Materials(and(methods( 67(
2.3.7.3.%Analysis%by%GC4MS/MS%
Steroids in derivatised extracts were quantified using a TSQ Quantum XLS Ultra™ 
triple quadrupole mass spectrometer connected to a TRACE Ultra Gas 
Chromatograph, (Thermo Scientific Inc, Waltham, MA). 
Gas%Chromatography%
Steroids in decane were injected (1 µl; room temperature) using a TriPlus 
autosampler (Thermo Scientific Inc) and vaporized in mobile phase (helium gas) 
heated (270 °C) and maintained at a constant flow rate (2 ml/min).  For final 
quantitative analysis (Table 2-1), chromatographic separation was achieved using a 
Zebron ZB-HT Inferno column (Phenomenex, Torrance, Ca) measuring 30 m x 0.25 
mm (internal diameter) x 0.25 µm (film thickness).  After injection by splitless 
programmable temperature vaporization (PTV), the column was heated by 30 
°C/min, maintained at 200 °C for 1 minute, and finally heated by 5 °C/min until 
target temperature was reached (300 °C; held for 3 minutes).  Total chromatographic 
run time was 27.7 mins.  Practice assays and full scan analyses (Figure 2-2) were 
performed under the same conditions using a J&W DB-17ms column (30 m x 0.25 
mm x 0.35 µm; Agilent Technologies, Santa Clara, CA). 
Tandem%mass%spectrometry%
Positively charged ions were formed by electron ionisation at 280 °C in a Durabrite 
Iris source (electron energy 70 eV, emission current 50 µA).  Quantitative analysis 
was performed in multiple reaction monitoring (MRM) mode (cycle time 0.3 s) using 
      Scott Mackenzie    PhD thesis, 2015 
 Chapter(2:(Materials(and(methods( 68(
collision induced dissociation (argon gas; 1.0 mTorr).  Collision energies and MRM 
transitions are listed in Table 2-1. 
Where an MS/MS method had not previously been established (17-deoxycortol and 
17-deoxycortolone), derivatised standards were analysed in full scan (Q1) mode 
(representative data for 17-deoxycortol are shown in Figure 2-2), followed by a 
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2.3.8.%Adipose%biopsy%real4time%reverse%transcription%PCR%(qRT4PCR)%
RNA purification was performed according to manufacturer’s instructions using an 
RNeasy® mini kit with QIAzol® lysis reagent (Qiagen, UK).  RNA integrity was 
confirmed by presence of two clear bands when run on a denature get agarose gel, 
with the intensity of the larger 28S ribosomal RNA band approximately twice as 
strong that of 18S ribosomal RNA.  cDNA (250 ng RNA/reaction) was synthesised 
using a high capacity cDNA kit (Invitrogen, Paisley, UK) according to 
manufacturer’s instructions.  Quantitative PCR (qPCR) was carried out using a 
Roche Lightcycler 480 (Roche Applied Science, Burgess Hill, UK).  Primers 
(Invitrogen, Paisley, UK) were designed for use with intron-spanning probes (Roche 
Universal Probe Library (UPL®); Primer sequences and UPL® probe numbers in 
Table 2-2).  Samples were initially denatured by heating (95 ºC, 5min) then 
underwent 50 cycles of PCR amplification comprising denaturation (95 ºC, 10 sec), 
annealing and elongation (60ºC, 30 sec).  After the final cycle, samples were cooled 
(40 ºC, 30 sec).  All samples were analysed in triplicate and amplification curves 
plotted  (fluorescence vs axis cycle number).  Triplicates were deemed acceptable if 
the standard deviation of crossing point (Cp) was less than 0.5 cycles.  A standard 
curve for each gene was generated by serial dilution of cDNAs pooled from different 
samples, and deemed acceptable if reaction efficiency was between 1.7 and 2.1.  
Transcript abundance in samples (in triplicate) was quantified by interpolation from 
the standard curve and expressed as a factor of the housekeeping gene 18S ribosomal 
rRNA (18S rRNA).  
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3.1.%Introduction%
In large-scale genome-wide association studies (GWAS) performed to identify 
genetic determinants of blood pressure, polymorphisms at a handful of key loci have 
been consistently associated with blood pressure in populations of various ancestries 
(Newton-Cheh et al, 2009; Kato et al, 2011).  One of these is CYP17A1, which 
encodes the steroidogenic enzyme 17α-hydroxylase (Newton-Cheh et al, 2009; Ehret 
et al, 2011; Kato et al, 2011; Fedorowski et al, 2012; Hotta et al, 2012).  In the 
adrenal gland, CYP17 is required for synthesis of the glucocorticoid hormone 
cortisol, whereas substrate that does not undergo 17-hydroxylation is converted to 
the mineralocorticoids 11-deoxycorticosterone (DOC) and aldosterone.  
Additionally, however, the ‘mineralocorticoid’ pathway also produces the 
glucocorticoid hormone corticosterone, which circulates at concentrations of 5-10 % 
of those of cortisol.  The product of CYP17A1 is therefore likely to be a key 
determinant of relative corticosterone vs cortisol production. 
The mechanisms underlying associations of variability in CYP17A1 with blood 
pressure have not been identified.  Rare genetic variation, with near-absent 
17α-hydroxylase activity, results in low-renin hypertension, associated with DOC 
and corticosterone excess (Yanase et al, 1991).  It is therefore widely inferred that 
associations of more common variability in CYP17A1 with increased blood pressure 
are mediated by reduced 17α-hydroxylase activity. 
Raised blood pressure is a key component of the ‘metabolic syndrome’, the 
collection of risk factors for cardiovascular disease, which also includes obesity, 
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dyslipidaemia and insulin resistance.  Intriguingly, risk alleles for hypertension are 
not associated with other features of metabolic syndrome, and in fact are associated 
with reduced risk of obesity (Hotta et al, 2012; Wen et al, 2014).  Polymorphism in 
CYP17A1 that predicts obesity has also been shown to associate with insulin 
resistance (Echiburu et al, 2008).  Therefore, alleles that are expected to result in 
relatively impaired CYP17 activity and increased ratio of corticosterone: cortisol are 
associated with increased blood pressure but with reduced risk of obesity, and 
perhaps also insulin resistance. 
This apparent paradox might be explained by relatively recent evidence, which 
points to a mechanism whereby increased production of corticosterone over cortisol 
may result in a favourable cardiometabolic profile.  Metabolic syndrome is 
associated with activation of the HPA axis, (Pasquali et al, 2006), occurring through 
unknown mechanisms.  HPA axis activation drives cortisol excess, which has clear 
adverse metabolic effects (Walker, 2007).  Corticosterone, unlike cortisol, is not 
exported from the CNS by the transmembrane protein ABCB1 (Karssen et al, 2001).  
Therefore relative deficiency of corticosterone may result in impaired negative 
feedback suppression of the HPA axis and drive elevated plasma cortisol in 
metabolic syndrome. 
The balance of corticosterone vs cortisol production may therefore be an important 
determinant of risk of metabolic syndrome, but the direction of association for blood 
pressure may differ to other components of the syndrome.  In the studies presented in 
the current chapter, we aimed to determine the associations of plasma corticosterone 
vs cortisol with features of metabolic syndrome.  We studied a large UK based 
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population cohort, the Orkney Complex Disease Study (ORCADES) group; a cohort 
of people with diabetes, the Edinburgh Type 2 Diabetes Study (ET2DS); and a 
smaller cohort of men and women who had undergone dynamic testing of the HPA 
axis, the East Hertfordshire (EHERTS) Study. 
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3.2.%Methods%
3.2.1.%Subjects%
All studies conformed to the Declaration of Helsinki and ethical approval and written 
informed consent were obtained. 
3.2.1.1.%Orkney%Complex%Disease%Study%(ORCADES)%
The ORCADES study is a genetic epidemiological study based in the Scottish 
archipelago of Orkney, comprising 2039 subjects 18-100 years of age, with at least 
two Orcadian grandparents, recruited between 2005 and 2011 (McQuillan et al, 
2008).  Subjects attended a local or mobile venesection clinic between 0730h and 
1100h, after fasting from 2200h the previous night.  On a separate occasion subjects 
attended a cardiovascular measurement clinic where weight, height and blood 
pressure were recorded. 
3.2.1.2.%Edinburgh%Type%2%Diabetes%Study%(ET2DS)%
The Edinburgh Type 2 Diabetes Study (ET2DS) is a prospective cohort study 
comprising 1066 men and women with established type 2 diabetes, living in the 
Lothian region of Scotland.  Recruitment and study design has been reported 
previously (Price et al, 2008).  Briefly, participants age 60-75 years with a diagnosis 
of type 2 diabetes according to WHO criteria (Alberti et al, 1998) were contacted 
using data from computerised records.  Following an overnight fast, subjects 
attended a local research clinic at 0800-0830h where they underwent venepuncture 
and physical examination. 
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3.2.1.3.%East%Hertfordshire%Study%(EHERTS)%
All births in East Hertfordshire from 1911 onwards were notified by the attending 
midwife (Barker et al, 1989).  As previously described, these records were used to 
recruit 309 women and 370 men, with no history of diabetes, for a standard 75 g oral 
glucose tolerance test (OGTT), performed at a local clinic at 0800-1020h following 
an overnight fast from 2100h (Hales et al, 1991).  In a follow up study (Reynolds et 
al, 2001a), 312 of these individuals, born between 1920 and 1930, ingested 0.25 mg 
dexamethasone at 2200h, fasted overnight and attended a local clinic at 0830h the 
next morning.  A baseline blood sample was obtained before 1.0 µg freshly diluted 
ACTH1-24 (tetracosactrin, Synacthen, Alliance, Chippenham, UK) was administered 
intravenously, and repeat sampling was undertaken after 30 minutes.  In both 
EHERTS and ORCADES, the homeostatic model assessment was used to quantify 
insulin resistance (HOMA-IR) (Turner et al, 1979).   
3.2.2.%Laboratory%analyses%
Serum cortisol was measured by radioimmunoassay with Guildhay antisera (Moore 
et al, 1985).  After exclusion of individuals prescribed glucocorticoid therapy 
(ORCADES n = 21; ETD2S n = 163; EHERTS n = 33), there was sufficient sample 
for analysis of corticosterone in 2018 individuals from ORCADES; 903 in ET2DS; 
and 279 in EHERTS. 
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3.3.%Statistical%Analysis%
All statistical analyses were undertaken using Minitab (version 16; State College 
PA).  Continuous response variables were log transformed to obtain normal 
distributions.  Student’s t-test (paired where appropriate) was used for group 
comparisons of corticosterone/cortisol ratios and responses to ACTH. 
Simple linear regression analysis of corticosterone or cortisol with a given 'response' 
(or dependent) variable was used to determine unadjusted p values for the regression 
coefficient.  Analyses were then repeated with potentially confounding co-variables 
in multiple regression analyses.  All analyses were adjusted for age and gender.  
Because the clearance of glucocorticoids is increased in obesity, BMI was included 
in all analyses as a predictor variable.  Additionally, because timing of fasting 
samples varied in the ORCADES and EHERTS cohorts, venesection time (expressed 
as minutes after the first sample in the cohort) was included as a predictor variable in 
all models, as previously described (Reynolds et al, 2006), in order to adjust for 
diurnal variation in glucocorticoid production (and to adjust for variations in the 
interval between dexamethasone administration and time of sample in EHERTS). 
Histograms and normal plots of residuals were examined to confirm the validity of 
the linear regression model.  In order to maintain this, and to minimise confounding 
due to prescribed medication, those prescribed glucose-lowering medications were 
excluded from regression analyses involving glucose or insulin in the ORCADES 
and EHERTS cohorts.  Because the majority of participants in ET2DS were 
prescribed these agents, their prescription was encoded as a binary variable and 
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entered into the regression equation.  This approach was used in all cohorts to adjust 
for the effect of relevant medications on lipids and blood pressure.   
In order to represent the magnitude of association of corticosterone and cortisol with 
a given response variable, the regression model was applied to fixed values of each 
glucocorticoid which represented the 1st and 3rd quartiles for the given cohort; this 
was preferred to calculating the change for each unit change in Z score, because of 
the non-normal distribution of cortisol and corticosterone values.  The standard error 
of the regression coefficient was used to calculate the standard error of the modelled 
change in response variable.  Results refer to adjusted analyses unless otherwise 
stated.  
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3.4.%Results%
Characteristics of the cohorts are summarised in Table 3-1. 
Table%341.%Characteristics%of%participants%in%epidemiological%studies%
ORCADES( =( Orkney( complex( diseases( study;( ET2DS( =( Edinburgh( type( 2( diabetes( study;(
EHERTS(=(East(Hertfordshire(study.((Baseline(glucocorticoid(concentrations(measured(after(








Gender((M/F)( 794/1224((39/61%)( 189/90((68/32%)( 476/427((53/47%)(
Age((years)( 53.3(±(0.34((16:91)( 71.3(±(0.18((67:78)( 67.9(±(0.14((60:68)(
Body(mass(index((kg/m2)( 27.7(±(0.11( 27.1(±(0.23( 31.2(±(0.19(
Anti:hypertensive( medication(
(n((%))( 412((20%)( 105((38%)( 704((79%)(
Systolic(BP((mmHg)( 129.9(±(0.43( 159.3(±(1.3( 133.3(±(0.55(
Diastolic(BP((mmHg)( 75.5(±(0.21( 86.9(±(0.69( 69.2(±(0.34(
Corticosterone( at( baseline(
(nM)( 50.7(±(1.2( 20.2(±(1.0( 22.3(±(0.49(
Corticosterone( 30( mins( after(
ACTH1:24((nM)( n/a( 84.0(±(2.5( n/a(
Cortisol(at(baseline((nM)( 724(±(7.4( 188(±(6.1( 732(±(6.4(
Cortisol( 30(mins( after( ACTH1:
24((nM)( n/a( 460(±(7.6( n/a(
Lipid(lowering(therapy((n((%))( 255((13%)( 71((25%)( 755((84%)(
Total(cholesterol((mM)( 5.39(±(0.03( 6.82(±(0.07( 4.28(±(0.03(
LDL(cholesterol((mM)( 3.37(±(0.02( 4.89(±(0.08( n/a(
HDL(cholesterol((mM)( 1.50(±(0.01( 1.33(±(0.02( 1.28(±(0.01(
Triglycerides((mM)( 1.15(±(0.02( 1.54(±(0.05( n/a(
Medication(for(diabetes((n)( 47((2.3%)( 10((3.6%)( 734((81%)(
(
Oral(agents( (( (( 660((74%)(
(
Insulin( (( (( 156((18%)(
Fasting(plasma(glucose((mM)( 5.33(±(0.02( 5.99(±(0.08( 7.57(±(0.07(
30(min(plasma(glucose((mM)( n/a( 9.38(±(0.14( n/a(
120(min(plasma(glucose((mM)( n/a( 7.13(±(0.18( n/a(
Fasting(plasma(insulin((mU/L)( 6.44(±(0.10( 7.18(±(0.35( n/a(
HOMA:IR( 1.59(±(0.34( 1.96(±(0.11( n/a(
      Scott Mackenzie    PhD thesis, 2015 
( Chapter(3: Corticosterone and Metabolic Syndrome( 81(
Cortisol and corticosterone were positively correlated in the ORCADES and ET2DS 
cohorts (Figure 3-1A); and in both dexamethasone-suppressed and ACTH1-24-
stimulated samples in EHERTS (Figure 3-1B).  After ACTH1-24, the response of 
plasma corticosterone was greater than that of cortisol in EHERTS (6.2 ± 0.3 vs 3.9 
± 0.4 fold increase, respectively; p <0.001).  
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Figure%341.%Relationships%between%plasma%cortisol%and%corticosterone.((
See(over(for(legend
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A)( Plasma( cortisol( and( corticosterone( in( the( Orkney( complex( diseases( study( group(
(ORCADES,( open( symbols)( and( the( Edinburgh( Type( 2( Diabetes( Study( (ET2DS,( closed(




following( overnight( dexamethasone( (0.25( mg)( suppression( testing( (pre( synacthen,( open(
symbols);( and( 30( minutes( following( intravenous( injection( of( ACTH1:24( (Synacthen( 1( µg,(




See Table 3-2 and Figure 3-2A.  Both higher plasma cortisol and higher plasma 
corticosterone were associated with lower body mass index, higher triglycerides and 
higher fasting plasma glucose.  Raised cortisol, but not corticosterone, was 
associated with raised systolic blood pressure.  Neither cortisol nor corticosterone 
were significantly associated with total cholesterol or LDL cholesterol after 
adjustment for co-variables, although higher cortisol was more strikingly associated 
with higher triglyceride levels while higher corticosterone was associated with 
paradoxically higher HDL-cholesterol.  Only plasma corticosterone was statistically 
significantly positively associated with fasting insulin and HOMA-IR, although 
similar trends were observed for plasma cortisol.  Consistent with this, higher 
corticosterone: cortisol ratio was associated with higher fasting glucose, insulin and 
HOMA-IR.  
3.4.2.%ET2DS%
See Table 3-2 and Figure 3-2B.  In people with type 2 diabetes, higher plasma 
cortisol and plasma corticosterone were associated with lower BMI and higher 
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fasting plasma glucose, but were unrelated to systolic blood pressure.  Corticosterone 
to cortisol ratio was not significantly associated with BMI, blood pressure or glucose. 
3.4.3.%EHERTS%
See Table 3-2 and Figure 3-2C & D.  Following low dose overnight dexamethasone 
suppression followed by low dose ACTH1-24 administration, plasma cortisol and 
corticosterone levels changed as expected (Table 1).  Plasma cortisol was not 
associated with any features of metabolic syndrome, except that ACTH1-24-
stimulated values were positively correlated with plasma glucose 30 min after an oral 
glucose load.  However, plasma corticosterone showed altered associations with 
metabolic syndrome variables.  After dexamethasone suppression, higher plasma 
corticosterone was associated with lower BMI but a paradoxically lower fasting 
insulin and HOMA-IR.  After ACTH1-24 stimulation, higher plasma corticosterone 
(and corticosterone/cortisol ratio) was associated with paradoxically lower glucose 












Unadjusted! Adjusted! Unadjusted! Adjusted! Unadjusted! Adjusted!
! !
β! p! β! p! β! p! β! p! β! p! β! p!
ORCADES!
(n=2018)!
BMI! F0.069! <0.001! F0.064! <0.001! F0.011! <0.001! F0.012! <0.001! F0.006! 0.33! F0.009! 0.11!
Systolic!BP! F0.021! 0.01! 0.022! 0.001! F0.002! 0.41! 0.002! 0.25! 0.003! 0.48! F0.002! 0.57!
Total!cholesterol! F0.006! 0.61! 0.021! 0.09! F0.004! 0.15! F0.011! 0.47! F0.010! 0.17! F0.008! 0.27!
LDL!cholesterol! F0.042! 0.02! 0.006! 0.74! F0.013! 0.004! F0.008! 0.08! F0.021! 0.06! F0.018! 0.09!
HDL!cholesterol! 0.063! <0.001! 0.022! 0.14! 0.011! 0.004! 0.090! 0.02! 0.007! 0.45! 0.014! 0.12!
Triglycerides! 0.047! 0.12! 0.176! <0.001! 0.007! 0.35! 0.025! <0.001! 0.012! 0.52! 0.010! 0.56!
Fasting!glucose! F0.007! 0.31! 0.014! 0.02! 0.005! 0.003! 0.006! <0.001! 0.015! <0.001! 0.011! 0.004!
Insulin! F0.066! 0.03! 0.030! 0.27! 0.004! 0.58! 0.018! 0.01! 0.038! 0.03! 0.038! 0.02!
HOMAFIR! F0.073! 0.03! 0.045! 0.13! 0.009! 0.27! 0.025! 0.001! 0.053! 0.01! 0.048! 0.01!
ET2DS!(n=903)!
BMI! F0.064! 0.003! F0.055! 0.01! F0.018! 0.05! F0.013! 0.12! F0.010! 0.30! F0.006! 0.50!
Systolic!BP! 0.015! 0.34! 0.014! 0.37! F0.003! 0.66! F0.003! 0.66! F0.005! 0.40! F0.005! 0.42!





BMI! F0.018! 0.13! F0.017! 0.18! F0.036! 0.003! F0.036! 0.004! F0.023! 0.14! F0.024! 0.12!
Systolic!BP! 0.008! 0.49! 0.005! 0.67! 0.008! 0.49! 0.008! 0.49! F0.002! 0.89! 0.000! 1.00!
Fasting!glucose! 0.018! 0.06! 0.010! 0.28! 0.003! 0.74! F0.001! 0.89! F0.019! 0.12! F0.012! 0.30!
30!min!glucose! 0.033! 0.05! 0.027! 0.12! 0.015! 0.39! 0.015! 0.38! F0.027! 0.23! F0.014! 0.51!
120!min!glucose! F0.049! 0.04! F0.034! 0.17! F0.050! 0.04! F0.032! 0.20! 0.016! 0.61! 0.012! 0.69!
Insulin! F0.138! 0.01! F0.096! 0.06! F0.192! <0.001! F0.131! 0.01! F0.046! 0.80! F0.040! 0.52!
HOMAFIR! F0.119! 0.03! F0.085! 0.11! F0.189! 0.001! F0.133! 0.01! F0.105! 0.59! F0.053! 0.42!
EHERTS!after!
ACTH1F24!(n=279)!
BMI! 0.012! 0.71! F0.020! 0.61! F0.015! 0.19! F0.018! 0.12! F0.019! 0.11! F0.017! 0.15!
Systolic!BP! 0.014! 0.65! 0.048! 0.19! F0.007! 0.58! F0.004! 0.77! F0.014! 0.32! F0.011! 0.41!
Fasting!glucose! F0.031! 0.19! 0.037! 0.20! F0.033! 0.003! F0.027! 0.01! F0.021! 0.06! F0.026! 0.02!
30!min!glucose! 0.019! 0.66! 0.146! 0.01! F0.023! 0.25! F0.010! 0.63! F0.021! 0.32! F0.019! 0.35!
120!min!glucose! 0.092! 0.15! 0.010! 0.90! F0.054! 0.06! F0.056! 0.05! F0.072! 0.02! F0.059! 0.05!
Insulin! 0.136! 0.32! 0.036! 0.82! F0.120! 0.04! F0.099! 0.07! F0.046! 0.02! F0.096! 0.09!
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Study! (ET2DS),!C)!East!Hertfordshire!study! (EHERTS)!after!overnight!dexamethasone! (0.25!
mg)!suppression,!and!D)!EHERTS!30!mins!after!ACTH1M24!(1!µg).!!Results!are!for!the!%!change!
in!each!response!variable!comparing!the!lower!and!upper!tertile!cutMoff!values!for!cortisol!
(filled! columns)! or! corticosterone! (hatched! columns),! calculated! from! the! adjusted!
regression!coefficients!shown!in!Table!3M2.!For!corticosterone,!tertile!cutMoffs!were!23!and!
61! nM! in! ORCADES,! 13! and! 29! nM! in! ET2DS,! ! 10! and! 24! nM! in! EHERTS! after!
dexamethasone,!and!60!and!104!nM!after!ACTH1M24.! !For!cortisol,!tertile!cutMoffs!were!521!
and! 847! nM! in! ORCADES,! 591! and! 842! nM! in! ET2DS,! 117! and! 245! nM! in! EHERTS! after!
dexamethasone,! and! 366! and! 544! nM! after! ACTH1M24.! ! Error! bars! were! calculated! from!
upper!or!lower!range!of!standard!error!of!the!regression!coefficient.!!*p!<!0.05,!**p!<!0.005!
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3.5.'Discussion'
This is the largest study investigating the associations between endogenous 
glucocorticoids and features of metabolic syndrome.  By analysing fasting morning 
plasma samples from 2 cohorts comprising 2921 participants, we confirm previous 
observations (Filipovsky et al, 1996; Phillips et al, 1998b; Reynolds et al, 2001b; 
Reynolds et al, 2003; Ward et al, 2003; Reynolds et al, 2010; Krishnaveni et al, 
2013) that elevated morning plasma cortisol is associated with higher blood pressure 
and blood glucose, but with lower body mass index, both in subjects with and 
without type 2 diabetes.  With such large numbers of participants, the chances of 
statistical errors are much reduced compared with smaller previous studies of plasma 
cortisol. 
This is the first study to investigate whether similar associations exist for plasma 
corticosterone.  Population genetic data raise the hypothesis that reduced adrenal 
CYP17 activity, expected to increase the ratio of plasma corticosterone: cortisol, 
contributes to raised blood pressure.  Our data demonstrate no associations between 
plasma corticosterone or the ratio of corticosterone: cortisol and blood pressure.  
Although we adjusted for the use of antihypertensive medication, their use may still 
limit the ability to test associations with blood pressure, especially in the ET2DS and 
EHERTS cohorts.  Perhaps also of relevance to blood pressure, we also hypothesised 
that relative deficiency of corticosterone would aggravate cortisol excess and be 
associated with other features of metabolic syndrome.  If such a mechanism existed, 
positive associations of corticosterone with blood pressure might be attenuated, or 
indeed obscured, by effects of corticosterone on the HPA axis, which would act to 
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limit cortisol excess and adverse effects on vascular smooth muscle (Sapolsky et al, 
2000).   
Seemingly against this hypothesis, our data show that in basal samples, associations 
of plasma corticosterone with fasting insulin and glucose are similar to those of 
cortisol, and in fact the ratio of corticosterone: cortisol indicates associations are 
greater for corticosterone than cortisol.  The stronger positive associations of 
corticosterone than cortisol with fasting insulin and glucose in non-diabetic subjects 
is intriguing.  We are not aware of evidence that corticosterone could have a greater 
action than cortisol on insulin resistance or glucose metabolism, but this now 
deserves more careful investigation.  Corticosterone and cortisol both bind 
corticosteroid-binding globulin, so changes in binding capacity in association with 
insulin resistance (Fernandez-Real et al, 2000; Fernandez-Real et al, 2002) are 
unlikely to explain stronger associations with corticosterone.  The observation might 
be explained by 'reverse causality', whereby insulin resistance mediates a change in 
adrenal steroidogenesis in favour of corticosterone.  It has been hypothesised that 
enhanced 17α-hydroxylase activity by insulin in vitro (Munir et al, 2004) explains 
adrenal hyperandrogenism in polycystic ovarian syndrome (Baptiste et al, 2010).  
This hypothesis assumes that the enzyme remains insulin-sensitive in an otherwise 
insulin resistant state; whereas loss of insulin-driven upregulation might in fact shift 
adrenal steroidogenesis towards corticosterone.  Alternatively, the combined 
elevation of cortisol and corticosterone with insulin resistance could reflect a central 
activation of the HPA axis, consistent with dysregulation of central control 
exemplified by altered responses to habituation and stress (Reynolds et al, 2001b). 
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In contrast to associations of basal samples, data from EHERTS indicate insulin 
sensitive individuals show a tendency to produce corticosterone over cortisol 
following ACTH1-24 stimulation, as indicated by inverse associations of the 
corticosterone: cortisol ratio with fasting glucose, glucose at 30 minutes in the 
OGTT, and HOMA-IR.  Although these observation were made in a different cohort, 
with smaller numbers than the other cohorts, the properties of these samples means 
they provide a unique opportunity to test the hypothesis that variability in CYP17 
results in dysregulation of adrenal steroidogenesis, whereby a biosynthetic bias 
towards corticosterone over cortisol predicts a favourable metabolic profile.  Basal 
glucocorticoids are prone to confounding by HPA axis tone: relative impairment in 
adrenocortical secretion of corticosterone may result in compensatory activation of 
the HPA axis to normalise corticosterone and elevate cortisol, potentially obscuring 
associations of plasma corticosterone with metabolic syndrome.  Changes in 
clearance that differentially affect corticosterone and cortisol may have similar 
effects.  Dexamethasone suppression followed by ACTH1-24 stimulation effectively 
‘normalises’ HPA axis tone across the cohort, and these samples therefore more 
accurately reflect the innate adrenal biosynthetic tendency towards corticosterone vs 
cortisol production.  If, as a result of the activity of ABCB1 excluding cortisol from 
the brain (Karssen et al, 2001) corticosterone makes a disproportionate contribution 
to negative feedback suppression of the HPA axis in humans, these observations 
could provide a key insight into the activation of the HPA axis and elevated plasma 
cortisol in metabolic syndrome. 
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In dexamethasone-suppressed, pre-ACTH1-24 samples from EHERTS, we found no 
significant associations between cortisol and features of metabolic syndrome.  This 
finding is in keeping with previous studies, which generally show 
dexamethasone-suppressed cortisol fails to demonstrate associations with metabolic 
syndrome variables (Abraham et al, 2013).  We did, however, demonstrate insulin 
resistance is accompanied by relatively deficiency of corticosterone, similar to 
samples following ACTH1-24 stimulation. 
Interestingly, in the diabetic cohort, fasting plasma corticosterone was low, whereas 
cortisol was similar to the values in the ORCADES cohort (mean 
corticosterone/cortisol ratio 0.03 in ET2DS vs 0.075 in ORCADES, p < 0.0001).  It 
is unlikely that this phenomenon is due to the older age of the ET2DS cohort, since 
corticosterone/cortisol ratio was not associated with age (r2 = 0.01, p = 0.27).  Within 
the diabetic group, corticosterone and cortisol were both associated with BMI and 
fasting plasma glucose, but corticosterone was not more strongly correlated with 
blood glucose, as it was amongst non-diabetics in ORCADES.  These findings 
cannot easily be explained by reverse causality (Baptiste et al, 2010).  Confounding 
by HPA axis activation and/or alterations in clearance may explain the lesser positive 
associations of corticosterone with hyperglycaemia in this patient group. 
Our data show corticosterone and cortisol are both reduced in obesity, and the ratio 
of corticosterone: cortisol is not associated with BMI.  Both glucocorticoids are 
subject to similar routes of metabolism.  It is likely that reduced plasma 
corticosterone in obesity is explained by the same factors which underlie increased 
clearance of cortisol in obesity, namely increased metabolism, eg by A-ring 
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reductases (Strain et al, 1980; Andrew et al, 1998; Lottenberg et al, 1998).  
Additionally, we found no clear association between the metabolic syndrome pattern 
of blood cholesterol and morning plasma glucocorticoid levels. The dyslipidaemia 
that accompanies metabolic syndrome is well characterised, and comprises raised 
total and LDL cholesterol, low HDL cholesterol and raised triglycerides, but 
previous studies have found inconsistent relationships between endogenous 
glucocorticoids and lipids.  The positive association between corticosterone and 
HDL cholesterol is difficult to explain, since previous studies have shown high 
(Taskinen et al, 1983), low (Colao et al, 1999) or unchanged (Friedman et al, 1996) 
HDL cholesterol in Cushing’s syndrome.  Elevated triglycerides, which are more 
closely responsive to insulin signalling, were consistently associated with both 
cortisol and corticosterone. 
An important limitation of these studies is the cross-sectional design, which means it 
is not possible to infer causation.  Moreover, the dynamic HPA axis tests were 
conducted in a different cohort from the measurement of fasting plasma 
glucocorticoids.  However, we have been able to draw upon comprehensive datasets 
to account for a number of potentially confounding variables.  Heterogeneity 
between the cohorts means it is difficult to draw comparisons between the study 
groups, and ideally the findings require replication in similar representative cohorts. 
In conclusion, we have demonstrated that elevated plasma corticosterone 
accompanies insulin resistance and elevated cortisol in metabolic syndrome, 
consistent with chronic up-regulation of the HPA axis.  However, discrepancies 
between associations with cortisol and corticosterone may reflect differences in 
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adrenal steroidogenesis, particularly by 17α-hydroxylase, and may be a consequence 
of dysregulated insulin signaling.  These findings throw the spotlight on 
corticosterone and suggest that further dissection of its biology in humans may be 
fruitful in understanding the basis for altered glucocorticoid signalling in metabolic 
syndrome.  
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Chapter'4:'In#vitro'metabolism'of'corticosterone'
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4.1.'Introduction'and'Aims'
Clearance of glucocorticoids occurs in humans by two principal pathways: reversible 
oxidation at position C-11, catalysed by the 11β-HSDs (section 1.1.4); and step-wise 
reduction at positions 5, 3 and 20 (section 1.1.5), catalysed by hepatic A-ring 
reductases and HSDs.  The importance of clearance by both pathways in determining 
glucocorticoid action is illustrated by the effects of therapeutic manipulation of the 
11β-HSDs (Hughes et al, 2008); and by the recent finding that altered hepatic 
glucocorticoid clearance is a key component of the stress response (Boonen et al, 
2013).  The metabolism of cortisol by these pathways has been extensively studied in 
humans, both in vitro and in vivo; but in contrast little is known regarding the 
corresponding metabolic pathways for corticosterone (Figure 4-1), although it is 
thought to be similar in profile to cortisol. 
In subsequent chapters, we aim to study the production and clearance of 
corticosterone in vivo, by analysis of urinary glucocorticoids and stable isotope tracer 
studies.  For the latter, a deuterium labelled corticosterone tracer (D8-corticosterone; 
Figure 4-2) is commercially available (2,2,4,6,6,17α,21,21-[2H]8-corticosterone).  
Because this tracer has not previously been validated in humans, we undertook 
studies to test whether the compound exhibits an ‘isotope effect’, whereby the tracer 
differs in metabolism to the endogenous compound.  Deuterium isotope effects are 
described as primary when the reaction involves cleavage of the bond to the 
isotopically labelled atom; and secondary when the D-H bond remains intact 
(Wiberg, 1955).  In vitro studies presented in the current chapter aim to determine 
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the kinetic properties of the principal enzymes involved in the clearance of 
corticosterone, in order to complement studies of its in vivo physiology; and to 
validate the deuterated tracer intended for use in these studies. 
Figure'4)1.'Proposed'metabolic'pathways'for'the'clearance'of'corticosterone'in'humans'
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• To validate the stable isotope D8-corticosterone as a tracer for corticosterone 
by testing for isotope effects in their metabolism by the key clearance 
enzymes 5β-reductase and 11β-HSD2  
• To characterise the in vitro metabolism of corticosterone by 5β-reductase and 
11β-HSD2; and compare it to that of cortisol 
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4.2.'Methods''
4.2.1.'Metabolism'of'glucocorticoids'by'5β)reductase'
As 5β-reduced glucocorticoids are metabolised quickly by 3α-hydroxysteroid 
dehydrogenases (HSDs) in vitro (Iyer et al, 1990), it was not possible to assess 
metabolism of corticosterone by 5β-reductase and 3α-HSD individually.  Therefore 
human hepatic cytosol was used to assess the combined action of these two enzymes 
resulting in formation of 3α, 5β-tetrahydrocorticosterone or its D8-labelled 
isotopologue.  The assay was adapted from one reported to quantify 5β-reductase 
activity in rat (Okuda et al, 1984) and human liver (Iyer et al, 1990).  Pilot 
experiments were performed in rodent hepatic homogenates to determine optimal 
protein concentration, unlabelled substrate concentration, incubation time and 
chromatographic conditions. 
4.2.1.1.'Determination'of'hepatic'cytosol'protein'content'
A colorimetric Bio-Rad DC® protein assay kit (Bio-Rad, Hemel Hempstead, UK) 
was used to determine protein concentration in hepatic cytosol.  A stock protein 
solution (2 mg/ml BSA, fraction V, in water) was used to prepare standard solutions 
(0.1 - 1.4 mg/ml) in triplicate in distilled water.  Protein standards (5 µl) were added 
to a 96-well plate in triplicate, with a solution of sodium dodecyl sulfate (SDS; 1 %) 
used as a blank.  Hepatic cytosol samples of unknown protein concentration were 
also added in triplicate.  Bio-Rad DC protein assay Reagents A (3 ml) and S (60 µl) 
were mixed to form working Reagent A.  Working Reagent A (25 µl) then dye 
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Reagent B (200 µl) was added into each of the wells.  The plate was allowed to stand 
(room temperature, 15 minutes) before determining absorbance of samples at λ 690 
nm using an ultra-violet spectrophotometer.  A standard curve was plotted with 
absorbance on the y axis vs concentration on the x axis, a line of best fit drawn using 
simple linear regression (Figure 4-3), and the regression equation was used to 
determine the concentration of protein in each sample.  Data were deemed acceptable 





5β-Reductase activity was assessed by incubating substrate (20 µl) with cytosol (180 
µl) and co-factor mix (50 µl).  Required volumes of stock substrate (in methanol) 
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µl), and vortexed thoroughly to ensure they were fully dissolved before adding 
potassium phosphate buffer (450 µl).  Hepatic cytosol and co-factor mix were 
prepared in potassium phosphate buffer.  Hepatic cytosol was required in a solution 
with a final concentration of 100 - 200 µg protein per assay volume (250 µl), and 
was therefore prepared initially at 0.56 - 1.11 µg protein/µl.  Co-factor mix was 
prepared fresh for each assay and stored (4 °C) for no longer than 2 hours and 
protected from the light.  G6P-DH was required at 2 units/ml in the final assay 
volume, and was therefore prepared initially at 10 units/ml.  This was used to 
dissolve G6P (final concentration 5 mM; prepared initially at 25 mM); which was 
used in turn to dissolve NADPH (final concentration 2 mM; prepared initially at 10 
mM).  The co-factor mix was then incubated in a water bath (37 °C, 10 minutes) to 
establish reducing conditions. 
The assay was started by mixing diluted cytosol (or assay buffer in ‘no-protein’ 
controls), co-factor mix (or assay buffer in ‘no co-factor’ controls), and substrate 
mix.  Samples were covered and incubated in a shaking water bath (37 °C; 40 
strokes/min).  Time courses were performed to determine the optimum incubation 
period. 
The reaction was terminated by adding 10 volumes (2.5 ml) ethyl acetate.  The 
organic (top) layer was removed, reduced to dryness under OFN (60 °C), 
re-constituted in mobile phase (water: acetonitrile: methanol, 60:15:25) and 
transferred to high performance liquid chromatography (HPLC) vials (VWR 
International, Radnor, PA).  Samples were stored (-20 °C) for analysis by HPLC 
with radio-detection (section 4.2.1.3).  When the assay mix contained 20 nM 
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[3H4]-substrate, 30 µl was injected from samples prepared in 200 µl mobile phase.  




Analysis of tritiated steroids was achieved using a 626 HPLC pump (Waters, 
Milford, MA), ASI 100 automated sample injector (Dionex, Leeds, UK) and a 
β-scintillation counter (Berthold LB509 detector (Harpenden, UK).  When 
simultaneous analysis of non-tritiated steroids was required, a 170U UV detector 
(Dionex, Leeds, UK) was employed.  Substrate and product eluted at 35 °C using a 
46 x 150 mm Sunfire C18 5 µM column (Waters, Milford, MA) under conditions 
described in Table 4-1.  To achieve optimal mixing and counting efficiency the 
scintillant (ProFlow G; Biotechnologies Ltd, Epsom, UK) flow rate  was 2.0 ml/ min. 
Where possible, the product was identified by comparison of its retention time with 
that of tritiated standard.  Radio-labelled standards were not available to confirm the 
identity of products of metabolism by hepatic cytosol; instead this was undertaken by 
analysis of unlabelled 3α, 5β-tetrahydro-steroid standard using UV detection (λ = 
200 nm).  
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Substrate! B/D8MB! F! B/D8MB! F!
Mobile!phase!composition!(water:!
acetonitrile:!methanol)!
60:15:25! 60:15:25! 60:15:25! 60:0:40!
Mobile!phase!flow!rate!(ml/min)! 1.5! 1.5! 1.5! 1!
Mobile!phase!volume!(µl)!! 200!M!250! 200!M250! 250! 250!
Injection!volume!(µl)! 30!M!200! 30!M!200! 60! 60!
Retention!time!
(mins)!
Substrate! 21.8! 12.2! 21.4! 34.7!
Product! 32.6! 22.5! 14.7! 27.8!
 
4.2.1.4.'Data'analysis'
Following chromatography, the area under each peak was integrated (Chromeleon 
version 6.8, Dionex, Leeds, UK) and the percentage conversion of tritiated substrate 
to tritiated product quantified and converted into substrate and product 
concentrations.  Peak areas were integrated when the response had a signal to noise 
ratio (SNR) >3.  Data points were accepted if coefficient of variation between 
replicates was <10 %.  Kinetic parameters were derived using least squares curve 
fitting (GraphPad Prism, version 5.01, GraphPad Software Inc, La Jolla CA).  The 
extra sum-of-squares F test was used to compare best fit parameters between 
substrates. 
4.2.2.'Metabolism'of'glucocorticoids'by'11β)HSD2'
Human embryonic kidney cells stably transfected with human HSD11B2 (HEK 293 
11ΒHSD2) were obtained from Dr Scott Webster and Mrs Margaret Binnie, 
University of Edinburgh (Webster et al, 2007).  Practice assays were performed to 
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determine the optimum range of labelled and unlabelled substrate concentrations, 
assay volume, cell density and incubation period.  
4.2.2.1.'Cell'culture'conditions'
Cells stored in liquid nitrogen were thawed at room temperature before adding 
Dulbecco’s Modified Eagle’s Medium (DMEM; 50 ml) and centrifuging (1000 x g, 5 
mins, room temperature).  Medium was removed and the cell pellet re-suspended in 
30 ml fresh medium. 
Cells were maintained in uncoated flasks (175 ml) containing DMEM (15 ml).  Cells 
were passaged when confluent (approximately twice weekly).  DMEM was aspirated 
from the flask and cells were washed with phosphate-buffered saline (PBS; 5-10 ml) 
to remove divalent cations and serum.  The cells were enzymatically displaced by 
adding trypsin / EDTA (3 ml) and cells were incubated (37 °C, 3-5) minutes.  Cells 
were dislodged and observed under the microscope.  Trypsin was neutralised with an 
equal volume of medium.  Cells were then centrifuged (1000 × g, 5 mins, room 
temperature) to remove any debris.  Medium was removed and the cell pellet was 
re-suspended in fresh medium.  The required volume of suspension was transferred 
into each flask and then topped-up to 15 ml of medium in total. 
4.2.2.2.'Assay'
Cells were suspended in fresh medium and mixed well, before placing 200 µl onto a 
haemocytometer and covering with a cover slip.  Cell count was determined from the 
average count of 4 × 100 nl volumes.  Cells were seeded onto poly-D-lysine 
hydrobromide-coated 12 well plates (BD Biosciences, Oxford, UK) at a density of 5 
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× 105 cells/well (using 2 ml DMEM/well) and incubated (20-24 hours, 37 °C).  
Unstripped medium was aspirated from the wells and cells were washed with PBS.  
Medium was replaced with DMEM containing stripped FCS (10% v/v; 2 ml) and 
cells were incubated (20-24 hours, 37 °C). 
DMEM was aspirated from the wells and medium was replaced with 2 ml fresh 
serum-free DMEM, containing [3H]4-corticosterone (5 nM) and unlabelled substrate 
(2.5 - 45 nM) in duplicate).  Controls were included which did not contain cells or 
substrate.  Time courses were performed to determine the optimal incubation time 
(60-300 minutes; 37 °C) for each substrate.  At the end of the incubation period, 
medium was aspirated, collected into 12 x 75 mm glass culture tubes and stored (-20 
°C) before extraction of glucocorticoids.  
4.2.2.3.'Steroid'Extraction'from'Cell'Culture'Medium'
Glucocorticoids were extracted from cell culture medium using a Sep-Pak C18 
column (360 mg; 55-105 µm, Waters, Milford, MA).  Columns were conditioned 
under atmospheric pressure with methanol (5 ml) then water (5 ml).  Cell culture 
medium was applied and the column was washed again with water (5 ml).  Steroids 
were eluted using methanol (2 ml) and the eluate collected in 12 × 75 mm glass 
culture tubes.  The eluate was reduced to dryness under 60 °C OFN and samples 
were reconstituted in water (200 µl).  Steroids were extracted using ethyl acetate (2 
ml).  The organic layer was then reduced to dryness under 60 °C OFN; dissolved in 
mobile phase, transferred to HPLC vials, and stored (-20 °C) for analysis by HPLC 
(section 4.2.1.3 and Table 4-1). 
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4.3.'Results'
4.3.1.'Metabolism'of'glucocorticoids'by'5β)reductase/3α)HSD'
Representative radio-chromatograms demonstrating the metabolism of [3H]-labelled 
corticosterone and cortisol by human hepatic cytosol are shown in Figure 4-4.  
[3H]4-products were not formed in control samples without cytosol or co-factor. 
Unlabelled 3α, 5β-tetrahydrocortisol could not be detected using UV detection.  
Attempts were therefore made to analyse the compound by mass spectrometry.  A 
Micromass ZMD single quadrupole mass spectrometer (Waters, Milford, MA) was 
used to determine the mass/charge (m/z) ratios of ions formed from the electrospray 
ionisation of infused standards (10 µg/ml in water: methanol: formic acid 50: 50: 0.1 
%; 30 µl/min).  Expected quasimolecular ions [M + H]+ and M + Na]+ were observed 
for cortisol but not reduced metabolites.  Final confirmation of product was achieved 
by derivatisation and analysis by GC-MS/MS.  Unlabelled substrate was incubated 
with hepatic cytosol under experimental conditions described (section 4.2.1.2) using 
10 µM substrate.  Substrate and product were then isolated by HPLC followed by 
collection of the fractions whose retention time matched those of the corresponding 
[3H]4 compounds.  Eluates were reduced to dryness then processed and analysed as 
described in section 2.3.7.1.  This confirmed the identity of the peaks at 22.5 and 
32.5 minutes as tetrahydrocortisol and tetrahydrocorticosterone respectively (Figure 
4-4).  The rate of formation of additional products, eluting approximately 0.8 
minutes before tetrahydro-reduced compounds, was not linear within the period 
studied.  Analysis by GC-MS/MS confirmed this peak corresponded to 
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5β-dihydrocortisol (where the substrate was cortisol), but in the case of 





with! [3H]4Mcorticosterone! (2!nM)!and!human!hepatic!cytosol! (100!µg!protein)! for!5!hours.!!






Rate of product formation over time was linear over the period 120-720 minutes for 
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4-5).  Time points for subsequent assays were selected in order to achieve 10-40 % 
conversion of substrate. 
Figure'4)5.'Metabolism'of'corticosterone'and'cortisol'by'human'5β)reductase/3α)HSD:'
time'course'
Glucocorticoid! incubated! in! duplicate!with! human! hepatic! cytosol! (200! µg! protein)! using!





Both corticosterone and D8-corticosterone were substrates for human hepatic 
5β-reductase/3α-HSD.  At supraphysiological substrate concentrations (> 6 µM), rate 
of metabolism declined with increasing concentration of both isotopologues (Figure 
4-6; panel A).  Enzyme kinetics were best modelled according to the 
Michaelis-Menten equation adjusted for substrate inhibition (Copeland, 2000): 
! = !!"#[!]
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At higher substrate concentrations, rate of metabolism of corticosterone (Figure 4-6; 
panels A and B) exceeded that of D8-corticosterone (p < 0.001), indicating a 
deuterium primary isotope effect.  The magnitude of this effect, expressed as the 




with! human! hepatic! cytosol! (200! µg! protein).! ! Panel! B:! corticosterone! (○)! or! D8M
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[Substrate]!µM! Substrate! Vmax!(pmol/min/mg!protein)! Km!(!µM)! Ki!(µM)! r
2!
2!–!27.5! Corticosterone! 50!±!32!! 8.2!±!5.0! 3.3!±!1.8! 0.90!
0.3!M!5!
Corticosterone*! 72!±!60! 9.5!±!8.9! 1.3!±!1.4! 0.96!
D8Mcorticosterone*! 18!±!5! 2.2!±!0.8! 4.5!±!2.3! 0.93!
*!p<0.001!(extra!sumMofMsquares!F!test;!null!hypothesis!=!single!curve!for!both!substrates)!
!
Repeat experiments undertaken within the physiological range revealed reaction 
velocity increased linearly (r2 > 0.99) with increasing substrate concentration (Figure 
4-6), and the gradient of the line of best fit for reaction velocity vs substrate 
concentration was not significantly different for each substrate (corticosterone: 
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4.3.1.2.'Metabolism'of'glucocorticoids'by'5β)reductase/3α)HSD:'corticosterone'vs'cortisol'
The metabolism of cortisol by 5β-reductase/3α-HSD was compared to that of 
corticosterone within the physiological range of both glucocorticoids.  For both 
substrates, non-saturable enzyme kinetics were observed (Figure 4-8), but the 
gradient of the regression line for corticosterone was greater than that for cortisol (by 
a factor of 4.3), indicating rate of metabolism of corticosterone exceeded that of 
cortisol for a given substrate concentration. 
Figure'4)8.'Metabolism'of'corticosterone'and'cortisol'by'5β)reductase/3α)HSD'




Representative radio-chromatograms demonstrating the metabolism of [3H]-labelled 
corticosterone and cortisol by HEK 293 cells stably transfected with 11β-HSD2 are 
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cells or substrate.  Following time-course experiments, an incubation time of 30 
minutes was chosen to ensure reaction velocity remained linear and conversion of 
substrate to product was between 10 and 40 %.  The identity of the products were 
confirmed by comparison of their retention times with those of [3H]4-standards. 
Figure'4)9.'Metabolism'of'[3H]4)corticosterone'and'[3H]4)cortisol'by'11β)HSD2:'
representative'chromatograms'




11βMHSD2! cells,! demonstrating! conversion! of! corticosterone! (B)! to! 11M
dehydrocorticosterone!(A);!and!cortisol!(F)!to!cortisone!(E).!
  
Both corticosterone and D8-corticosterone were substrates for human 11β-HSD2.  
Reaction velocity increased asymptotically with increasing substrate concentrations 
according to Michaelis-Menten kinetics (Figure 4-10).  No statistically significant 
differences were found between modelled kinetic parameters for corticosterone (Vmax 
= 28.6 ± 2.3 pmol/hr/106 cells; Km = 22.9 ± 3.9 nM) and D8-corticosterone (Vmax = 
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resulted in the following best-fit kinetic parameters (Figure 4-10): Vmax = 26.7 ± 2.1 
pmol/hr/106 cells; Km = 20.0 ± 3.4 nM. 
Metabolism of [3H]4-cortisol increased linearly with increasing substrate 
concentration (r2 > 0.99).  Direct comparison of the kinetic properties of the enzyme 
for cortisol and corticosterone was not possible due to the different kinetic models 
employed for each substrate.  However, reaction velocities were broadly similar for a 
given substrate concentration within the range studied.    
Figure'4)10.'Metabolism'of'corticosterone,'D8)corticosterone'and'cortisol'by'11β)HSD2'
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4.4.'Discussion'
Assessment of the in vitro metabolism of the stable isotope tracer D8-corticosterone 
has demonstrated that, across the range of concentrations likely to be relevant to 
human health and disease, the tracer is metabolised similarly to endogenous 
corticosterone.  Use of the tracer in vivo is therefore unlikely to be confounded by a 
deuterium isotope effect, meaning valid observations regarding the endogenous 
compound can be made from such studies. 
For human hepatic 5β-reductase/3α-HSD, a deuterium isotope effect was observed at 
supraphysiological substrate concentrations.  It is likely that the effects seen in the 
above data are due to a secondary rather than primary isotope effect, since reduction 
of the steroidal A-ring occurs at the C=C bond adjacent to the deuterium at position 4 
and not at deuterium-hydrogen bond itself.  The magnitude of effect is consistent 
with a secondary deuterium isotope effect, where kH/kD is usually < 1.5 (Carey et al, 
2008). 
The data also reveal the metabolism of corticosterone and D8-corticosterone by 
human hepatic cytosol is subject to substrate inhibition, but that this phenomenon is 
also confined to supraphysiological concentrations.  Similar  observations have been 
made for other steroids, including testosterone (Di et al, 2008) and aldosterone (Chen 
et al, 2011), and are thought to be due to the presence of an alternative 
non-productive binding pocket within human 5β-reductase (Faucher et al, 2008) 
which accommodates steroids with a short C-17 constituent and prevents access of 
substrate to the active binding site. 
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Within the physiological range of concentrations for both cortisol and corticosterone, 
however, rate of catalysis shows an effectively linear response to increasing substrate 
concentration, suggesting the enzyme does not become saturated when 
glucocorticoid concentrations are relatively high, such as during the stress response. 
Under these circumstances, changes in clearance may occur in the absence of 
enzyme saturation, due to altered expression of the enzyme (Boonen et al, 2013) and 
potentially changes in hepatic blood-flow.  Our kinetic findings are are consistent 
with those reported by others in which the Km of 5β-reductase for cortisol is within 
the micromolar range (Iyer et al, 1990; Chen et al, 2011).  However, the rate of 
metabolism of corticosterone by human 5β-reductase/3α-HSD is approximately 4-
fold greater than that of cortisol. 
The current data reflect the metabolism of active glucocorticoids by 5β-reductase and 
3α-HSD in combination, and do not enable conclusions to be drawn regarding each 
reaction in isolation (although the intermediate metabolite dihydrocortisol was 
detected, its rate of formation was not linear over the incubation periods studied).  
The combined action of both enzymes on cortisol and corticosterone has not 
previously been assessed, but when purified human 5β-reductase has been studied in 
isolation (Chen et al, 2011), findings also suggest the enzyme metabolises 
corticosterone more efficiently than cortisol (kcat/Km = 0.87 vs 0.21 min-1 µM-1). 
Inactivation of cortisol by 11β-HSD2 is a second major pathway for glucocorticoid 
clearance, reflected in urinary excretion rates of 11-keto metabolites which are 
broadly similar to those of 11-hydroxyl metabolites (Andrew et al, 1998; Baudrand 
et al, 2011; Arlt et al, 2011).  The current data are consistent with previous studies 
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carried out in tissue homogenates, which suggest the Km of 11β-HSD2 for 
corticosterone is within the physiological range (low nanomolar) of the substrate 
(Albiston et al, 1994; Stewart et al, 1994; Gong et al, 2008).  Reaction velocity 
continued to increase linearly with cortisol concentration beyond the Km for 
corticosterone, indicating that should saturable kinetics occur for cortisol, the Km 
exceeds that of corticosterone.  This finding is also consistent with the above studies, 
which suggest the Km of 11β-HSD2 for cortisol is approximately one order of 
magnitude greater than that for corticosterone.  To assess the interconversion of 
11-hydroxy and 11-keto steroids fully would require similar experiments to be 
performed using 11β-HSD1, but the current data suggest that both glucocorticoids 
are metabolised by 11β-HSD2 in a similar manner, in that the enzyme is unlikely to 
be saturated by either substrate under normal circumstances.     
In the absence of significant differences in the proportion of free to bound substrate 
(Stroupe et al, 1978; Dunn et al, 1981), a proportionately higher affinity of 
5β-reductase/3α-HSD for corticosterone suggests its hepatic extraction ratio, and 
therefore clearance, exceeds that of cortisol.  Clearance also reflects the metabolism 
of glucocorticoids by processes not assessed in the current study, including oxidative 
removal of the C20, C21 side chain and 6β-hydroxylation, although these processes 
do not make a major contribution to total rates of clearance in healthy individuals 
(Sandberg et al, 1957; Voccia et al, 1979).  
In conclusion, in vitro data suggest human hepatic enzymes clear corticosterone 
approximately 4-fold more rapidly than cortisol.  In order to assess the in vivo 
metabolism of corticosterone, use of the stable isotope tracer 
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2,2,4,6,6,17α,21,21-[2H]8-corticosterone is proposed.  Metabolism of this tracer 
reflects metabolism of the tracee.  The following chapter (Chapter 5) discusses the 
development of an assay to quantify the deuterium labelled tracer and endogenous 
compound, in order for its use to be taken forward into pharmacokinetic (Chapter 6) 
and pharmacodynamic (Chapter 7) studies. 
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5.1.'Introduction'and'Aims'
The aim of the work presented in the current chapter was to develop and validate a 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay to quantify 
the deuterium labelled compound 2,2,4,6,6,17α,21,21-[2H]8-corticosterone 
(D8-corticosterone) in human serum. 
5.2.'MS/MS'optimisation'
The assay was developed on a QTRAP® 5500 triple quadrupole mass spectrometer 
(Ab Sciex, Framingham, MA) using atmospheric pressure chemical ionisation 
(APCI) in positive ionisation mode (500 °C).  Nitrogen was used as source and 
curtain gas (40 psi). 
5.2.1.'Q1'MS'
A full scan (Q1) was undertaken (m/z 353–357) to confirm the presence of the 
expected [M+H]+ ion for D8-corticosterone (average MW 354.46).  The precursor 
ion, selected based upon maximal intensity at m/z 355.1 (Figure 5-1A) was analysed 
in Q1 selected ion monitoring (SIM) mode while varying voltage was applied to the 
orifice plate to determine optimal declustering potential (DP; Figure 5-1B).  Default 
entrance potential for positive ions was chosen (10 V).  
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Figure'5)1.'D8)Corticosterone'Q1'MS'
Panel! A:! Full! scan! (Q1)! mass! spectrum! (m/z& 353M357)! confirming! presence! of! expected!
protonated!molecule! (m/z! 355.1).! ! Panel! B:!Q1! selected! ion!monitoring! (SIM;!m/z&355.1)!




The precursor ion (m/z 355.1) was isolated by SIM (Q1) using the voltages 
determined above, and a full scan of Q3 (product ion scan) was performed to 
determine optimal MRM transitions (Figure 5-2A) following collision-induced 
dissociation (nitrogen gas; 2.6 x 10-5 Torr).  The four most abundant product ions 
were selected for MRM mode, and collision energy (CE) and collision cell exit 
potential (CXP) were optimised for each transition by monitoring the signal intensity 
produced across a range of applied voltages (Figure 5-2B and C).  The final product 
ion for quantitative analysis (m/z 337.2), corresponding to loss of water from the [M 
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The above procedure was also applied to unlabelled corticosterone to determine 
MRM transitions and voltages for quantitation by MS/MS.  In the clinical studies 
described in Chapter 6 and 7, quantification of a number of other steroids was 
required.  Optimal MS parameters for these analytes (previously established 




Compound! dependent! parameters! for! simultaneously! quantified! compounds! listed!













D8Mcorticosterone! 355.147! 337.000! 250! 116.000! 10! 19.000! 14.000!
Corticosterone! 347.136! 91.100! 100! 66.000! 10! 69.000! 8.000!
Cortisol! 363.203! 121.000! 100! 131.000! 10! 29.000! 14.000!
EpiMcortisol! 363.203! 77.000! 100! 141.000! 10! 101.000! 14.000!
D3Mcortisol! 366.198! 121.200! 100! 121.000! 10! 27.000! 20.000!
D4Mcortisol! 367.017! 121.100! 100! 121.000! 10! 25.000! 20.000!
 





with! varying! collision! energy! (CE;! panel! B)! and! collision! cell! exit! potential! (CXP;! panel! C).!!
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5.3.'Liquid'chromatography'
Sample injection and chromatography was performed on the Acquity ultra 
performance liquid chromatography platform (UPLC®; Waters, Milford, MA).  
During assay development, chromatographic separation was achieved by gradient 
elution using a pentafluorophenyl (PFP) HPLC column (XSelect HSS PFP 100Å, 2.5 
µm, 3 mm x 100 mm; Waters) with a total chromatographic run time of 9.0 minutes.  
To reduce run time, the assay was transferred to a UPLC column (Acquity UPLC 
HSS PFP 100Å, 1.8 µm, 2.1 mm x 50 mm; Waters), with a run time of 3.2 minutes.  
For the final method, which required quantification of multiple endogenous and 
deuterated compounds, a run time of 6.0 minutes was required using an octadecyl 
carbon (C18) column (SunFire, 100Å, 3.5 µm, 2.1 mm x 100 mm; Waters), using an 
isocratic method to separate compounds by reverse-phase chromatography.  Sample 
(15 µl) was injected onto the column and steroid eluted with mobile phase (70 % 
water, 30 % acetonitrile; 0.1 % formic acid; flow rate 0.5 ml/min; temperature 10 
°C). 
Representative mass chromatograms (347.1 - 91.1 and 355.1 - 337.2) for 
corticosterone and D8-corticosterone are shown in Figure 5-3. 





91.1! (panel! B)! corresponding! to! fragmentation! of! [M+H]+! ions! for!D8Mcorticosterone! and!
corticosterone/epiMcorticosterone! respectively! (standards! prepared! in! stripped! serum!
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5.4.'Extraction'of'glucocorticoids'from'serum'samples'and'standards'
In 16 × 150 mm glass culture tubes, serum was enriched with internal standard 
(epi-corticosterone; 20 ng (Chapter 6) or 200 ng (Chapter 7), dissolved in 10 - 20 µl 
methanol).  Glucocorticoids were extracted from serum using a liquid-liquid 
extraction, which was optimised by assessing recovery of serum spiked with various 
steroids using different solvents and sample: solvent ratios (Figure 5-4).  Ethyl 
acetate extraction produced a visibly contaminated organic phase, whereas extracts 
following chloroform extraction were clear.  Following addition of chloroform (10 
volumes), tubes were capped and mixed thoroughly.  Excess plasma and lipid were 
removed using a glass pipette and discarded.  The chloroform layer containing 
steroids was decanted into a clean 13 × 100 mm glass culture tube, and then 
transferred into a second clean glass tube before drying under 60 ºC OFN.  Steroidal 
extracts were dissolved in mobile phase (70 % water, 30 % acetonitrile, 0.1 % formic 
acid v/v; 100 µl), transferred to disposable microcentrifuge tubes containing filter 
units (Spin-X, pore size 0.22 µm, Corning, San Nicolás, Mexico) and centrifuged 
(6000 rpm, 3 mins).  The filtrate was transferred to auto sampler vials and either 
stored (-20 °C) or analysed immediately by LC-MS/MS (injection volume 15 µl). 
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Figure'5)4.'Recovery'of'steroids'from'serum'using'chloroform'extraction'
Human! serum! (900!µl)!was! spiked!with!D8Mcorticosterone,!D4Mcortisol,! epiMcorticosterone!







Serum was obtained during the clinical studies detailed in chapters 6 and 7.  
Commercially obtained stripped serum was used for standards and assay validation.  
Serum was thawed at room temperature prior to extraction.   
5.5.2.'Preparation'of'standard'solutions'
From stock solution (1 mg/ml in methanol), standard solutions were prepared in 12 × 
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D8-corticosterone in methanol.  From these, 20 µl was transferred to 600 µl 
charcoal-stripped human serum to give the total mass of analyte required (0.15 - 10 
ng per standard for clinical studies in Chapter 6 and 1 - 200 ng per standard for 
Chapter 7).  Aqueous standards were also prepared (containing 10 ng analyte) to 
confirm retention times and instrumental sensitivity. 
5.5.3.'Sample'volume'
A sample volume of 600 µl was used for assay validation and in the bolus 
pharmacokinetic study (6.2.6).  Because data derived from serum samples were not 
consistent with expected sensitivity derived from analysis of stripped serum 
standards (section 5.6.3), the assay volume was increased (1 ml) in subsequent 
clinical studies. 
5.5.4.'Data'analysis'
Compounds were quantified using Analyst software (version 1.6, AB SCIEX).  The 
area under the peak of interest was integrated and expressed as a ratio of the area 
under internal standard (epi-corticosterone).  Peak area ratio (! axis) was plotted 
against mass of steroid (! axis), and a line of best fit was drawn in the form 
! = !" + !. 
Figure 5-8A and Figure 5-8B show representative standard curves for corticosterone 
and D8-corticosterone, respectively.  Weighting was adjusted if necessary to 
optimise reproducibility of quantitation of low concentrations.  Interpolation using 
the line of best-fit equation was used to determine steroid concentrations of serum 
samples.  Controls containing mobile phase only were included at the start and end 
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of each batch of standards or unknowns to ensure carry-over of analyte did not arise 
between adjacent samples. 




A linear response was defined by a regression coefficient (r) value of >0.99 across 
the range of expected serum concentrations.  In repeated experiments (n = 3) during 
development of the assay in aqueous standards, a linear response was readily 
demonstrated for unlabelled corticosterone, but could not be demonstrated for 
D8-corticosterone under identical experimental conditions (See Figure 5-5 for 
representative data).  
Figure' 5)5.' Linearity' of' response' in' LC)MS/MS' analysis' of' corticosterone' and' D8)
corticosterone'
Methanolic! standards! prepared! in! duplicate! containing! analyte! (0! –! 40! ng)! and! internal!




In troubleshooting of the assay, loss of deuterium from the D8-corticosterone tracer 
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because they commonly display similar extraction recovery, chromatographic 
retention times and ionisation efficiency to the analyte of interest.  However, 
instability of the compounds is a recognised problem, reflected in loss of deuterium 
in exchange for hydrogen and reduced or absent signal intensity (Chavez-Eng et al, 
2002; Stokvis et al, 2005).  D-H exchange was confirmed by performing Q1 MS in 
SIM mode using m/z ratios which corresponded to the protonated products of D-H 
exchange from the D8-labelled compound (Figure 5-6).  




H! exchange! from! D8Mcorticosterone! ([M+H]+! 355.1,! black! line)! occurring! at! number! of!
positions!indicated!by!coloured!lines:!1!(green),!2!(blue),!3!(red)!and!4!(purple).!
 
To attempt to stabilise deuterium labels on the compound, methoxime-trimethylsilyl 
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GC-MS/MS as described in section 2.3.7.3.  However, this technique could not be 
optimised to achieve sensitivity required for quantification of the compound at the 
concentrations required. 
Linearity was achieved (Figure 5-8) in the final LC-MS/MS method employed to 
quantify the tracer in the presence of D-H exchange comprised summing peak areas 
corresponding to [M + H]+ corticosterone ions labelled with 4 - 8 deuteriums. 
5.6.2.'Ion'suppression'
Ion suppression describes the phenomenon of reduced ionisation efficiency as a 
result of endogenous or exogenous compound(s) in the sample matrix which co-elute 
with the analyte of interest and compete for ionisation efficiency in the ionisation 
source (Annesley, 2003).  Although ion suppression is more frequently a problem 
during electrospray ionisation, it can occur in APCI during the transfer of charge 
from the corona discharge needle to the analyte. 
To investigate whether ion suppression occurs in the analysis of D8-corticosterone 
by LC-MS/MS, detector response (analyte peak area) was assessed in sample matrix 
(mobile phase prepared from human serum (1 ml), processed as described in section 
5.4) spiked with analyte (50 ng D8-corticosterone, D4-cortisol, epi-corticosterone 
and epi-cortisol) after processing).  Comparison was made with matrix used in 
standards (human steroid-stripped serum) spiked post-processing, and spiked mobile 
phase that had not undergone processing. 
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5.6.2.1.'Data'analysis'
Comparison of analyte peak area between experimental matrices was undertaken by 
one-way ANOVA with Tukey’s post hoc-test (GraphPad Prism V5.01, GraphPad 
Software Inc, La Jolla CA).  Independent analyses were undertaken for each analyte. 
5.6.2.2.'Results'
Analyte peak area in sample matrix (unstripped serum) did not differ to that in 
standard matrix (stripped serum) for any of the analytes studied (Figure 5-7).  For all 
analytes, peak area was lower in aqueous standards in comparison to both biological 
matrices (p < 0.05, reflecting a degree of ion enhancement and/or increased 
background signal in serum vs aqueous samples.  Therefore, stripped serum was used 
in all assays for preparation of standards to minimise matrix effects. 
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Figure'5)7.'Analysis'of'glucocorticoids'by'LC)MS/MS:'assessment'of'ion'suppression'
Comparison! of! analyte! peak! area! following! addition! of! analyte! (50! ng;! n! =! 3)! to! three!





The limits of quantitation (LoQ) for corticosterone and D8-corticosterone were 
calculated by assessing the analyte/internal standard peak area in steroidal extracts (n 
= 6 at each concentration) from stripped human serum (600 µl) spiked with analyte 
and internal standard (epi-corticosterone 20 ng).  The quantifiable range of the 
standard curve was defined as the range at which the coefficient of variation (CV) 
and accuracy of estimates was ≤ 15 % (20 % at the lower LoQ).  Using these criteria, 
the LoQ for corticosterone was 0.25 ng/ml and for D8-corticosterone 0.42 ng/ml 
(Figure 5-8 and Table 5-2).  Accuracy and precision were also confirmed to be 
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mid-range (15 ng/ml; 43.3 nM) and high-range (35 ng/ml; 101 nM) serum samples 
from clinical studies. 




Standard! curves! in! stripped! serum! spiked! with! corticosterone! (panel! A)! and! D8M
corticosterone! (panel! C);! internal! standard! epiMcorticosterone.! ! Standard! curve! (weighted!
1/x)! derived! from! a! single! standard! at! each! point.! ! Dashed! box! indicates! range! of!
concentrations! chosen! to! determine! lower! limit! of! quantitation,! detailed! in! (B! &! D):!
Replicates! (n!=!5)!performed!at!0.25,!0.42,!0.83!and!1.25!ng/ml! (assuming!600!µl! sample!


























































































































IntraMassay! coMefficient! of! variation! (CV)! determined! from! replicates! of! 5! as! detailed! in!










RMSE! Range! RMSE! Range!
0.25! 6.0!%! 95.3!%!M!109.6!%! 5.3!%! 14.2!%! 78.8!%!M!126.3!%! 17.8!%!
0.42! 7.0!%! 92.8!%!M!110.6!%! 7.5!%! 8.4!%! 85.2!%!M!108.7!%! 10.6!%!
0.83! 3.3!%! 99.0!%!M!105.8!%! 4.2!%! 6.3!%! 85.8!%!M!108.8!%! 8.9!%!
1.25! 4.6!%! 96.0!%!M!105.8!%! 5.4!%! 5.5!%! 96.0!%!M!113.2!%! 5.8!%!
3.33! 2.5!%! 110.8!%!M!105.3!%! 1.7!%! 4.1!%! 96.3!%!M!108.3!%! 4.4!%!
16.7! 2.2!%! 100.3!%!M!106.1!%! 2.3!%! 2.7!%! 99.1!%!M!107.2!%! 2.9!%!
'
5.7.'Discussion'
We have developed and validated a LC-MS/MS assay to quantify corticosterone and 
the deuterium labelled tracer D8-corticosterone in human serum.  Deuterium-
hydrogen exchange affects the quantification of D8-corticosterone, and the assay has 
been adjusted to account for this.  The assay is highly sensitive and unaffected by ion 
suppression in human serum, with a lower limit of quantitation of 0.25 ng/ml (0.7 
nM) for corticosterone and 0.42 ng/ml (1.2 nM) for D8-corticosterone.  Development 
and validation of the assay is a key requirement for subsequent clinical studies, 
which aim to assess D8-corticosterone pharmacokinetics (Chapter 6) and 
pharmacodynamics (Chapter 7). 
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Chapter'6:'In#vivo'metabolism'of'corticosterone
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6.1.'Introduction'and'Aims'
Data presented in Chapter 4 demonstrate the enzymes that catalyse the key steps in 
glucocorticoid clearance metabolise corticosterone more rapidly than cortisol.  When 
clearance of substrate is greater, rate of production must also be greater in order to 
sustain a given substrate concentration.  Therefore, the rate of turnover of 
corticosterone may be disproportionately high, despite the relatively low circulating 
concentration of the compound.  Rapid turnover of substrate is expected to result in 
circulating concentrations that are highly sensitive to changes in rates of production 
and/or clearance.  Turnover is therefore an important determinant of hormone action 
within a dynamic system such as the HPA axis. 
In this chapter, the aim was to establish whether differential hepatic metabolism of 
corticosterone and cortisol demonstrated in vitro are reflected in higher clearance of 
corticosterone than cortisol in vivo.  Two different approaches were employed to 
address these aims.  Firstly, isotope dilution at steady state was assessed using the 
deuterium-labelled corticosterone tracer discussed in the previous two chapters.  
Data from these studies were used to design dosing protocols for the clinical study 
presented in Chapter 7.  Secondly, production rates were assessed by analysis of 
urinary steroids by gas-chromatography mass tandem spectrometry (GC-MS/MS).  
6.1.1.'Aims'
i. To establish the volume of distribution and half life of the stable isotope 
tracer D8-corticosterone following bolus injection in healthy male volunteers 
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ii. Using results from (i), to undertake primed steady state infusion, to establish 
rate of clearance and production of corticosterone and pilot optimal infusion 
rates for ACTH suppression (Chapter 7) 
iii. To quantify normal daily urinary excretion rates of corticosterone and 
metabolites (17-deoxysteroids), and compare these to the excretion rates of 
cortisol and metabolites (17-hydroxysteroids) 
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6.2.'Methods:'D8)corticosterone'pharmacokinetic'studies'
6.2.1.'Ethical'and'Research'Governance'Approvals'
Approvals were obtained from the South East Scotland Research Ethics Committee 
(11/SS/0046) and NHS Lothian Research and Development (2011/R/END/03).  
Research support approvals were obtained from the Wellcome Trust Clinical 
Research Facility (WTCRF), clinical laboratories, and radiopharmacy at the Royal 
Infirmary, Edinburgh (RIE). 
6.2.2.'Participants'
Healthy male volunteers (bolus study: n = 3; steady state infusion study: n = 6) were 
recruited by advertisement at the University of Edinburgh. 
6.2.2.1.'Inclusion'criteria'
• Male 
• Age 20-50 years 
• Able to give informed consent 
• No major illnesses 
• BMI 20-25 kg/m2 
• No regular medication 
• Alcohol intake < 28 units per week 
• Normal full blood count (FBC), urea and electrolytes (UE), liver function 
tests (LFT), thyroid function tests (TFT), and blood glucose. 
6.2.2.2.'Exclusion'criteria'
• Glucocorticoid treatment within the previous 3 months by any route 
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• Blood donation within the preceding 3 months 




Standing height was measured to the nearest 0.1 cm with volunteers stood (without 
shoes), feet parallel and head, shoulder blades and heels against the back of a wall 
mounted ruler. 
6.2.3.2.'Measurement'of'weight'
Weight was measured to the nearest 0.1 kg using an electronic scale (Seca, 
Birmingham, UK) after volunteers removed outdoor clothing, shoes and heavy items 
from pockets. 
6.2.3.3.'Measurement'of'systolic'and'diastolic'blood'pressure'
Blood pressure was measured after sitting for at least 10 minutes using a 705IT 
automatic blood pressure monitor (OMRON Healthcare Europe BV, Hoofddorp, 
NL). 
6.2.4.'Screening'visits'
Participants attended the WTCRF at RIE, where written informed consent was 
obtained, weight and height recorded, and a brief medical history documented to 
ensure no contraindications to participation were present.  Blood samples were taken 
for FBC, UE, LFT, TFT, and glucose (analysed at clinical laboratories, RIE). 
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6.2.5.'Study'visits'
Participants attended the WTCRF, RIE at 0830h following an overnight fast (from 
2200h).  Intravenous cannulae (18G) were inserted in each antecubital fossa using an 
aseptic technique.  Blood pressure and pulse were recorded, and venous blood was 
collected for basal assessment of cortisol, D8-corticosterone and corticosterone.  
Beginning at 0900h, D8-corticosterone was administered through the cannula in the 
left arm, and blood samples collected according to the sampling protocol through the 
cannula in the right arm.  At the end of the study visit, cannulae were removed, blood 
pressure and pulse were rechecked and participants provided with lunch.  In the 




D8-corticosterone was dissolved in pharmaceutical grade ethanol and filtered in the 
radiopharmacy to form a sterile stock solution, stored (-40 °C) for a maximum of 8 
weeks.  Solutions were defrosted and infusions prepared in the clinical research 
facility on the morning of each study.   
6.2.6.2.'Tracer'administration'protocol'
D8-corticosterone stock solution was prepared in ethanol as above at 100 µg/ml (1 
ml aliquots).  For a single bolus dose, stock solution (0.5 ml) was added to sodium 
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chloride 0.9% w/v (49.5 ml) to give a final concentration 1 µg/ml.  An intravenous 
bolus (50 µg) was administered over 5 minutes. 
6.2.6.3.'Sample'collection'and'processing'
Serum samples for D8-corticosterone were obtained in serum gel tubes (4.9 ml, 
Monovette®, Sarstedt, Nümbrecht, Germany).  Samples were gently mixed by 
inverting several times, left for centrifugation (1912 × g, 10 min, 4 °C) to obtain 
serum, which was separated and stored (aliquots of 600 - 700 µl) at -80 ºC for 
analysis by LC-MS/MS (Chapter 5). 
6.2.6.4.'Sampling'protocol'
Samples were drawn at 2 minute intervals from t  = 0 (time of beginning of bolus 
injection) until t = 16 mins, 5 minute intervals from t = 20 - 45 mins, and 15 mins 
from t = 45 - 180 mins. 
6.2.7.'Steady'state'study'
Data from the bolus study were used to determine doses (section 6.2.8) for a primed 
steady state infusion in healthy male subjects (n = 6), recruited according to the 
methods and criteria described in section 6.2.2.  We aimed for a target steady state 
concentration of 15 nM. 
6.2.7.1.'Tracer'administration'protocol'
D8-corticosterone stock solution was prepared in ethanol (section 6.2.6.1) at 909 
µg/ml (3 ml aliquots).  For each study visit, stock solution (2 ml) was added to 
sodium chloride 0.9 % w/v (498 ml) to give a final concentration 3.64 µg/ml.  An 
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intravenous bolus (76.7 µg) was administered over 3 minutes, followed by constant 
infusion (7.4 µg/min) until t = 180 mins.  A sample of infusate (1 ml) from each 
study visit was retained in order to confirm the infused concentration of 
D8-corticosterone. 
6.2.7.2.'Sampling'protocol'
Samples were drawn at 15 minute intervals from t = 0 - 180 mins.  Sample 
processing and analysis was undertaken as described in section 6.2.6 with samples 
stored in larger aliquots as compared to the bolus study (900 µl serum vs 450 - 600 
µl).  In addition to D8-corticosterone, LC-MS/MS analysis of endogenous 
corticosterone and cortisol was also undertaken in order to assess tracer enrichment 
and to gain preliminary data on the impact of tracer infusion on the normal diurnal 
profile of circulating glucocorticoid concentrations. 
6.2.8.'Pharmacokinetic'analysis'
Pharmacokinetic analysis was undertaken using Kinetica software (Adept Scientific, 
Letchworth Garden City, UK). 
6.2.8.1.'Bolus'pharmacokinetic'study'
Pharmacokinetic parameters were derived according to the following equations: 
Elimination'rate'constant'(Kel)'
! !!" = !" !!!! !
  
Volume'of'distribution'(Vd)'
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! !! = !"#$!!  
Where dose = bolus dose and C0 = plasma concentration at t = 0 (peak plasma 
concentration was used as an approximation for C0). 
Clearance'(Cl)'
! !" = !!!!×! !" 
6.2.8.2.'Steady'state'pharmacokinetic'study'
Priming'dose'
The priming dose required for the target steady state concentration Css was 
calculated according to the following equation: 
 !"#$#%&!!"#$ = !!!×!! 
Rate'of'infusion'(Ri)'
! !! = !!!×!" 
Where (Cl) = clearance estimated from bolus study (section 6.2.6) 
Clearance'(Cl)'
! !" = !!!!! 
Volume'of'distribution'(Vd)'
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! !! = !!! ! 
Where ! ! = tracer: tracee ratio 
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6.3.'Urinary'metabolism'of'corticosterone'vs'cortisol'
6.3.1.'Source'of'samples'
In a recent randomised controlled trial conducted by the supervisors’ group (Upreti et 
al, 2014), 24 hour excretion rates of 17-hydroxysteroids had previously been 
quantified in healthy male volunteers (age 20-85 years).  Principal exclusion criteria 
were glucocorticoid use in the previous 3 months; diabetes mellitus or impaired 
glucose tolerance; significant hepatic, renal or thyroid disease; and BMI ≥ 40 kg/m2.  
Each participant collected a 24 hour urine sample (beginning at the 2nd void), the 
volume of which was measured. 
6.3.2.'Methods'
From aliquots (20 ml) of urine collected before administration of the study drug, 
steroids were extracted, derivatised and quantified (section 2.3.7).  Repeat analysis (n 
= 24; chosen at random) of remaining organic extracts stored (-20 °C) from samples 
collected pre-randomisation was undertaken to extend the range of steroids 
quantified to include both 17-deoxy- and 17-hydroxy-steroids.   
6.3.3.'Data'Analysis'
Data were analysed using Xcalibur 2.1 software (Thermo Scientific Inc, Waltham, 
MA).  In stored organic extracts used to quantify 24 hour urinary steroid excretion 
rates, original standard curves did not contain 17-deoxysteroids.  Concentrations of 
these analytes were therefore calculated from a new standard curve spiked with the 
same mass of internal standard as the original samples.  Validity of this approach 
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was assessed by assessing equivalence of original and new standard curves produced 
for 17-hydroxysteroids (RMS for difference in gradient = 10.9 %), and by comparing 
estimates of concentrations produced from each standard curve (Figure 6-3). 
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6.4.'Results'
6.4.1.'Pharmacokinetic'studies'







Age!(years)! 24.0! ±! 2.6! 24.7! ±! 5.6!
BMI!(kg/m2)! 23.4! ±! 1.4! 22.2! ±! 1.3!
 
6.4.1.1.'Bolus'pharmacokinetic'study'
A bolus dose of 50 µg D8-corticosterone resulted in a peak serum concentration 
(occurring at t = 4 mins) of 9.77 ± 1.85 nM (Figure 6-1) and estimated Vd  14.1 ± 1.6 
litres.  The tracer was rapidly eliminated, and was not quantifiable in samples beyond 
t = 30 mins.  The decline in serum corticosterone concentration was modelled 
according to a single compartment model (Kel 0.121 ± 0.042 min-1; t ½ 9.7 ± 3.3 
mins).  Clearance, derived from these parameters, was 1.46 ± 0.36 l/min. 
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Measured infusate concentration was higher than anticipated concentration 
(measured 4.12 ± 0.13 µg/ml; calculated 3.64 µg/ml; CV 6.0 %).  Data are derived 
from measured rather than calculated concentrations. 
Preliminary analysis (n = 3) was performed while the study was underway in order to 
determine whether any adjustment to the infusion protocol was required.  
D8-corticosterone reached steady state at t ~ = 105 mins (Figure 6-2).  The interval 
to steady state was longer than expected from the bolus pharmacokinetic data, and 
given the use of a priming dose.  As a result, in the final 3 participants, an 
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15 min intervals) after discontinuing D8-corticosterone infusion, in order to 





Mean Css (t = 105 - 180 mins) was 21.3 ± 0.5 nM.  Over the same interval, mean 
tracer: tracee ratio was 9.7 ± 1.3, and corticosterone production rate (Ra) at steady 
state 0.49 ± 0.06 µg/min (1.42 ± 0.18 nmol/min).  Calculated clearance was 1.1 ± 
0.20 l/min.  The decay in serum corticosterone concentrations following 
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with Kel 0.031 ± 0.014 min-1 and t ½ 28.5 ± 3.3 mins.  Apparent Vd  derived from 
clearance and half life in the steady state study was 45.7 ± 5.3 l. 












Mean age (± standard deviation) of the study participants (n = 24) was 40.9 ± 21.0 
(range 21-85).  Mean BMI (± standard deviation) was 27.0 ± 3.0 (range 22.5-33.9).  
Excretion rates of urinary glucocorticoids over 24 hours are illustrated in Figure 6-3 
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Table&6(3.&Daily&excretion&rate&of&urinary&corticosterone&(B)&metabolites&(17(
deoxysteroids)&and&cortisol&(F)&metabolites&(17&hydroxysteroids)&in&male&volunteers&
A( =( 118dehydrocorticosterone;( THA( =( 118dehydro8tetrahydrocorticosterone;( THB( =(
tetrahydrocorticosterone;( E( =( cortisone;( THE( =( 5β8tetrahydrocortisone;( THF( =( 5β8








118Dehydrocorticosterone( 9.4( 7.3( 11.2( 2.9( 19.1(
Corticosterone( 11.1( 8.1( 12.5( 2.5( 21.5(
THA(
(
106.6( 77.9( 142.5( 38.3( 258.6(
THB(
(
70.5( 56.8( 119.8( 39.4( 187.6(
Allo8THB( 305.9( 232.0( 462.5( 131.9( 791.6(
178deoxy8β8cortolone(( 31.1( 7.1( 53.5( 0.5( 157.3(





Cortisone( 107.3( 86.9( 156.8( 53.0( 183.1(
Cortisol(
(
96.1( 83.4( 119.1( 39.4( 161.0(
THE(
(
2989.1( 2187.2( 3305.5( 1794.7( 4297.9(
THF(
(
1479.1( 1223.2( 1733.6( 816.3( 2033.7(
Allo(8(THF( 1599.5( 1024.3( 2210.1( 493.0( 2995.1(
β8Cortolone( 394.1( 306.9( 515.9( 253.5( 780.9(
α8Cortolone( 357.9( 278.0( 435.9( 229.5( 868.7(
β8Cortol(( (( 354.2( 301.7( 474.8( 182.0( 704.5(
Total(
(µg/24(hours)(
178deoxysteroids( 615.4( 476.5( 744.2( 291.2( 1238.6(
178hydroxysteroids( 6844.1( 5753.8( 8600.5( 4524.7( 9627.5(
Ratio(17(deoxy/hydroxy( 8.8%( 7.7%( 11.0%( 5.4%( 13.3%(
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6.5.&Discussion&
The half-life, clearance and volume of distribution of the stable isotope tracer D8-
corticosterone following bolus injection and steady-state infusion have been 
established in the above studies, which enable a number of observations to be made 
regarding the in vivo metabolism of corticosterone.  The key finding of both 
pharmacokinetic studies is the rapid clearance of corticosterone, consistent with in 
vitro studies, which demonstrate the hormone, is a high-affinity substrate for the key 
enzymes required for hepatic clearance (Chapter 4).  The magnitude of the difference 
in rates of metabolism of corticosterone and cortisol by human hepatic cytosol is in 
keeping with the current in vivo data: clearance of corticosterone derived from the 
bolus study (1.11 l/min) and steady state study (1.46 l/min) proceeds 3-5 times more 
rapidly than that of cortisol – for which recently reported clearance is consistently 
between 0.27 and 0.33 L/min (Derendorf et al, 1991; Thomson et al, 2007; Stimson 
et al, 2009; Perogamvros et al, 2011).   
Rapid clearance of corticosterone is reflected in its elimination half-life (t ½), which 
in both studies is short in comparison to that of cortisol.  However, estimates of t ½ 
differed considerably between bolus and steady state studies, and t ½ was 
approximately 3-fold longer in the steady state study.  Similar differences were seen 
in Vd.  A number of factors might account for these apparent discrepancies.  Firstly, 
assay factors reduce certainty around estimates of circulating tracer concentrations in 
the bolus study, where concentrations achieved were lower, particularly at later time 
points.  Sample volume was also increased in the steady state study to improve assay 
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sensitivity.  Secondly, administration of tracer as a slow bolus injection results in 
potential error in modelling the ‘peak’ of the concentration curve, which was 
exaggerated due to the shorter than expected t ½.  For these reasons, and because of 
assumptions made in modelling the data to first order kinetics (discussed below), 
confidence is higher in estimates of pharmacokinetic parameters derived from 
administration of tracer at steady state rather than as a bolus injection. 
Although experimental error due to the above factors might account to some extent 
for differences in the pharmacokinetic parameters derived from the two studies, 
biological factors may also be of importance.  Unlike clearance, estimated t ½ and Vd 
for cortisol vary considerably across different studies, with estimated mean t ½ 
between 60 and 130 minutes in healthy volunteers, and Vd varying from 20 to 50 L 
(Derendorf et al, 1991; Bright, 1995; Thomson et al, 2007; Perogamvros et al, 2011).  
Inter-individual variability is also high within the above studies.  Reproducible data 
on these measures is therefore difficult to achieve.  Due to this variability, it is 
difficult to fit glucocorticoid pharmacokinetics to a given compartmental model.  In 
the current studies, a single compartment model has been assumed for the calculation 
of clearance of a bolus dose; whereas the steady state study has been analysed 
without compartmental constraints.  Previous investigators have variably fitted data 
to single- or two-compartment models (Toothaker et al, 1982; Thomson et al, 2007; 
Perogamvros et al, 2011).  In the two-compartment model, rapid distribution of free 
hormone into tissues precedes a slower elimination phase, resulting in non-linear 
kinetics.  Non-linearity also occurs as clearance enzymes approach saturation; 
although the previously discussed in vitro data suggest this is unlikely. 
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A final factor that requires consideration in interpreting the pharmacokinetic data for 
D8-corticosterone is the role of plasma protein binding.  A relatively high proportion 
of free: bound hormone is expected to increase Vd and therefore tend to increase t ½ 
without altering clearance.  This phenomenon might explain dose dependent kinetics 
previously reported for cortisol and corticosterone (Peterson et al, 1960; Toothaker et 
al, 1982).  However, clearance of cortisol has recently been shown to correlate 
inversely with binding capacity (Perogamvros et al, 2011), via as yet undefined 
mechanisms.  In the current study, bolus pharmacokinetics were assessed near the 
diurnal peak, when saturation of the high affinity binding protein CBG might be 
exerting an effect, and therefore capacity for binding of the corticosterone tracer is 
reduced.  Conversely, in the steady-state study the decline in tracer concentration 
was measured in the early afternoon when occupancy of CBG by endogenous 
hormone is expected to be lower.  Protein binding might therefore influence kinetics 
according to prevailing concentrations of endogenous glucocorticoid. 
The current studies also aimed to estimate the rate of production of corticosterone 
using the principle of isotope dilution.  Although this was achieved, the physiological 
relevance of the estimate is limited because the high tracer: tracee ratio (required for 
accurate quantitation of tracer) means that the tracer may have impacted upon the 
rate of appearance of the tracee.  Perhaps related to this, the rate of production is low 
compared to previous estimates derived from infusion of radiolabelled tracer 
(Peterson et al, 1960; Huther et al, 1970), although non-specific assay methodology 
may have over-estimated production rates in these studies. 
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In addition, urinary corticosterone metabolites were assessed in healthy men.  
Analysis of urinary steroid profiles has enabled the quantitation of a number of 
corticosterone metabolites which have not, to our knowledge, previously been 
quantified.  In general, urinary profiles suggest the metabolism of corticosterone 
mirrors that of cortisol.  Tetrahydro-reduced metabolites of both 11-hydroxy- and 
11-ketosteroids are by far the most abundant metabolites; and the total excretion rate 
is broadly proportional to basal plasma concentrations (Zumoff et al, 1974).  Our 
data are broadly consistent with this, with estimated production rates of 6.84 mg/24 
hours for cortisol and 0.62 mg/24 hours for corticosterone, corresponding to a 
corticosterone/cortisol ratio of 8.8 %.  
Use of urinary glucocorticoid profiles to determine glucocorticoid production rate is 
limited by the inability to quantify all urinary metabolites.  In the above study this 
was a particular problem for some 17-deoxymetablites due to the unavailability of 
standard; and for α-cortol where co-elution prevented quantitation.  An additional 
limitation of using urinary glucocorticoid profiles to determine production rates is 
the uncertainty regarding completeness of sample collection.  Thus the data are 
mainly useful to provide a qualitative description of corticosterone metabolism, and 
as an indication of expected ranges in a normal population. 
In summary, data presented in the current chapter and chapter 4 demonstrate 
corticosterone is a high affinity substrate for human hepatic 5β-reductase/3α-HSD 
and is cleared rapidly in vivo.  Accurate quantitation of production was not possible 
due to the high tracer: tracee ratio required for stable isotope tracer studies.  Rapid 
clearance, however, suggests turnover of the hormone is high despite its low 
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circulating concentration.  Altered clearance, as expected during the stress response 
(Boonen et al, 2013), might therefore affect circulating corticosterone concentrations 
to a proportionately greater extent than cortisol,  Moreover, our data, (section 3.4.3) 
and that of others (Peterson et al, 1960; Nabors, Jr. et al, 1974; Nishida et al, 1977; 
Ganguly et al, 1977) show that compared to cortisol, circulating corticosterone 
concentrations show exaggerated sensitivity to ACTH.  In tissues which respond to 
corticosterone signalling, high turnover of the circulating corticosterone pool may 
therefore confer sensitivity to rapid changes in HPA axis tone and/or clearance, and 
the ability to ‘fine-tune’ corticosteroid receptor activation.   
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Chapter&7:&Corticosterone&vs&cortisol&in#vivo&
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7.1.&Introduction&
The transmembrane protein ABCB1 preferentially exports cortisol over 
corticosterone, whereas an alternative transporter, ABCC1, exports corticosterone 
over cortisol (Karssen et al, 2001).  The expression of these transporters in humans is 
known to be tissue specific, with ABCB1 present at the blood-brain barrier (BBB) 
(Cordon-Cardo et al, 1989), and ABCC1 present in adipose tissue (Figure 1-9).  
Consistent with selective expression of ABCB1 at the BBB, relative accumulation of 
corticosterone over cortisol has been demonstrated in the human CNS (Karssen et al, 
2001; Raubenheimer et al, 2006).  Tissue specific ABC transporter expression 
therefore provides a mechanism whereby important differences might exist in tissue 
sensitivity towards corticosterone vs cortisol in the human CNS and adipose tissue.   
In the clinical study presented in this chapter, we aimed to test the hypothesis that 
negative feedback suppression of ACTH is disproportionately sensitive to 
corticosterone, while adipose tissue is disproportionately sensitive to cortisol.  We 
therefore compared cortisol and corticosterone effects on the HPA axis, adipose 
tissue and circulating metabolic biomarkers in vivo in a random-order crossover 
study, using ramped steady state infusion to enable assessment of dose-response 
effect.  To minimise confounding by endogenous glucocorticoids, we infused 
glucocorticoids labelled with stable isotopes – D8-corticosterone (validated in 
Chapter 4), and the previously validated tracer 9,11,12,12-[2H]4 cortisol (D4-cortisol) 
(Andrew et al, 2002) -  in individuals with Addison’s disease.   
      Scott Mackenzie    PhD thesis, 2015 
 Chapter(7:(Corticosterone(vs(cortisol(in(vivo( 162( (
7.2.&Methods&
7.2.1.&Ethical&and&Research&Governance&Approvals&
Approvals were obtained from the South East Scotland Research Ethics Committee 
(13/SS/0210) and NHS Lothian Research and Development (2013/0305).  Research 
support approvals were obtained from the Wellcome Trust Clinical Research Facility 
(WTCRF), clinical laboratories, and radiopharmacy at the Royal Infirmary, 
Edinburgh (RIE). 
7.2.2.&Participants&
Participants with Addison’s disease were identified by review of medical records for 
patients attending endocrinology clinics at the RIE and Western General Hospital 
(WGH), Edinburgh.  Patients were invited to attend a screening visit at the WTCRF, 
where informed consent was obtained and eligibility to proceed was assessed by 
means of a medical questionnaire, physical examination and routine blood tests.  
Weight, height and blood pressure were recorded as described in section 6.2.3. 
7.2.2.1.&Inclusion&criteria&
• Addison’s disease 
• Age > 18 years 
• Able to give informed consent 
• Alcohol intake < 28 units per week 
• Normal FBC, UE, TFT and LFT 
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7.2.2.2.&Exclusion&criteria&
• Intercurrent illness 
• Pituitary disease 
• Pregnancy or breastfeeding 
• Cardiac, renal or liver failure 
• Glucocorticoid treatment within the previous 3 months by any route (other 
than replacement therapy) 
• Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or 
diastolic blood pressure ≥ 100 mmHg)  
• Blood donation within the preceding 3 months 
• Research study participation within the preceding 6 weeks 
7.2.3.&Sample&size&
The primary study outcome was plasma ACTH, which was sampled at 10 minute 
time intervals, and used to calculate mean concentrations over 4 time periods, each 
lasting 60 - 90 minutes.  Frequent time points were chosen to maximise statistical 
power by reducing variability in mean ACTH arising from ultradian pulsatility.  To 
our knowledge, no similar studies have been undertaken in patients with Addison’s 
disease, but data from healthy volunteers in which ACTH was measured in duplicate 
at 10 minute intervals following administration of metyrapone (Veldhuis et al, 2001) 
were used to produce estimates of the mean (49 pmol/l) and standard deviation (6.8 
pmol/l) for the primary outcome.  The following equation (Van Belle, 2008), derived 
from Student’s unpaired t-test was used to calculate sample size (n):  
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Entering the above values for standard deviation (σ) and mean (µ), a sample size of 
10 was required for 90 % statistical power (1 – β) at p 0.05 (α), to detect a 20 % 
difference in the primary outcome. 
7.2.4.&Clinical&protocol&
7.2.4.1.&Study&visits&
Participants withheld hydrocortisone from 1400h on the day before each study visit, 
and omitted fludrocortisone (when prescribed) the morning before the study visit and 
on the morning of the study visit.  They attended the WTCRF, RIE at 0800h 
following an overnight fast (from 2200h).  At t = -15 minutes, intravenous cannulae 
(18G) were inserted in each antecubital fossa using an aseptic technique.  At t = 0, 
saline infusion (0.9 %, 125 ml/hr) was commenced through the cannula in the left 
arm, and blood samples collected according to the sampling protocol through the 
cannula in the right arm.  At t = 60, infusion of deuterium-labelled glucocorticoid 
(D8-corticosterone or D4-cortisol) was commenced according to the steroid infusion 
protocol (section 7.2.4.3).  Order of steroid infusion was chosen randomly, and study 
participants were blinded to the order of infusate. 
At t = 330, biopsy of subcutaneous abdominal adipose tissue was undertaken.  
Cannulae were then removed, and participants provided with lunch before discharge.  
After an interval of at least 1 week, participants re-attended for a repeat study visit 
using the second labelled glucocorticoid. 
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7.2.4.2.&Preparation&of&the&stable&isotope&tracers&D8(corticosterone&and&D4(cortisol&
Deuterium labelled steroids were dissolved in pharmaceutical grade ethanol/water 
(90/10 %) and filtered in the radiopharmacy to form a sterile stock solution, stored (-
40 °C) for a maximum of 8 weeks.  Solutions were defrosted and infusions prepared 
in the clinical research facility on the morning of each study.   
7.2.4.3.&Steroid&infusion&protocol&
D8-corticosterone (4.18 mg/ml) and D4-cortisol (2.5 mg/ml) stock solutions were 
prepared in ethanol/water as above (5.5 ml aliquots).  Stock solution (5 ml) was 
added to sodium chloride 0.9% w/v (495 ml).  At t = 60 mins, a priming dose was 
administered over 4 minutes, followed by steady state infusion (target concentration 
25 nM) for 86 minutes.  Further priming doses were administered at t = 140 and 250 
mins, each followed by constant infusions, aiming for target concentrations 100 and 
250 nM respectively (Table 7-1).  For D8-corticosterone, pharmacokinetic 
parameters derived in the clinical studies described in section 6.4.1.2 were used to 
calculate priming doses and steady state infusion rates, using calculations described 
in section 6.2.8.2.  The same calculations were used to calculate priming doses and 
steady state infusion rates for D4-cortisol, using pharmacokinetic data derived from 
steady state infusion in healthy volunteers (Stimson et al, 2009). 
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7.2.4.4.&Sample&collection&and&processing&
Samples were obtained in potassium EDTA tubes (2.7 ml) pre-chilled on wet ice and 
serum gel tubes (9 ml; both Monovette®, Sarstedt, Nümbrecht, Germany).  Samples 
were gently mixed by inverting several times.  Potassium EDTA samples were 
placed on wet ice prior to centrifugation within 30 minutes of sampling; serum gel 
samples were left at room temperature for 30-45 minutes before centrifugation (1912 
× g 10 min, 4 °C).  Serum/plasma was separated and stored (-80 ºC) for analysis.  In 
plasma, ACTH was quantified by ELISA within 6 weeks of sampling, and NEFAs 
and glycerol quantified by colorimetric assay (section 2.3).  Serum samples were 
used for quantification of glucocorticoids by LC-MS/MS (Chapter 5); and insulin 
and glucose by ELISA and colorimetric assay, respectively (section 2.3).  
7.2.4.5.&Sampling&protocol&
Potassium EDTA samples were drawn at 10 minute intervals from t  = 0 (start of 
saline infusion) until t = 330 mins.  Serum gel samples were drawn at t  = 0 & 60 
mins; and thereafter at 20 minute intervals until t  = 320 mins, with additional 
samples following priming at t  = 70 & 250 mins (Figure 7-1). 
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Table&6(3.&Daily&excretion&rate&of&urinary&corticosterone&(B)&metabolites&(17(
deoxysteroids)&and&cortisol&(F)&metabolites&(17&hydroxysteroids)&in&male&volunteers&
A( =( 118dehydrocorticosterone;( THA( =( 118dehydro8tetrahydrocorticosterone;( THB( =(
tetrahydrocorticosterone;( E( =( cortisone;( THE( =( 5β8tetrahydrocortisone;( THF( =( 5β8








118Dehydrocorticosterone( 9.4( 7.3( 11.2( 2.9( 19.1(
Corticosterone( 11.1( 8.1( 12.5( 2.5( 21.5(
THA(
(
106.6( 77.9( 142.5( 38.3( 258.6(
THB(
(
70.5( 56.8( 119.8( 39.4( 187.6(
Allo8THB( 305.9( 232.0( 462.5( 131.9( 791.6(
178deoxy8β8cortolone(( 31.1( 7.1( 53.5( 0.5( 157.3(





Cortisone( 107.3( 86.9( 156.8( 53.0( 183.1(
Cortisol(
(
96.1( 83.4( 119.1( 39.4( 161.0(
THE(
(
2989.1( 2187.2( 3305.5( 1794.7( 4297.9(
THF(
(
1479.1( 1223.2( 1733.6( 816.3( 2033.7(
Allo(8(THF( 1599.5( 1024.3( 2210.1( 493.0( 2995.1(
β8Cortolone( 394.1( 306.9( 515.9( 253.5( 780.9(
α8Cortolone( 357.9( 278.0( 435.9( 229.5( 868.7(
β8Cortol(( (( 354.2( 301.7( 474.8( 182.0( 704.5(
Total(
(µg/24(hours)(
178deoxysteroids( 615.4( 476.5( 744.2( 291.2( 1238.6(
178hydroxysteroids( 6844.1( 5753.8( 8600.5( 4524.7( 9627.5(
Ratio(17(deoxy/hydroxy( 8.8%( 7.7%( 11.0%( 5.4%( 13.3%(
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6.5.&Discussion&
The half-life, clearance and volume of distribution of the stable isotope tracer D8-
corticosterone following bolus injection and steady-state infusion have been 
established in the above studies, which enable a number of observations to be made 
regarding the in vivo metabolism of corticosterone.  The key finding of both 
pharmacokinetic studies is the rapid clearance of corticosterone, consistent with in 
vitro studies, which demonstrate the hormone, is a high-affinity substrate for the key 
enzymes required for hepatic clearance (Chapter 4).  The magnitude of the difference 
in rates of metabolism of corticosterone and cortisol by human hepatic cytosol is in 
keeping with the current in vivo data: clearance of corticosterone derived from the 
bolus study (1.11 l/min) and steady state study (1.46 l/min) proceeds 3-5 times more 
rapidly than that of cortisol – for which recently reported clearance is consistently 
between 0.27 and 0.33 L/min (Derendorf et al, 1991; Thomson et al, 2007; Stimson 
et al, 2009; Perogamvros et al, 2011).   
Rapid clearance of corticosterone is reflected in its elimination half-life (t ½), which 
in both studies is short in comparison to that of cortisol.  However, estimates of t ½ 
differed considerably between bolus and steady state studies, and t ½ was 
approximately 3-fold longer in the steady state study.  Similar differences were seen 
in Vd.  A number of factors might account for these apparent discrepancies.  Firstly, 
assay factors reduce certainty around estimates of circulating tracer concentrations in 
the bolus study, where concentrations achieved were lower, particularly at later time 
points.  Sample volume was also increased in the steady state study to improve assay 
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sensitivity.  Secondly, administration of tracer as a slow bolus injection results in 
potential error in modelling the ‘peak’ of the concentration curve, which was 
exaggerated due to the shorter than expected t ½.  For these reasons, and because of 
assumptions made in modelling the data to first order kinetics (discussed below), 
confidence is higher in estimates of pharmacokinetic parameters derived from 
administration of tracer at steady state rather than as a bolus injection. 
Although experimental error due to the above factors might account to some extent 
for differences in the pharmacokinetic parameters derived from the two studies, 
biological factors may also be of importance.  Unlike clearance, estimated t ½ and Vd 
for cortisol vary considerably across different studies, with estimated mean t ½ 
between 60 and 130 minutes in healthy volunteers, and Vd varying from 20 to 50 L 
(Derendorf et al, 1991; Bright, 1995; Thomson et al, 2007; Perogamvros et al, 2011).  
Inter-individual variability is also high within the above studies.  Reproducible data 
on these measures is therefore difficult to achieve.  Due to this variability, it is 
difficult to fit glucocorticoid pharmacokinetics to a given compartmental model.  In 
the current studies, a single compartment model has been assumed for the calculation 
of clearance of a bolus dose; whereas the steady state study has been analysed 
without compartmental constraints.  Previous investigators have variably fitted data 
to single- or two-compartment models (Toothaker et al, 1982; Thomson et al, 2007; 
Perogamvros et al, 2011).  In the two-compartment model, rapid distribution of free 
hormone into tissues precedes a slower elimination phase, resulting in non-linear 
kinetics.  Non-linearity also occurs as clearance enzymes approach saturation; 
although the previously discussed in vitro data suggest this is unlikely. 
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A final factor that requires consideration in interpreting the pharmacokinetic data for 
D8-corticosterone is the role of plasma protein binding.  A relatively high proportion 
of free: bound hormone is expected to increase Vd and therefore tend to increase t ½ 
without altering clearance.  This phenomenon might explain dose dependent kinetics 
previously reported for cortisol and corticosterone (Peterson et al, 1960; Toothaker et 
al, 1982).  However, clearance of cortisol has recently been shown to correlate 
inversely with binding capacity (Perogamvros et al, 2011), via as yet undefined 
mechanisms.  In the current study, bolus pharmacokinetics were assessed near the 
diurnal peak, when saturation of the high affinity binding protein CBG might be 
exerting an effect, and therefore capacity for binding of the corticosterone tracer is 
reduced.  Conversely, in the steady-state study the decline in tracer concentration 
was measured in the early afternoon when occupancy of CBG by endogenous 
hormone is expected to be lower.  Protein binding might therefore influence kinetics 
according to prevailing concentrations of endogenous glucocorticoid. 
The current studies also aimed to estimate the rate of production of corticosterone 
using the principle of isotope dilution.  Although this was achieved, the physiological 
relevance of the estimate is limited because the high tracer: tracee ratio (required for 
accurate quantitation of tracer) means that the tracer may have impacted upon the 
rate of appearance of the tracee.  Perhaps related to this, the rate of production is low 
compared to previous estimates derived from infusion of radiolabelled tracer 
(Peterson et al, 1960; Huther et al, 1970), although non-specific assay methodology 
may have over-estimated production rates in these studies. 
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In addition, urinary corticosterone metabolites were assessed in healthy men.  
Analysis of urinary steroid profiles has enabled the quantitation of a number of 
corticosterone metabolites which have not, to our knowledge, previously been 
quantified.  In general, urinary profiles suggest the metabolism of corticosterone 
mirrors that of cortisol.  Tetrahydro-reduced metabolites of both 11-hydroxy- and 
11-ketosteroids are by far the most abundant metabolites; and the total excretion rate 
is broadly proportional to basal plasma concentrations (Zumoff et al, 1974).  Our 
data are broadly consistent with this, with estimated production rates of 6.84 mg/24 
hours for cortisol and 0.62 mg/24 hours for corticosterone, corresponding to a 
corticosterone/cortisol ratio of 8.8 %.  
Use of urinary glucocorticoid profiles to determine glucocorticoid production rate is 
limited by the inability to quantify all urinary metabolites.  In the above study this 
was a particular problem for some 17-deoxymetablites due to the unavailability of 
standard; and for α-cortol where co-elution prevented quantitation.  An additional 
limitation of using urinary glucocorticoid profiles to determine production rates is 
the uncertainty regarding completeness of sample collection.  Thus the data are 
mainly useful to provide a qualitative description of corticosterone metabolism, and 
as an indication of expected ranges in a normal population. 
In summary, data presented in the current chapter and chapter 4 demonstrate 
corticosterone is a high affinity substrate for human hepatic 5β-reductase/3α-HSD 
and is cleared rapidly in vivo.  Accurate quantitation of production was not possible 
due to the high tracer: tracee ratio required for stable isotope tracer studies.  Rapid 
clearance, however, suggests turnover of the hormone is high despite its low 
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circulating concentration.  Altered clearance, as expected during the stress response 
(Boonen et al, 2013), might therefore affect circulating corticosterone concentrations 
to a proportionately greater extent than cortisol,  Moreover, our data, (section 3.4.3) 
and that of others (Peterson et al, 1960; Nabors, Jr. et al, 1974; Nishida et al, 1977; 
Ganguly et al, 1977) show that compared to cortisol, circulating corticosterone 
concentrations show exaggerated sensitivity to ACTH.  In tissues which respond to 
corticosterone signalling, high turnover of the circulating corticosterone pool may 
therefore confer sensitivity to rapid changes in HPA axis tone and/or clearance, and 
the ability to ‘fine-tune’ corticosteroid receptor activation.   
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Chapter&7:&Corticosterone&vs&cortisol&in#vivo&
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7.1.&Introduction&
The transmembrane protein ABCB1 preferentially exports cortisol over 
corticosterone, whereas an alternative transporter, ABCC1, exports corticosterone 
over cortisol (Karssen et al, 2001).  The expression of these transporters in humans is 
known to be tissue specific, with ABCB1 present at the blood-brain barrier (BBB) 
(Cordon-Cardo et al, 1989), and ABCC1 present in adipose tissue (Figure 1-9).  
Consistent with selective expression of ABCB1 at the BBB, relative accumulation of 
corticosterone over cortisol has been demonstrated in the human CNS (Karssen et al, 
2001; Raubenheimer et al, 2006).  Tissue specific ABC transporter expression 
therefore provides a mechanism whereby important differences might exist in tissue 
sensitivity towards corticosterone vs cortisol in the human CNS and adipose tissue.   
In the clinical study presented in this chapter, we aimed to test the hypothesis that 
negative feedback suppression of ACTH is disproportionately sensitive to 
corticosterone, while adipose tissue is disproportionately sensitive to cortisol.  We 
therefore compared cortisol and corticosterone effects on the HPA axis, adipose 
tissue and circulating metabolic biomarkers in vivo in a random-order crossover 
study, using ramped steady state infusion to enable assessment of dose-response 
effect.  To minimise confounding by endogenous glucocorticoids, we infused 
glucocorticoids labelled with stable isotopes – D8-corticosterone (validated in 
Chapter 4), and the previously validated tracer 9,11,12,12-[2H]4 cortisol (D4-cortisol) 
(Andrew et al, 2002) -  in individuals with Addison’s disease.   
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7.2.&Methods&
7.2.1.&Ethical&and&Research&Governance&Approvals&
Approvals were obtained from the South East Scotland Research Ethics Committee 
(13/SS/0210) and NHS Lothian Research and Development (2013/0305).  Research 
support approvals were obtained from the Wellcome Trust Clinical Research Facility 
(WTCRF), clinical laboratories, and radiopharmacy at the Royal Infirmary, 
Edinburgh (RIE). 
7.2.2.&Participants&
Participants with Addison’s disease were identified by review of medical records for 
patients attending endocrinology clinics at the RIE and Western General Hospital 
(WGH), Edinburgh.  Patients were invited to attend a screening visit at the WTCRF, 
where informed consent was obtained and eligibility to proceed was assessed by 
means of a medical questionnaire, physical examination and routine blood tests.  
Weight, height and blood pressure were recorded as described in section 6.2.3. 
7.2.2.1.&Inclusion&criteria&
• Addison’s disease 
• Age > 18 years 
• Able to give informed consent 
• Alcohol intake < 28 units per week 
• Normal FBC, UE, TFT and LFT 
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7.2.2.2.&Exclusion&criteria&
• Intercurrent illness 
• Pituitary disease 
• Pregnancy or breastfeeding 
• Cardiac, renal or liver failure 
• Glucocorticoid treatment within the previous 3 months by any route (other 
than replacement therapy) 
• Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or 
diastolic blood pressure ≥ 100 mmHg)  
• Blood donation within the preceding 3 months 
• Research study participation within the preceding 6 weeks 
7.2.3.&Sample&size&
The primary study outcome was plasma ACTH, which was sampled at 10 minute 
time intervals, and used to calculate mean concentrations over 4 time periods, each 
lasting 60 - 90 minutes.  Frequent time points were chosen to maximise statistical 
power by reducing variability in mean ACTH arising from ultradian pulsatility.  To 
our knowledge, no similar studies have been undertaken in patients with Addison’s 
disease, but data from healthy volunteers in which ACTH was measured in duplicate 
at 10 minute intervals following administration of metyrapone (Veldhuis et al, 2001) 
were used to produce estimates of the mean (49 pmol/l) and standard deviation (6.8 
pmol/l) for the primary outcome.  The following equation (Van Belle, 2008), derived 
from Student’s unpaired t-test was used to calculate sample size (n):  
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Entering the above values for standard deviation (σ) and mean (µ), a sample size of 
10 was required for 90 % statistical power (1 – β) at p 0.05 (α), to detect a 20 % 
difference in the primary outcome. 
7.2.4.&Clinical&protocol&
7.2.4.1.&Study&visits&
Participants withheld hydrocortisone from 1400h on the day before each study visit, 
and omitted fludrocortisone (when prescribed) the morning before the study visit and 
on the morning of the study visit.  They attended the WTCRF, RIE at 0800h 
following an overnight fast (from 2200h).  At t = -15 minutes, intravenous cannulae 
(18G) were inserted in each antecubital fossa using an aseptic technique.  At t = 0, 
saline infusion (0.9 %, 125 ml/hr) was commenced through the cannula in the left 
arm, and blood samples collected according to the sampling protocol through the 
cannula in the right arm.  At t = 60, infusion of deuterium-labelled glucocorticoid 
(D8-corticosterone or D4-cortisol) was commenced according to the steroid infusion 
protocol (section 7.2.4.3).  Order of steroid infusion was chosen randomly, and study 
participants were blinded to the order of infusate. 
At t = 330, biopsy of subcutaneous abdominal adipose tissue was undertaken.  
Cannulae were then removed, and participants provided with lunch before discharge.  
After an interval of at least 1 week, participants re-attended for a repeat study visit 
using the second labelled glucocorticoid. 
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7.2.4.2.&Preparation&of&the&stable&isotope&tracers&D8(corticosterone&and&D4(cortisol&
Deuterium labelled steroids were dissolved in pharmaceutical grade ethanol/water 
(90/10 %) and filtered in the radiopharmacy to form a sterile stock solution, stored (-
40 °C) for a maximum of 8 weeks.  Solutions were defrosted and infusions prepared 
in the clinical research facility on the morning of each study.   
7.2.4.3.&Steroid&infusion&protocol&
D8-corticosterone (4.18 mg/ml) and D4-cortisol (2.5 mg/ml) stock solutions were 
prepared in ethanol/water as above (5.5 ml aliquots).  Stock solution (5 ml) was 
added to sodium chloride 0.9% w/v (495 ml).  At t = 60 mins, a priming dose was 
administered over 4 minutes, followed by steady state infusion (target concentration 
25 nM) for 86 minutes.  Further priming doses were administered at t = 140 and 250 
mins, each followed by constant infusions, aiming for target concentrations 100 and 
250 nM respectively (Table 7-1).  For D8-corticosterone, pharmacokinetic 
parameters derived in the clinical studies described in section 6.4.1.2 were used to 
calculate priming doses and steady state infusion rates, using calculations described 
in section 6.2.8.2.  The same calculations were used to calculate priming doses and 
steady state infusion rates for D4-cortisol, using pharmacokinetic data derived from 
steady state infusion in healthy volunteers (Stimson et al, 2009). 
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7.2.4.4.&Sample&collection&and&processing&
Samples were obtained in potassium EDTA tubes (2.7 ml) pre-chilled on wet ice and 
serum gel tubes (9 ml; both Monovette®, Sarstedt, Nümbrecht, Germany).  Samples 
were gently mixed by inverting several times.  Potassium EDTA samples were 
placed on wet ice prior to centrifugation within 30 minutes of sampling; serum gel 
samples were left at room temperature for 30-45 minutes before centrifugation (1912 
× g 10 min, 4 °C).  Serum/plasma was separated and stored (-80 ºC) for analysis.  In 
plasma, ACTH was quantified by ELISA within 6 weeks of sampling, and NEFAs 
and glycerol quantified by colorimetric assay (section 2.3).  Serum samples were 
used for quantification of glucocorticoids by LC-MS/MS (Chapter 5); and insulin 
and glucose by ELISA and colorimetric assay, respectively (section 2.3).  
7.2.4.5.&Sampling&protocol&
Potassium EDTA samples were drawn at 10 minute intervals from t  = 0 (start of 
saline infusion) until t = 330 mins.  Serum gel samples were drawn at t  = 0 & 60 
mins; and thereafter at 20 minute intervals until t  = 320 mins, with additional 
samples following priming at t  = 70 & 250 mins (Figure 7-1). 
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7.2.4.6.&Biopsy&of&subcutaneous&abdominal&fat&
Biopsy of subcutaneous abdominal fat was undertaken using an aseptic technique 
from a site approximately 10 cm lateral to the umbilicus.  Following injection of 
local anaesthetic (2 % lignocaine, 5 ml, Hameln Pharmaceuticals, Gloucester, UK), a 
14-gauge needle attached to a 60 ml syringe was inserted subcutaneously, directed 
towards the umbilicus.  The plunger was withdrawn to create a vacuum, and held in 
place using a 13 x 100 mm glass culture tube while a sample of adipose tissue was 
obtained (using two passes).  Samples were placed on autoclaved IsoponTM 
aluminium mesh (DF Wishart, Edinburgh, UK), washed with DEPC water, then 
placed on dry ice before storage (-80 °C) for analysis of glucocorticoid-responsive 
gene expression by qRT-PCR (section 2.3.8).  Samples were not obtained from 
subjects in whom the procedure was deemed to be unsafe (due to low adiposity). 
 
 Chapter(7:(Corticosterone(vs(cortisol(in(vivo( 169( (
7.3.&Data&Analysis&
LC-MS/MS data were analysed as described in section 5.5.4.  For the quantification 
of D4-cortisol, which is converted to D3-cortisol in vivo (Andrew et al, 2002), 
interference from [M+4] isotopomers of cortisol was corrected for by adjusting D4-
cortisol peak area according to the abundance of [M+4] cortisol in a standard of 
D3-cortisol (approximately 13 %; calculated for each assay).  A similar correction 
was applied to adjust D3-cortisol for the abundance of [M+3] cortisol isotopomers in 
a standard of D4-cortisol (approximately 4 %).  Naturally occurring [M+3] and 
[M+4] isotopomers of unlabelled cortisol were detected at less than 2 %, and were 
not adjusted for. 
In the analysis of glucocorticoid-responsive biomarkers (ACTH, glucose, insulin, 
NEFAs and glycerol), to account for differences in steady state concentrations of 
labelled cortisol vs corticosterone, analyses were performed both unadjusted and 
adjusted for steady-state concentration of infused steroid.  Mean changes in 
circulating concentration are expressed as % change from baseline (t = 0-60 mins).  
In analyses adjusted for steroid concentration, each steroid was coded as a 
categorical variable (cortisol = 0; corticosterone = 1) and entered into a multiple 
linear regression model as a co-variable with steady state concentration of labelled 
steroid.  Response variable was % change in a given circulating glucocorticoid-
responsive biomarker.  The validity of the linear regression model was confirmed by 
analysis of histograms and normal plots of residuals. 
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Relative gene abundance (RGA) in subcutaneous adipose biopsy was adjusted for 
differences in steady-state steroid concentration over the duration of each study visit 
by calculating area under the curve (AUC) for infused D4-cortisol (D4-F) and 
D8-corticosterone (D8-B) to produce a correction factor for each participant, used in 
the following equation: 
Adjusted RGA D4-F  = RGA D4-F  × 
AUC D8-B
AUC D4-F  
Student’s paired t-test was used for all comparisons of means between study phases.  
All statistical analyses were performed using Minitab (Version 17; State College 
PA). 
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7.4.&Results&
7.4.1.&Characteristics&of&study&participants&
Of 10 study participants, one was excluded from all analyses because baseline 
ACTH in both study visits (2.8 & 4.0 pmol/l) and baseline endogenous cortisol 
concentration on one study visit (533 nM) suggested the diagnosis of primary adrenal 
insufficiency was incorrect, and/or hydrocortisone replacement had not been 
withheld as per study protocol.  Characteristics of the remaining study participants (n 
= 9) are summarised in Table 7-2, and concentrations of endogenous cortisol are 
presented in Figure 7-2.  Concentrations of endogenous corticosterone were too low 
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Figure& 7A2.& Endogenous& cortisol& in& patients& with& Addison's& disease& during& infusion& of&
deuterated&glucocorticoids&





Assessment of circulating concentrations of labelled cortisol (sum of D3-cortisol + 
D4-cortisol) and corticosterone indicated ramped steady state had been achieved with 
appropriate priming (Figure 7-3). Steady state concentrations achieved tended to be 
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Figure&7A3.&Serum&concentration&of&deuterium&labelled&corticosterone&and&cortisol&
Total(deuterated(cortisol((closed(circles)(=(sum([D3Ecortisol](+([D4Ecortisol].((Open(circles(=(
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7.4.3.&Plasma&ACTH&concentration&
Change in plasma ACTH for all subjects according to infused steroid is shown in 
Figure 7-4.  ACTH at baseline was elevated but did not differ between study phases 
(41.4 ± 2.7 vs 40.9 ± 2.1 pmol/l in cortisol vs corticosterone groups respectively; p = 
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serum concentration of infused steroid was positively associated with degree of 
suppression of plasma ACTH from baseline (β = 0.062 ± 0.014; p < 0.0001).  The 
coded categorical variable (D4-cortisol = 0; D8-corticosterone = 1) was not a 
significant predictor variable (β = -0.22 ± 0.49; p = 0.96), indicating ACTH 
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Circulating concentrations of glucose, insulin, glycerol and NEFAs are shown in 
Figure 7-5.  Rise in plasma NEFA concentration was positively associated with 
concentration of infused steroid (β = 0.11 ± 0.05, p = 0.01) but did not differ 
significantly during D4-cortisol vs D8-corticosterone infusion in analyses unadjusted 
(51.3 ± 26.3 % vs 26.5 ± 15.2 %, p = 0.17) or adjusted (β = -19.0 ± 16.7, p = 0.26) 
for steroid concentration.  Changes in concentration of all other analytes (glucose, 
insulin or glycerol) were not significantly associated with concentration of steroid 
infused and did not vary according to administration of D4-cortisol or 




Circulating! glucose! (A),! insulin! (B),! glycerol! (C)! and!non-esterified! fatty! acids! (NEFAs;!D)! during! infusion!of! saline! (t! =! 0! –! 60)! then!D4-cortisol!
(closed!circles)!or!D8-corticosterone!(open!circles).!!
 














































































































(i)(%(Change( in( circulating(glucose,( insulin,(non:esterified( fatty(acids( (NEFAs)(and(glycerol(
from(baseline((0:60(mins)(during(D4:cortisol((D4:F)(and(D8:corticosterone((D8:B)(infusion(in(
analysis(unadjusted(for(steroid(concentration.( ( (ii)(Each(steroid(coded(as(a(binary(variable(
and( entered( into( a( multiple( linear( regression( equation( in( analysis( adjusted( for( steroid(








β( p( β( p(
Glucose( :0.002(±(0.014( 0.81( 3.29(±(2.90( 0.26( 3.0(%(
Insulin( :0.023(±(0.017( 0.64( :2.43(±(5.89( 0.68( 3.8(%(
Glycerol( :0.011(±(0.021( 0.60( :10.2(±(7.74( 0.19( 4.1(%(









80:140( :3.2%( ±( 3.4%( :3%( ±( 4%( 0.14(
160:240( :2.6%( ±( 2.8%( 4.3%( ±( 3.1%( 0.31(
260:330( 3.3%( ±( 4.4%( 2.7%( ±( 3.1%( 0.91(
Insulin(
80:140( :5.4%( ±( 4.5%( :3.0%( ±( 7.0%( 0.73(
160:240( :5.4%( ±( 8.0%( :8.3%( ±( 7.6%( 0.74(
260:330( :12.9%( ±( 8.1%( :16.2%( ±( 8.0%( 0.74(
Glycerol(
80:140( 19.7%( ±( 10.5%( 16.2%( ±( 7.2%( 0.62(
160:240( 19.9%( ±( 12.5%( 42.1%( ±( 34.7%( 0.54(
260:330( 16.1%( ±( 11.4%( 66.0%( ±( 63.2%( 0.20(
NEFAs(
80:140( 35.2%( ±( 21.4%( 20.1%( ±( 11.1%( 0.36(
160:240( 56.9%( ±( 28.4%( 29.7%( ±( 18.2%( 0.15(
260:330( 60.4%( ±( 29.5%( 28.8%( ±( 17.2%( 0.15(




Relative expression of glucocorticoid responsive genes in biopsies of subcutaneous 
adipose tissue sampled following infusion of D4-cortisol or D8-corticosterone are 
compared in Figure 7-6.  Abundance of PER1 mRNA was greater following 
D4-cortisol than D8-corticosterone (2.2 fold; p < 0.01).  This association was 
attenuated, but more statistically robust (1.8 fold; p < 0.001), following adjustment 
for differences in concentration of infused steroid.  No statistically significant 
differences were seen in the relative abundance of other gene transcripts analysed, 
with the exception of LPL, which was more abundant following D4-cortisol infusion 
(1.3 fold, p = 0.03), but not after correction for concentration of infused steroid. 
 &
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Figure& 7(6.& & Relative& expression& of& glucocorticoid& responsive& genes& in& subcutaneous&
adipose&tissue&following&infusion&of&D4(cortisol&or&D8(corticosterone.&
Relative( gene( abundance( (RGA;( normalised( to( expression( of( 18S( rRNA)( in( subcutaneous(
adipose( biopsy( tissue,( following( D4:cortisol( (D4:F;( closed( bars)( or( D8:corticosterone(
infusion( (D8:B;(open(bars).( (D4:F(concentration,(expressed(as(area(under( the(curve( (AUC)(
was( higher( than( D8:B( (60194( ±( 11047( vs( 47099( ±( 4467( nM.min.( ( RGA( following( D4:F(
infusion(was(therefore(adjusted((hatched(bars)(as(follows:((
Adjusted(RGA((D4%F)##=#RGA#(D4%F)##×##(AUC#(D8%B))/(AUC((D4%F)).((P(values(refer(to(Student’s(










PER1* 1.70( ±( 0.27( 1.35( ±( 0.16( 0.76( ±( 0.08( <0.01( <0.001(
PEPCK* 1.47( ±( 0.29( 1.30( ±( 0.29( 1.35( ±( 0.14( 0.61( 0.82(
HSL* 0.91( ±( 0.15( 0.78( ±( 0.15( 0.75( ±( 0.13( 0.24( 0.81(
ADIPOQ* 1.27( ±( 0.09( 1.14( ±( 0.18( 1.08( ±( 0.09( 0.17( 0.76(
ATGL* 0.93( ±( 0.08( 0.85( ±( 0.15( 0.83( ±( 0.05( 0.26( 0.87(
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7.5.&Discussion&
In a random-order crossover study of patients with Addison’s disease, we have 
demonstrated that gene expression in adipose tissue responds disproportionately  
sensitivity to cortisol is enhanced relative to corticosterone, using doses which are 
equipotent for ACTH suppression.  Changes in adipose gene expression were not, 
however, reflected in systemic metabolic markers, and suppression of ACTH by both 
glucocorticoids was less than expected. 
We chose to study patients with Addison’s disease to minimise confounding due to 
endogenous glucocorticoids.  Pharmacokinetic studies in healthy volunteers enabled 
accurate priming and closely matched steady state concentrations of each 
glucocorticoid.  The dosing protocol was designed to achieve glucocorticoid 
concentrations representative of those occurring at varying times in the diurnal cycle, 
and to allow a dose-response assessment to account for differences in serum 
concentrations between groups and individuals. 
As expected in Addison’s disease, ACTH was elevated before glucocorticoid 
administration.  However, suppression was incomplete, and in the final steady state, 
where glucocorticoid concentrations were approximately equivalent to those at the 
cortisol diurnal peak, ACTH remained elevated.  This finding is of interest and 
suggests the HPA axis is to an extent ‘resistant’ to negative feedback control in 
Addison’s disease.  Suppression of ACTH in Addison’s disease has been described 
as normal (Besser et al, 1971), although generally where ‘physiological’ doses of 
steroid are used (Holdaway, 1973; Clayton et al, 1977; Feek et al, 1981) incomplete 
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suppression is reported.  The situation may be analogous to that of the hypothalamo-
pituitary-thyroid axis, where TSH fails to suppress to the normal range following 
acute administration of thyroid hormone in treatment-naïve patients with primary 
hypothyroidism (Clayton et al, 1977).  The mechanism behind abnormal feedback 
control of the HPA axis in primary adrenal insufficiency has not been established.  
However, periods of glucocorticoid deficiency are likely to occur in treated 
Addison’s disease due to inadequacies in the pharmacokinetics of oral 
hydrocortisone (Debono et al, 2009; Forss et al, 2012; Grossman et al, 2013), and 
these may result in a degree of autonomous function and/or hyperplasia of 
corticotrophs.  Consistent with this, a number of reports describe persistently 
elevated ACTH in Addison’s disease accompanied by corticotroph hyperplasia 
(Miyabo et al, 1990) or adenomata  (Jara-Albarran et al, 1979; Krautli et al, 1982; 
Yanase et al, 1985; Sugiyama et al, 1996).  The development of autonomous ACTH 
secretion in Addison’s disease may therefore be analogous to Nelson’s syndrome, in 
which glucocorticoid deficiency contributes to growth of ACTH-producing pituitary 
tumours following bilateral adrenalectomy (Barber et al, 2010). 
Our data do not provide clear evidence to support the hypothesis that the presence of 
ABCB1 at the blood-brain barrier (BBB) renders the feedback centres of the CNS 
differentially sensitive to corticosterone over cortisol.  It remains possible that 
ABCB1 enhances sensitivity of the hippocampus and hypothalamus to 
corticosterone, but not the pituitary, which is outside the BBB.  In our study, 
corticosteroid receptors in the hippocampus and hypothalamus, thought to be 
predominantly high-affinity MR (de Kloet et al, 1998) may have been saturated 
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during the final steady state.  Limited suppression of ACTH at lower glucocorticoid 
concentrations may have reduced the power of our study to detect differences in 
feedback at lower glucocorticoid concentrations, and it remains possible that in 
individuals without primary adrenal insufficiency differential feedback occurs 
outwith the diurnal peak.  However, where clear changes in ACTH are seen towards 
the end of our study, the absence of significant differences during infusion of each 
steroid, despite steady state concentrations of cortisol which tended to be higher than 
those of corticosterone, suggest the effects of corticosterone on the HPA axis is at 
least equivalent in potency to those of cortisol. 
In contrast, data from subcutaneous adipose tissue demonstrate potentially important 
differences.  Expression of the glucocorticoid-responsive gene PER1 during cortisol 
infusion was approximately two-fold greater than during corticosterone infusion, and 
enhanced expression of LPL was also seen following cortisol infusion, although 
slight differences in serum steroid concentrations make the latter finding difficult to 
interpret.  PER1 encodes period circadian homolog 1, a key component of the 
circadian clock in peripheral tissues, disruption of which is associated with metabolic 
dysregulation (Eckel-Mahan et al, 2013).  PER1 is rapidly induced by 
glucocorticoids (Stavreva et al, 2009) and uniquely sensitive at low doses which do 
not alter expression of other ‘glucocorticoid-responsive’ genes (Reddy et al, 2012). 
The absence of differences in expression of other genes in our study may reflect an 
inadequate period of time for glucocorticoids, which turn over slowly in human 
adipose tissue (Hughes et al, 2010), to equilibrate.  The relatively small changes in 
circulating metabolic markers may also be explained by this phenomenon; previous 
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investigators have found plasma glucose, insulin and glycerol show a small and 
delayed response to several hours of ‘physiological’ glucocorticoid infusion, and 
although the rise in NEFAs generally occurs more rapidly, there is wide inter- and 
intra-individual variability (Dinneen et al, 1993; Djurhuus et al, 2002).  Our data also 
needs to be interpreted in the light of the limtations of qRT-PCR, which does not 
quantify protein product.    
A number of factors are potentially involved in differential tissue sensitivity to 
cortisol and corticosterone.  These include glucocorticoid receptor affinity, although 
this is thought to be similar for both glucocorticoids (Veldhuis et al, 1982; 
Krozowski et al, 1983; Sutanto et al, 1987; Reul et al, 1990); and pre-receptor 
metabolism by 11β-HSD1, which may amplify cortisol action to a greater extent than 
corticosterone (Maser et al, 2002; Arampatzis et al, 2005).  Modulation of 
glucorticoid sensitivity by transmembrane export has received very little research 
attention.  Export of corticosterone by ABCC1, known to be highly expressed in 
adipose tissue, may explain our findings, with expression of alternative transporters 
in the BBB resulting in retained sensitivity to corticosterone in the CNS.  Regardless 
of the underlying mechanism, the concept of differential tissue sensitivity to multiple 
endogenous glucocorticoids is a novel one, with potentially important clinical 
implications.  Corticosterone, which may induce a limited metabolic response 
relative to that in the CNS, offers promise as a therapeutic tool to optimise CNS 
glucocorticoid action whilst limiting adverse metabolic effects of glucocorticoid 
replacement.  
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The studies presented in this thesis are the first to explore in detail the role of 
corticosterone, the ‘neglected second glucocorticoid’, in human health and disease.  
In earlier chapters, I have described the development of a robust LC-MS/MS assay 
for corticosterone, the validation of a novel stable isotope tracer, and experiments 
that provide key data on the ‘pharmacokinetics’ of corticosterone in humans.  These 
studies have provided the tools required to design a clinical study that has broken 
new ground by infusing corticosterone in humans in a manner that enables direct 
comparison with cortisol. 
The data indicate differences in a number of the key physiological properties of 
corticosterone and cortisol.  We have demonstrated rapid clearance of corticosterone 
in comparison to cortisol in vivo, consistent with our in vitro studies.  Together these 
show approximately 3-fold differences in clearance, half-life and rate of hepatic 
metabolism between two endogenous glucocorticoids.  It is increasingly recognised 
that the HPA axis is regulated by changes in glucocorticoid clearance in addition to 
production.  Given the rapid clearance of corticosterone, a relative reduction in the 
activity of clearance enzymes common to both glucocorticoids may be raise plasma 
corticosterone to a greater extent than cortisol.  We have also shown corticosterone is 
disproportionately sensitive to ACTH stimulation.  During times of rapid changes in 
HPA axis tone, and/or clearance, the corticosterone pool may be of particular 
importance.  Corticosterone has largely been neglected in humans because of it low 
basal circulating concentrations, yet it is clear this is only one of a number of 
parameters which require consideration when studying glucocorticoid physiology. 
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Key among these parameters, with respect to the findings of this thesis, is the relative 
affinities of each glucocorticoid for ABC transporter proteins, which have recently 
been shown to differ for cortisol and corticosterone.  We have shown that 
corticosterone is no less potent than cortisol in suppressing ACTH.  In contrast, 
mRNA expression in adipose tissue is disproportionately sensitivity to cortisol over 
corticosterone.  The data are the first to suggest differential sensitivity to endogenous 
glucocorticoids in humans.  Findings in adipose tissues are consistent with known 
expression of ABCC1; while in the CNS we hypothesised ABCB1 would confer 
sensitivity to corticosterone over cortisol.  The failure to detect this may however 
reflect inadequate sensitivity of ACTH as marker of acute glucorticoid action in the 
CNS in Addison’s disease.   
Confirmation of differential adipose tissue sensitivity towards corticosterone vs 
cortisol may have important clinical implications.  Elevated cortisol action in adipose 
tissue is implicated in the pathogenesis of metabolic syndrome, a collection of major 
risk factors for cardiovascular disease.  Our data from the East Hertfordshire cohort 
show that those individuals who have a ‘steroidogenic bias’ producing relatively 
high levels of circulating cortisol and low levels of corticosterone under ACTH 
stimulation have an adverse metabolic profile.  It is likely that the activity of CYP17 
is a key determinant of this ‘bias’.  Furthermore, cortisol excess, driven by high 
CYP17 activity, may be compounded by relative corticosterone deficiency, which 
drives activation of the HPA axis.  In these individuals, corticosterone therapy might 
allow control of HPA axis activation without inducing adverse metabolic effects. 
Scott Mackenzie    PhD thesis, 2015 
( Chapter(8: Conclusions( 188(
This concept might also be of importance for individuals with glucocorticoid 
deficiency.  Current glucocorticoid replacement strategies fail to optimise CNS 
function, whilst risking peripheral glucocorticoid toxicity (Grossman et al, 2013).  
Even in the absence of confirmed CNS sensitivity to corticosterone over cortisol, 
enhanced adipose tissue sensitivity to cortisol over corticosterone would imply that, 
at equivalent doses, metabolic side-effects might be less with corticosterone therapy 
in comparison to cortisol. 
The short half-life of corticosterone means that modification of its formulation, 
similar to that currently being undertaken for cortisol (Johannsson et al, 2009; Verma 
et al, 2010), would be required for oral administration.  However, interest has arisen 
recently in subcutaneous glucocorticoid replacement (Oksnes et al, 2014), which 
could be employed in a proof-of-principle study to compare effects of corticosterone 
and cortisol on ACTH and metabolic parameters assessed over a longer time-period 
than that of the current study.  The use of functional MRI also offers a promising 
means of assessing the CNS effects of glucocorticoids at physiological doses in 
humans (Lovallo et al, 2010; Sudheimer et al, 2013), perhaps providing an additional 
CNS biomarker for use in future studies. 
A number of other questions are raised by our studies, which deserve further 
attention.  These include whether the distinct properties of corticosterone, with rapid 
clearance and response to ACTH, are of physiological relevance.  One area where 
this may be the case is that of ultradian regulation of the HPA axis, the significance 
of which is increasingly recognised (Young et al, 2004; Stavreva et al, 2009).  
Mathematical modelling, using kinetics derived from rodents, suggests ultradian 
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pulsatility is an intrinsic product of feedback and delayed feed-forward signalling 
between the pituitary and adrenal glands (Walker et al, 2010).  Due to its long half-
life, cortisol signalling alone may not explain pulsatility in the human HPA axis; 
whereas for corticosterone, higher-frequency oscillations are possible, which may be 
key for pulsatile ACTH release in humans. 
Secondly, following on from our epidemiological studies, it would of interest to 
assess associations of variability in CYP17A1, encoding 17α-hydroxylase, with 
plasma corticosterone and cortisol levels.  Polymorphism in CYP17A1 has been 
previously been associated with hypertension (Newton-Cheh et al, 2009), obesity 
(Yan et al, 2012; Hotta et al, 2012), and coronary artery disease (Schunkert et al, 
2011), but the mechanisms behind these associations have not been established.  
Studies to assess the functional relevance of polymorphism in CYP17A1, and to 
determine whether associations with metabolic syndrome are mediated by relative 
production of corticosterone and cortisol, may be fruitful. 
Finally, while we hypothesise that our results in the study of patients with Addison’s 
disease are explained by corticosterone export from adipose tissue by ABCC1, it 
would be of interest to test this hypothesis by repeating the study using specific 
inhibitors of transport function.  ABC transporter inhibitors previously used in 
humans have relatively high toxicity (Pennock et al, 1991; Eyal et al, 2010), although 
more recently discovered agents appear to be better tolerated (Bauer et al, 2012).   
Ongoing investigation of these questions will continue to challenge the assumption 
that a single endogenous glucocorticoid is of importance in humans.  Our findings 
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raise the possibility of distinct roles for corticosterone and cortisol in human health 
and disease.  Corticosterone may optimise glucocorticoid action in the human CNS, 
and simultaneously limit adverse metabolic effects driven by cortisol excess. 
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